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Summary 
 
Neurodegeneration with brain iron accumulation (NBIA) comprises a heterogeneous group of 
genetically defined disorders clinically characterized by progressive extrapyramidal deterioration 
and by iron accumulation in the basal ganglia. The clinical spectrum of NBIA is extremely wide 
and includes early-onset neurodegeneration and adult-onset parkinsonisms-dystonia. Recessive 
NBIA syndromes may be due to mutations in the PANK2, PLA2G6, FA2H, and C19orf12 genes, 
but still in a large proportion of patients, no genetic alteration can be found. Using Whole Exome 
Sequencing (WES) strategy we identified, in a NBIA patient, a homozygous missense mutation in 
the gene codifying for coenzyme A synthase (COASY). By performing traditional Sanger 
sequencing in a cohort of NBIA subjects, we found another mutant patient. COASY is a 
bifunctional mitochondrial enzyme involved in the two last steps of coenzyme A (CoA) 
biosynthesis, a molecule of primary importance for several metabolic pathways. The missense 
mutation found affects a highly conserved aminoacid residue in the catalytic site of COASY. 
Western-blot analysis showed that the protein is absent in patient-derived skin fibroblasts. We 
synthesized human wild-type and mutated catalytic domain and full-length COASY to analyze, by 
HPLC, in-vitro protein activity. Additional experiments were performed on yeast cells and on 
patient-derived skin fibroblasts. Together with mutations in PANK2, coding for the first enzyme 
involved in CoA biosynthesis, mutations in COASY impinge on the same biosynthetic pathway 
causing NBIA. For this reason further analysis were performed also on PKAN patient-derived skin 
fibroblasts and on Pank2 knockout mouse model, to better understand the link between CoA 
synthesis defect and neurodegeneration.  
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State of the Art 
 
NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 
 
Neurodegeneration with brain iron accumulation (NBIA) is a group of neurodegenerative disorders 
clinically characterized by iron overload in discrete brain regions, specifically in the basal ganglia. 
Prevalence data regarding this disorder remains incomplete, however it is estimated that anywhere 
between 1 in 1,000,000 to 3 in 1,000,000 individuals will be afflicted with this disorder [Gregory 
and Hayflick, 2013]. The basal ganglia consist of four interconnected nuclei: striatum, globus 
pallidus, substantia nigra and subthalamic nucleus. A family of basal ganglia circuits are involved in 
skeletomotor, oculomotor and limbic functions. Other basal ganglia circuits are involved in 
regulation of eye movements, mood, reward and executive functions. Diseases in the basal ganglia 
are associated with movement disorders and neuropsychiatric diseases [Kandel et al., 2013].  
In NBIA, excess iron accumulates in the globus pallidus and in the substantia nigra and can be 
visualized with magnetic resonance imaging (MRI). The substantia nigra and the globus pallidus 
naturally contain high iron concentrations (up to 450 g per g wet weight of brain) and also have a 
high metabolic requirement, potentially predisposing these areas to iron-related damage. The 
accumulation of iron has neither been proven to be cause nor symptom in NBIA. Iron is 
indispensable in mammalian metabolism because it is integral to the formation of haem and iron–
sulphur clusters and functions as a cofactor in numerous metabolic reactions [Roualt, 2013]. 
Abnormalities in brain iron metabolism are involved in the pathogenesis of several degenerative 
brain diseases. It is often not known whether iron accumulation contributes to disease progression 
or whether accumulation of iron occurs only after widespread neuronal death. In general, when iron 
accumulation is detected by MRI, it is often assumed to have a causal role in disease by enhancing 
free radical formation and contributing to oxidative stress and neuronal death in iron-overloaded 
cells [Sian-Hulsmann et al., 2011; Weinreb et al., 2010].  
As well as iron accumulation, patients with NBIA, exhibit dystonia, parkinsonism and spasticity. 
Genetically confirmed pathological studies have identified protein aggregates and axonal swellings 
that are reminiscent of other common neurodegenerative disorders. 
Most NBIA disorders are inherited in an autosomal recessive mode and generally begin in 
childhood or adolescence. NBIA diseases are associated with mutations in identified genes. Genetic 
screening over the last decade has identified 10 disease-associated genes, which lead to NBIA; 
 however, around 20% of NBIA cases remain genetically undefined [Arber et al., 2015]. At first 
glance, these 10 genes appear to be unrelated and are involved in diverse cellular pathways. Only 
two genes related to NBIA, encode proteins that are specifically involved in iron metabolism: 
ceruloplasmin (CP) and ferritin light chain (FTL). The other NBIA disease genes encode proteins 
with other functions, some of which are related to coenzyme A biosynthesis (PANK2 and COASY), 
fatty acid metabolism (C19orf12, PLA2G6, FA2H), DNA damage response (DCAF17), autophagy 
(WDR45) or lysosomal activity (ATP13A2) [Table 1]. 
 
DISEASE DISEASE 
GENE 
INHERITANCE SYMPTOMS 
Neuroferritinopathy FTL (19q13.3) Autosomal dominant Extrapyramidal signs, 
dystonia, 
orofacial dystonia, 
cognitive 
decline 
Acaeruloplasminaemia CP (3q23.25) Autosomal recessive Iron in the basal 
ganglia, liver, 
pancreas and 
myocardium; 
cognitive 
impairment, diabetes 
mellitus, 
retinal degeneration, 
blepharospasm, 
facial and neck 
dystonia, chorea, 
dysarthria, ataxia 
PANK2-associated 
neurodegeneration 
(PKAN) 
PANK2 
(20p12.3) 
Autosomal recessive Dystonia, spasticity, 
cognitive 
decline, pigmentary 
retinopathy 
PLA2G6-associated 
neurodegeneration 
(PLAN) 
PLA2G6 
(22q12.13) 
Autosomal recessive Infantile neuroaxonal 
dystrophy, 
progressive motor 
and mental 
retardation, 
cerebellar ataxia, 
pyramidal signs 
Mitochondrial 
membrane 
protein-associated 
neurodegeneration 
(MPAN) 
C19orf12 
(19q12) 
Autosomal recessive Iron-containing 
deposits, dystonia, 
parkinsonism, 
psychiatric 
symptoms, spastic 
paraparesis 
FA2H-ssociated 
neurodegeneration 
(FAHN) 
FA2H (16q23) Autosomal recessive Spastic quadriparesis, 
severe ataxia, 
dystonia 
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Kufor–Rakeb disease ATP13A2 
(1p36) 
Autosomal recessive Early-onset 
levodopa-responsive 
parkinsonism with 
pyramidal tract 
involvement, 
dementia 
Woodhouse–Sakati 
syndrome 
DCAF17 
(2q31.1) 
Autosomal recessive Hypogonadism, 
alopecia, diabetes 
mellitus, mental 
retardation, 
deafness, 
electrocardiographic 
abnormalities 
β-Propeller protein-
associated 
neurodegeneration 
(BPAN) 
WDR45 
(Xp11.23) 
X-linked Cognitive 
impairment, 
progressive 
dystonia-
parkinsonism, 
corticospinal signs 
COASY-associated 
neurodegeneration 
(CoPAN) 
COASY 
(17q12.21) 
Autosomal recessive Oro-mandibular 
dystonia, dysarthria, 
spastic dystonic 
paraparesis, 
obsessive-compulsive 
behaviour 
 
Table 1. NBIA and associated genes. The table summarizes the currently known genes involved in NBIA. FTL, ferritin 
light chain polypeptide; CP, ceruloplasmin; PANK2, pantothenate kinase 2; PLA2G6, phospholipase A2, group VI; 
C19orf12, chromosome 19 open reading frame 12; FA2H, fatty acid 2 hydroxylase; ATP13A2, ATPase type 13A2; 
DCAF17, DDB1- and CUL4-associated factor 17; WDR45, WD40 repeat domain 45; COASY, CoA synthase. 
 
1. NBIA caused by defective lipid metabolism 
 
1.1 NBIA caused by defective coenzyme A biosynthesis 
 
Coenzyme A  
Coenzyme A (CoA) is an indispensable cofactor in all living organisms. CoA is utilized in about 
100 biosynthetic and degrading reactions. Over 4% of cellular reactions utilize CoA. As a high-
energy carrier of acetyl and acyl groups, CoA is central to diverse cellular metabolic processes 
including citric acid cycle, fatty acid biosynthesis, β-oxidation, cholesterol and sphingolipid 
synthesis. In addition, CoA is a crucial factor in regulating a variety of enzymatic reactions and 
cellular metabolic processes. De novo synthesis of CoA is a highly conserved pathway that includes 
five enzymatic steps: pantothenic acid (vitamin B5) phosphorylation, cysteine conjugation, 
decarboxylation, conjugation to an adenosyl group and phosphorylation. In mammals, the first step 
 is catalysed by PANK, whereas the last two steps are catalysed by COASY, a mitochondrial 
bifunctional enzyme having a PPAT (4-phosphopantetheine-adenylyl transferase) and a DPCK 
(dephospho-CoA kinase) activities [Figure 1]. 
 
 
Figure 1. Coenzyme A biosynthetic pathway in human 
 
In other organisms, such as bacteria and yeast, PPAT and DPCK activities reside in two different 
enzymes:  Cab4 and Cab5 in yeast, CoAD and CoAE in bacteria.    
The reaction catalysed by PANK is the primary rate-limiting step in CoA biosynthesis and it is 
controlled by CoA and CoA thioesters, the end-products of the pathway. In bacteria, a second level 
of regulation is evident at PPAT (or CoAD). CoA consists of 3’-phosphoadenosine linked through 
the 5’ position of the ribose, to pantothenic acid via pyrophosphate linkage. The carboxyl end of 
pantothenic acid is linked through a peptidic bond to 2-mercaptoethanol amine. The thiol group at 
the end is essential to the chemical reactions where CoA is involved in, for this reason the enzymes 
involved in CoA biosynthesis are highly specific in incorporating cysteine, but not other amino 
acids [Strauss and Begley, 2005].  
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Tissue levels can vary widely depending on the organ in question, diet and fed/fasting state. The 
ratio of free CoA to acyl-CoA is important for regulating many key metabolic enzymes, such as 
acyl-CoA synthetase, PDH (pyruvate dehydrogenase) and 2-OG (2-oxoglutarate) dehydrogenase. 
The level of CoA is regulated by numerous extracellular stimuli, including hormones, 
glucocorticoids, nutrients and cellular metabolites [Tahiliani and Beinlich, 1991] and a link between 
the complex signaling mTOR pathway, which is implicated in numerous metabolic and signalling 
processes, and CoA biosynthesis has been proposed [Nemazanyy et al., 2004]. 
CoA is required in mitochondria for the citric acid cycle, in chloroplasts for fatty acid synthesis, and 
in peroxisomes for β-oxidation. CoA must be imported into these organelles from the cytosol. Yeast 
and mammalian mitochondria and peroxisomes have to import CoA because they cannot make it 
[Agrimi et al., 2012]. Mitochondrial CoA transporters belong to the mitochondrial carrier family 
(MCF) and have been identified in yeast [Prohl et al., 2001] and human [Fiermonte et al., 2009]. 
The compartmentalization of CoA in all eukaryotes appears to be highly regulated: cytosol and 
organelles maintaining separate CoA pools whose levels can modulate fluxes through CoA-
dependent reactions. Mammalian cytosolic concentrations are estimated to be in the range 0.02–
0.14 mM in animal tissues, whereas mitochondrial concentrations are much higher: from 2 to over 5 
mM [Leonardi et al., 2005]. 
Mutations in PANK2 and COASY have been identified as responsible for some forms of NBIA, 
namely PKAN and CoPAN. It is interesting to notice that PANK2 and COASY are both localized 
into mitochondria. Mitochondria are the main sites of iron utilisation in the cell [Levi and Rovida, 
2009]. This organelle employs iron for the biosynthesis of the iron sulphur cluster and heme 
cofactors, which are prosthetic groups of many proteins involved in key biological processes, such 
as electron transfer, DNA synthesis and repair, metabolic and regulatory processes [Stehling et al., 
2014]. 
 
Pantothenate kinase-associated neurodegeneration (PKAN) 
Mutations in the pantothenate kinase 2 gene (PANK2) lead to pantothenate kinase-associated 
neurodegeneration (PKAN) that represents the most common genetic cause of NBIA and occurs in 
around two-thirds of NBIA patients [Hayflick et al., 2003; Zhou et al., 2001]. 
PKAN, previously known as Hallervorden-Spatz syndrome is the best-known example of neuronal 
brain iron accumulation associated with neurological impairments, including childhood-onset 
dystonia and spasticity [Kruer et al., 2012]. The gene associated with the disease was identified in 
2001 as the gene that encodes pantothenate kinase 2 (PANK2), an enzyme that occupies the 
mitochondrial inter-membrane space [Leonardi et al., 2007; Brunetti et al., 2012] and is important 
 for biosynthesis of coenzyme A from pantothenate. PANK2 is a gene with seven exons, which is 
alternatively spliced to form two transcript variants. There is a strong correlation between loss of 
enzymatic activity and disease onset. Despite the fact that PANK2 proteins form homodimers, it is 
unlikely that mutant PANK2 has a dominant negative effect, as co-expression of mutant PANK2 
and wild-type PANK2 shows similar activity to wild-type PANK2 alone [Zhang et al., 2006]. 
PANK2 is one of four human pantothenate kinase proteins and is specifically located in the 
mitochondria [Hortnagel, 2003; Kotzbauer, 2005]. PANK4 is proposed to be nonfunctional while 
PANK1 and PANK3 are active in the cytosol. PANK2 dysfunction is compatible with life, and the 
two functional homologues, PANK1 and PANK3, may compensate for the loss of PANK2. The 
PANK2 polypeptide contains a mitochondrial localization signal. There is a catalytic ATP binding 
domain located at the N-terminus of the protein and a domain of unknown function at the C-
terminus of the protein. PANK2 homodimers are located in the mitochondrial intermembrane space. 
Mutations in PANK2 result in enzyme deficiency, leading to insufficiency of the final product and 
accumulation of upstream substrates, such as N-pantothenoil-cysteine and pantetheine, which are 
potentially toxic [Leoni et al., 2012]. In particular, cysteine is a potent iron chelator, and it has been 
proposed that high local levels of cysteine are the basis of the subsequent accumulation of iron, 
resulting in increased oxidative stress. The other hypothesis to explain the observed iron 
accumulation suggests that alterations in phospholipid metabolism due to CoA-deficiency may 
injure the membranes, with consequent oxidative stress that leads to iron accumulation [Leonardi et 
al., 2005]. 
Different animal models have been developed using Drosophila melanogaster and Mus musculus. 
Mice lacking Pank2 (Pank2-/- mice) did not develop brain iron accumulation or apparent 
neurological difficulties as expected, but they developed retinal problems and had a lack of viable 
sperm [Kuo et al., 2005]. A subsequent study showed that neurological symptoms occurred only 
when Pank2-/- mice were deprived of dietary pantothenic acid [Kuo et al., 2007]. D. melanogaster 
PANK2 homologue (fumble) hypomorphs did not show CNS iron overload, although they 
developed neurodegeneration and had diminished CoA levels [Bosveld et al., 2008; Wu et al., 
2009]. Both effects could be prevented by providing pantethine in the diet, which may allow bypass 
of the mutant enzyme and may be a possible approach for the treatment of human subjects [Rana et 
al., 2010]. A very recent study has demonstrated that there are alternative mechanisms, which allow 
cells and organisms to adjust intracellular CoA levels by using exogenous CoA.   CoA was 
hydrolyzed extracellularly by the enzyme ectonucleotide pyrophosphatases to 4′-
phosphopantetheine, a biologically stable molecule able to translocate through membranes via 
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passive diffusion. Inside the cell, 4′-phosphopantetheine was enzymatically converted back to CoA 
[Srinivasan et al., 2015]. 
Patients with PKAN have increased serum levels of lactic acid and pantothenate, and an analysis of 
fibroblasts from these patients suggested that cholesterol levels and fatty acid synthesis were 
decreased [Leoni et al., 2012]. Moreover, mitochondria from Pank2-/- mice have a reduction in 
mitochondrial potential, oxygen consumption and ATP generation, and that numerous mitochondria 
are swollen and contain disrupted cristae [Brunetti et al., 2012]. It is unknown the reason why 
PANK2 deficiency is associated with iron overload specifically in the globus pallidus. Abnormal 
ferroportin expression has been described in PANK2-deficient cell lines [Poli et al., 2010].  
PKAN fibroblasts, maintained in chronic iron supplementation, showed disturbed iron sensor 
protein iron regulatory protein 1 (IRP1) activity, resulting in deregulation of ferritin and transferrin 
receptor1 (TfR1), as well as a larger intracellular bioactive labile iron pool (LIP). This effect results 
in higher ROS development and leads to increased cellular oxidative status [Campanella et al., 
2012]. 
Perhaps the globus pallidus is particularly affected in PKAN because the expression levels of 
PANK1 and/or PANK3 are too low to compensate for the loss of PANK2. In the globus pallidus 
area, iron was increased in the cytoplasm of degenerating neurons, implying that neurons manifest 
iron overload before their death and that iron overload may contribute to neuronal loss in PKAN. 
Astrocytes showed marked iron overload in the globus pallidus of patients with PKAN, but there 
was no substantial iron accumulation in microglia or oligodendrocytes. These findings provided an 
explanation for the characteristic MRI finding in PKAN patients, known as the ‘eye of the tiger’ 
[Kruer et al., 2011], that is a region of hyperintensity surrounded by an area of hypointensity 
(characteristic of iron accumulation) [Figure 2].  
 
  
Figure 2. MRI of a PKAN patient. It is shown the classical ‘eye of the tiger’ sign. Hyperintense (white) signals 
indicative of tissue rarefaction are seen (centre of red rectangle) surrounded by areas of hypointensity (black areas) 
attributable to iron accumulation. 
 
In PKAN patients, cortical and subcortical brain regions show axonal swellings and spheroid 
bodies. These represent degenerating neurones and dystrophic axons. A loss of myelin and 
vacuolization has been described in the pallidum [Li et al., 2012], potentially linking PKAN to other 
demyelinating conditions. 
 
Coenzyme A synthase protein-associated neurodegeneration (CoPAN) 
Mutations in the Coenzyme A synthase (COASY) gene were recently shown to lead to NBIA. 
COASY protein-associated neurodegeneration (CoPAN) patients display similar clinical features to 
PKAN patients [Dusi et al., 2014]. 
COASY is a bifunctional enzyme that contains a mitochondrial localization signal, a regulatory 
region and a domain for each of the two catalytic domains: adenyl-transferase and dephospho-CoA 
kinase. COASY is localized to the mitochondrial matrix [Dusi et al., 2014; Daugherty et al., 2002]. 
There are two COASY isoforms, α and β produced from alternate splicing. The longer β isoform 
is brain specific and has an additional proline-rich protein interaction domain but has identical 
enzymatic activity to the ubiquitous α isoform [Nemazanyy et al., 2006]. The mutation identified in 
two NBIA patients, affects a conserved residue involved in ATP binding and dephospho-CoA 
kinase activity (R499C). This mutation is proposed to completely abrogate the protein functionality 
in a homozygous condition [Dusi et al., 2014]. Yeast knockout model for the two COASY 
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orthologue lead to a lethal phenotype. Human wild-type COASY can rescue this lethality, while 
mutant COASY containing the R499C change, are able to rescue knockout cells but lead to a higher 
requirement for pantothenate in the growth media [Dusi et al., 2014]. COASY belongs to the same 
metabolic pathway as PANK2 and catalyzes the final two steps of CoA synthesis [Nemazanyy et 
al., 2006; Aghajanian and Worral, 2002]. Mutant dephospho-CoA kinase domain appears to have 
no activity in vitro, whereas CoA levels in patient and control fibroblasts appear normal [Dusi et al., 
2014]. This suggests CoA levels are maintained by a residual activity of the COASY, or via an 
alternative, as yet unknown, pathway for CoA synthesis. The fact that COASY acts in the same 
pathway as PANK2 suggests common mechanisms may be shared between PKAN and COPAN, 
such as reduced acyl-CoA and lipid synthesis leading to mitochondrial insufficiencies. COASY 
shows a putative iron response element (IRE). The sequence is a putative 3’ IRE and could lead to 
mRNA stabilization in the presence of iron. This could potentially link COASY expression to iron 
availability in the cell. 
 
1.2 NBIA caused by defective fatty acid metabolism 
 
Phospholipase A2, group VI-associated neurodegeneration (PLAN) 
The first disease to be recognized as a distinctive non-PKAN type of NBIA disease was PLAN. 
Mutations in the gene encoding phospholipase A2 group VI calcium-independent (PLA2G6, also 
known as iPLA2β) have been associated with two diseases: phospholipase-associated 
neurodegeneration (PLAN) and dystonia-parkinsonism. PLA2G6-associated disease may have 
previously represented infantile neuroaxonal dystrophy (INAD) before NBIA reclassification. There 
are four groups of PLA2 enzymes containing more than 20 proteins: secreted PLA2s, calcium-
dependent cytosolic PLA2s, platelet-activating acetylhydrolases and calcium-independent PLA2s 
(iPLA2). PLA2G6 is responsible for 70% of total PLA2 activity in the brain. The PLA2G6 gene 
encodes an 806 amino acid protein with predicted size of 88 kDa. The mature protein is tetrameric 
and composed of an ankyrin repeat domain that is involved in protein interaction, a GXSXG lipase 
motif, an ATP binding pocket and a Calmodulin binding domain [Balsinde and Balboa, 2005]. 
There are at least five splice variants, three of which contain the lipase motif GXSXG, whereas two 
contain only the ankyrin repeats and most likely act as competitive inhibitors within the tetramer 
[Larsson et al., 1998]. PLA2G6 has been shown to be expressed in the mitochondria [Liou et al., 
2005] and be important for mitochondrial health [Seleznev et al., 2006]. PLA2G6 is ubiquitously 
expressed [Song et al., 2010]. Autosomal recessive mutations are found throughout PLA2G6 and 
lead to reduced enzyme activity. Some adult patients with PLAN develop dystonia and spasticity. 
 The major pathological hallmark of PLAN is the presence of axonal swellings throughout the 
cortex, globus pallidus, striatum, cerebellum, brain stem and spinal cord [Morgan et al., 2006].  
PLA2G6 hydrolyses glycerophospholipids at the sn-2 position of acyl chains to produce 
lysophospholipids and free fatty acids, such as arachidonic acid. The downstream metabolites of 
free fatty acids, such as leukotrienes and prostaglandin, perform essential cellular functions and 
contribute to a variety of signalling events including membrane remodelling, fatty acid oxidation, 
cell signalling and growth, and apoptosis [Balsinde and Balboa, 2005]. The 2-lysophophospholipid 
may also play a role in signalling such as in the production of platelet activating factor. 
Phospholipase activity is crucial for membrane integrity via phospholipid recycling and 
homeostasis. PLA2G6-mediated neurodegeneration may occur via the inability to remodel oxidized 
and damaged phospholipids. Polyunsaturated inner-membrane mitochondrial components, such as 
cardiolipin, are extremely sensitive to ROS. Mice that lack PLA2G6 (Pla2g6
-/-
) have disorganized 
mitochondrial inner membranes, which are distinctive because they contain large amounts of 
cardiolipin. It is a flexible molecule in which two fatty acid-bearing glycerol molecules are bridged by a 
single glycerol. The structure of cardiolipin envelopes respiratory chain complexes, tether these com-
plexes to the inner mitochondrial membrane and protect proteins from free radical damage by 
donating electrons from the unsaturated fatty acid side-chains of cardiolipin. The role of PLA2G6 
may be to remove saturated fatty acid side-chains from newly synthesized cardiolipins so that they 
can be replaced with unsaturated linoleic fatty acids (which are characteristic of cardiolipins) and 
also to remove fatty acids damaged by oxidative stress. A study in mice revealed that one of the 
first pathological signs of PLA2G6 deficiency is disorganization of the mitochondrial inner 
membrane cristae, followed by mitochondrial rupture, release of cytochrome C and formation of 
swollen axons as the disease progresses. Presynaptic membranes were also abnormal in 
PLA2G6-deficient mice, perhaps because mitochondria at these sites require PLA2G6-mediated 
phospholipid remodelling to maintain integrity [Beck et al., 2011]. 
PKAN and PLAN have common features maybe because PANK2 and PLA2G6, converge on 
cardiolipin metabolism in the mitochondrial inner membrane, either by synthesizing coenzyme A to 
activate fatty acids required for its remodelling and repair (this is the case for PKAN), or by 
supplying an enzyme that facilitates deacylation and remodelling of mature cardiolipin (this is the 
case for PLAN) [Figure 3]. A study in mouse model of PKAN, showed that mitochondrial inner 
membranes are highly disorganized in Pank2
-/-
 mice [Brunetti et al., 2012], similar to the 
mitochondrial inner membrane abnormalities observed in mouse models of PLAN [Beck et al., 
2011].  Studies in Saccharomyces cerevisiae demonstrated that loss of cardiolipin synthase results 
in diminished synthesis of iron–sulphur clusters and mitochondrial iron overload [Paisán-Ruiz et al., 
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2012], a complication that is frequently observed in human diseases caused by dysfunctional 
assembly of iron–sulphur clusters.  
 
Figure 3. PANK2 and PLA2G6 in mitochondria. Mutations in PANK2 and in PLA2G6 may interfere with synthesis 
and remodelling of cardiolipin. PANK2 is needed for the formation of CoA from pantothenate. CoA condenses with 
fatty acids to form acyl-CoA, which crosses into the mitochondrial matrix using the carnitine carrier system. Acyl-CoA 
in the mitochondrial matrix either delivers fatty acids for incorporation into complex intra-mitochondrial lipids, such as 
cardiolipin, or may alternatively undergo oxidation by the mitochondrial respiratory chain to generate ATP. The matrix 
membrane contains cardiolipin that enables the inner membrane to bend and turn. PLA2G6 may remove damaged fatty 
acids to allow incorporation of flexible unsaturated fatty acids, such as linoleic acid, from the acyl-CoA pool in the 
matrix [Rouault, 2013]. 
 
Cells that aberrantly produce ROS sequester PLA2G6 to the mitochondria, and this is protective 
against apoptosis [Seleznev et al., 2006]. Patient cells were shown to display faulty mitochondrial at 
the ultrastructural level [Itoh et al., 1993; Mahadevan et al., 2000]. Uncoupling of the mitochondrial 
respiratory chain and associated depolarization can lead to activation of PLA2G6 within the 
mitochondria and therefore free fatty acid accumulation [Broekemeier et al., 2002]. This can initiate 
apoptosis through stimulating the permeability transition pore and cytochrome C release leading to 
further lipid damage and apoptotic signals [Gadd et al., 2006]. Reduced PLA2G6 activity may lead 
to deregulation of this process. Related to this, ER stress can increase the expression and activity of 
PLA2G6, bringing about the loss of mitochondrial membrane potential and increasing the 
likelihood of apoptosis [Lei et al., 2012]. Altered axonal and/or organelle membrane integrity may 
 lead to improper axonal transport and accumulation of cellular components at distal axon locations, 
subsequently leading to axonal blockage and degeneration [Roy et al., 2005]. Both products of 
PLA2G6 catalysis, lysophospholipids and free fatty acids, may be able to increase membrane fusion 
via increased fluidity in the local environment [Balsinde and Balboa, 2005]. This could have 
important roles in autophagy, mitophagy and other vesicle-based processes that have been shown to 
be involved in neurodegeneration. Docosahexaenoic acid (DHA) is an essential fatty acid that 
cannot be synthesized in neurons. Astrocytes have been shown to produce and release DHA due to 
PLA2G6 action [Green et al., 2008]. Knockdown of the enzyme in astrocytes leads to a reduction of 
arachidonic acid and DHA in neurons and increased prostaglandin production [Strokin et al., 2007], 
which could lead to increased apoptosis [Kondo et al., 2002]. PLA2G6 is also mutated in cases of 
Parkinson disease and, for this reason, it is classified as a PD gene (PARK14) [Lu et al., 2012]. Iron 
accumulation is found in macrophages and in aggregates in the globus pallidus of patients with the 
parkinsonian presentation [Paisán-Ruiz et al., 2012]. In addition, a reduction of PLA2G6 protein 
levels has been shown in the brains of patients affected by Alzheimer’s disease [Ross et al., 2002].  
 
Mitochondrial membrane protein-associated neurodegeneration (MPAN) 
Mutations in chromosome 19 open reading frame 12 (C19orf12) lead to mitochondrial membrane 
protein-associated neurodegeneration (MPAN). MPAN accounts for around 30% of NBIA cases 
[Hogarth et al., 2013]. Chromosome 19 open reading frame 12 (C19orf12) protein is a 17 kDa 
mitochondrial membrane-associated protein whose function is still unknown but it is co-expressed 
with genes involved in fatty acid metabolism and branched chain amino acid degradation. C19orf12 
is a two-pass transmembrane protein with two alternative start codons. Missense mutations have 
been described to add charged amino acids to putative hairpin domains, potentially disrupting the 
3D structure [Hartig et al., 2011]. MPAN has been successfully modelled in Drosophila 
melanogaster [Iuso et al., 2014]. Post-mortem examination of two MPAN cases showed iron 
accumulation mainly confined to the globus pallidus. Iron accumulation was accompanied by 
neuronal atrophy, and depositions were present in neurons, macrophages and, to a lesser extent, 
astrocytes. Lewy bodies and Lewy neurites were a characteristic feature of MPAN [Hogarth et al., 
2013]. Lewy neurites in the globus pallidus were adjacent to the atrophied region and Lewy 
pathology extended to the SN where they were associated with near complete neuronal loss. Lewy 
bodies were also present in the cortex, striatum and hippocampus. Axonal swellings and 
hyperphosphorylated tau were also present in the cortex, globus pallidus, caudate/putamen, 
substantia nigra and brain stem. Demyelination was evident in the spinal pyramidal tracts and optic 
nerve. 
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C19orf12 codes for a transmembrane glycine zipper containing mitochondrial protein and a recent 
study have demonstrated that wild-type C19orf12 was not exclusively present in mitochondria, but 
also in the endoplasmic reticulum (ER) and MAM (Mitochondria Associated Membrane), while 
missense mutant C19orf12 variants presented a different localization. After induction of oxidative 
stress, a GFP-tagged C19orf12 wild-type protein was able to relocate to the cytosol. On the 
contrary, mutant isoforms were not able to respond to oxidative stress [Venco et al., 2015].  
 
Fatty acid hydroxylase-associated neurodegeneration (FAHN) 
Fatty acid hydroxylase-associated neurodegeneration (FAHN) is caused by mutations in the gene 
encoding fatty acid-2-hydroxylase (FA2H). FAHN is characterized initially by spasticity, a mixed 
movement disorder, ataxia, dystonia, optic atrophy and oculomotor abnormalities, and later by 
progressive intellectual impairment and seizures [Kruer et al., 2010]. FA2H is a 43 kDa membrane-
bound protein, residing in the ER [Eckhardt et al., 2005]. The protein has a C-terminal sterol 
desaturase domain, which contains an iron binding histidine motif and is responsible for catalytic 
activity, and an N-terminal cytochrome b5 haem-binding domain, involved in redox activity and 
electron donation. [Alderson et al., 2004; Hama, 2010]. FA2H produces the 2-hydroxylated fatty 
acids that are incorporated into sphingolipids [Dan et al.,2011]. 2-hydroxylated fatty acids are 
precursors for the synthesis of ceramide, a critical component of myelin sheaths [Eckhardt et al., 
2005]. Inactivating mutations in FA2H are likely to affect normal myelin production due to loss of 
the hydroxylase activity of the enzyme. The late onset and slow progression are consistent with this 
idea, analogous to demyelinating diseases such as multiple sclerosis. Altered ceramide signalling 
may have roles in Lewy body formation, and the role of ceramide in apoptosis and 
neurodegeneration has been implicated [Bras et al., 2008; Jana et al., 2009]. FA2H also has a role in 
lipid signalling pathways that can affect cell cycle and apoptotic pathways [Hama, 2010]. 
Moreover, axonal function is compromised in mice lacking FA2H. In mouse models of FAHN, 
regions of pronounced white matter degeneration showed accumulation of microglia-like cells. 
These cells may accumulate iron-loaded ferritin [Potter et al., 2011]. MRI studies in patients with 
FAHN have detected iron accumulation not only in the globus pallidus but also in the substantia 
nigra and subcortical and periventricular regions [Gregory and Hayflick, 2011]. 
 
 
 
 
 
 2. NBIA caused by defective iron homeostasis 
 
Neuroferritinopathy 
Neuroferritinopathy is an autosomal dominant neurodegenerative disease caused by mutations in 
the ferritin light chain (FTL). Seven distinct disease-causing mutations have been reported in this 
disease, but it is most commonly caused by the insertion of an extra nucleotide in the fourth exon of 
the gene encoding the FTL, which causes a frame-shift and synthesis of an abnormal C-terminus 
[McNeill and Chinnery, 2011]. When FTL with this abnormal C-terminus (that may constitute an 
important part of the iron entry pore [Burn and Chinnery, 2011] is incorporated into the ferritin 
heteropolymer, the spherical ferritin no longer has an intact proteinaceous shell to protect 
sequestered iron, and as a result, it is likely that iron ‘leaks’ out of ferritin [Friedman et al., 2011]. 
This could cause iron-dependent oxidation, particularly in cells that normally express high amounts 
of FTL. The presence of one abnormal allele that encodes a truncated form of ferritin is sufficient to 
cause neuroferritinopathy associated with cognitive and behavioural impairments, which generally 
manifest between the third and sixth decades of life [Baraibar et al., 2010]. Pathological 
investigations have shown ferritin inclusions in glia and neurons, as well as iron deposition. 
Mitochondrial abnormalities have been observed, and an increased oxidative stress of the cells, 
possibly due to iron, was shown via peroxidation and nitrosylation [Curtis et al., 2001; Vidal et al., 
2004; Mancuso et al., 2005]. A mouse model of neuroferritinopathy recapitulates many aspects of 
the disease [Vidal et al., 2008]. Crystal structures of ferritin containing the mutant light chain, have 
revealed that the initial iron sequestration is impaired and that iron-induced ferritin precipitation is 
enhanced [Baraibar et al., 2010]. 
 
Aceruloplasminaemia 
Aceruloplasminaemia is caused by mutations in ceruloplasmin (CP), which result in loss of the 
functional protein. CP is a glycoprotein containing many copper atoms (and potentially iron atoms) 
that acts as a ferroxidase to facilitate ferroportin mediated cellular iron export. Oxidation of ferrous 
iron (Fe
2+
) to ferric iron (Fe
3+
) enables binding to transferrin for iron transport in the extracellular 
environment. In aceruloplasminaemia, iron entering the CNS as ferrous iron might not undergo 
oxidation. Consequently, cells exposed to the resulting excess ferrous iron could readily become 
iron-loaded through an unregulated pathway of non-transferrin-bound iron uptake [Brissot et al., 
2012]. The unregulated uptake of ferrous iron, coupled with an inability to export iron, could 
produce the astrocytic iron overload that has been observed in this disease. Marked astrocytic iron 
overload, in conjunction with neuronal loss, was observed not only in the basal ganglia but also in 
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the cerebrum in a human case report [Kaneko et al., 2012]. Some mutant forms of ceruloplasmin 
may also accumulate in aggresomes and cause cell death through a non-iron related mechanism 
[Kono and Miyajima 2006; Kono et al., 2006]. 
Symptoms of aceruloplasminaemia include a triad of adult-onset neurological disease, diabetes 
mellitus and retinal degeneration. This pathology has been characterized in human autopsy samples 
[Gonzalez-Cuyar et al., 2008] and in mice lacking Cp, which develop ataxia [Jeong and David, 
2006]. Iron overload has been observed in astrocytes in the affected brain regions of patients with 
aceruloplasminaemia, particularly in the basal ganglia [Jeong and David, 2003]. There is evidence 
for increased levels of oxidative stress, as indicated by increased lipid peroxidation and protein 
carbonylation [Kono and Miyajima 2006]. 
 
3. NBIA caused by defects in autophagy 
 
-propeller protein-associated neurodegeneration (BPAN) 
Mutations in the WD repeat domain 45 gene (WDR45) are linked to β-propeller protein-associated 
neurodegeneration (BPAN). Despite WDR45 being on the X chromosome, BPAN does not follow 
normal X-linked dominant inheritance. Both genders have similar clinical features, and the disease 
is always sporadic. Disease-associated mutations are predicted to lead to inactive proteins, and are 
presumed to be lethal for male embryos. Male BPAN sufferers are presumed to have de novo 
mutations and were shown to have somatic or germline mosaicism [Haack et al., 2012]. 
WDR45 is a β-propeller scaffold protein that has been predicted to have a role in autophagy. 
WDR45 is a member of the WD40 protein family, which is involved in protein–protein interactions 
and perform cellular functions such as autophagy, cell cycle progression and transcriptional control. 
WDR45 binds to phospholipids and autophagy-related proteins [Lu et al., 2011]. 
Yeast has over 30 autophagy-related genes (atg). Many mammalian atg-homologues have been 
found. WDR45 is one of 4 atg18 homologues, crucial for autophagosome formation. atg18 binds 
the ER membrane via a phosphotidylinositide-3-phosphate binding motif and facilitates 
downstream protein complex formation. Phosphatidylinositol-3-phosphate (PI3P) is a critical factor 
in autophagy and is a major component of autophagosome membranes. Upstream signalling (e.g. 
mTOR) controls PI3P and autophagic flux. PI3P may be involved in early membrane curvature and 
autophagosome size, for this reason WDR45 could regulate autophagosome size and maturation 
[Dall’Armi et al., 2013]. Lymphoid cells from five patients with truncated or mutated WDR45, 
show a blockage in autophagic flux when exposed to inhibitors or activators of autophagy [Saitsu et 
al., 2013]. 
 In BPAN, iron deposition was strongest in the substantia nigra but also evident in the globus 
pallidus. Axonal spheroids were present in the basal ganglia and gliosis was prominent [Hayflick et 
al., 2013].  
Recently, a central nervous system-specific Wdr45 knockout mouse model was generated. It shows 
poor motor coordination, greatly impaired learning and memory, and extensive axon swelling with 
numerous axon spheroids. Also its autophagic flux is defective and ubiquitin-positive protein 
aggregates accumulate in neurons and swollen axons [Zhao et al., 2015].  
 
4. NBIA caused by defects in lysosomal metabolism 
 
Kufor-Rakeb disease 
Mutations in ATPase type13A2 (ATP13A2, also known as PARK9) lead to Kufor-Rakeb disease, a 
pathology characterized by juvenile onset parkinsonism and dementia [Di Fonzo et al., 2007], 
neuronal ceroid-lipofuscinosis [Bras et al., 2012] and NBIA [Schneider et al., 2010]. 
The protein is a lysosomal P-type ATPase that functions as divalent cation transporter. This 
superfamily of ATPases comprises transporters like calcium pumps, proton pumps and 
phospholipid flipases, and consists of highly conserved, 10-pass transmembrane proteins, which 
utilize the energy stored in ATP to transport ions across membranes [Kühlbrandt, 2004]. 
Fibroblasts from patients with ATP13A2 mutations show lysosomal deficiencies that lead to 
cytotoxic effects in the presence of α-synuclein [Usenovic et al., 2012] and zinc [Tsunemi and 
Krainc, 2014]. Intracellular manganese levels were shown to be higher in cells with mutant 
ATP13A2 compared with wild type, hinting to reduced secretion ability [Tan et al., 2011]. This may 
directly lead to cytochrome C release from mitochondria and apoptosis. Patient-derived fibroblasts 
have shown an impaired respiratory chain function and reduced ATP production. A quantification 
of mitochondrial DNA (mtDNA) levels resulted in a significantly increase of mtDNA to nuclear 
DNA in patient-derived fibroblasts. However, patient-derived fibroblast showed more mtDNA 
lesions (nicks, breaks, base modifications or bulky DNA adducts) than controls [Grünewald et al., 
2012]. 
Mitochondria are very dynamic organelles that continuously shift between fusion to each other and 
division, to form a mitochondrial network in the cell. The proteins that mediate mitochondrial 
dynamics are highly regulated and loss of either fusion or division activity results in dysfunctional 
mitochondria. Mitochondrial fusion may buffer partially defects and transient stresses in the cell. 
For this reason a high fragmented mitochondrial network could be related to a cell-suffering state 
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[Nunnari and Suomalainen, 2012]. Mitochondrial network in fibroblast from patients with 
ATP13A2 mutations, resulted more fragmented than controls [Grünewald et al., 2012]. 
 
5. NBIA caused by defects in DNA damage response 
 
Woodhouse-Sakati syndrome 
DDB1 and CUL4 associated factor 17 (DCAF17) is a protein of unknown function that is expressed 
in the nucleolus. Mutations in this gene lead to Woodhouse-Sakati syndrome. A subset of patients 
with Woodhouse-Sakati syndrome displays brain iron accumulation [Alazami et al., 2008]. 
DCAF17 is a multipass transmembrane protein that is named due to protein–protein interactions, 
Ddb1 and Cul4-associated factor (damaged DNA binding protein 1 and cullin 4 ubiquitin ligase 
complex) [Jin et al., 2006]. This association links DCAF17 to protein ubiquitination involved in 
DNA damage and cell cycle control. The nucleolar localization leads to intriguing questions about 
specific function and any links to other NBIA-linked mutations. 
 
6. Current treatment of NBIA 
 
Understanding the pathogenesis of NBIA is necessary for the development of successfully 
treatments. To date the therapeutic options for NBIA disorders remain largely symptomatic. 
Pharmacotherapy, such as dopaminergic drugs, anticholinergics, tetrabenazine, and other drugs may 
bring some relief. Deep brain stimulation can produce some benefit. However, these approaches are 
rarely fully satisfactory and do not slow disease progression. 
With the assumption that iron plays a causative role, chelators, which reduce the amount of free iron 
have moved into the centre of attention. In a clinical trial on PKAN patients, the oral iron-chelator 
deferiprone produced significant (median 30%) reduction in globus pallidus iron content, ranging 
from 15 to 61%, but there was no clinical benefit [Cossu et al., 2014]. 
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Aim of the Project 
 
The specific aims of my PhD project were: 
 
1. Identification and characterization of new disease genes involved in NBIA pathology. 
We have performed Whole Exome Sequencing (WES) analysis in one subject with clinical 
presentation and neuroimaging suggestive of NBIA but without any mutations in previously 
associated genes. We have identified a homozygous missense mutation in coenzyme A synthase 
gene (COASY), the enzyme involved in the last two steps of CoA biosynthesis. After that, we have 
performed traditional Sanger sequence analysis on a larger cohort of idiopathic NBIA cases and we 
found a second subject carrying mutations in the same gene. We have performed several studies to 
characterize COASY to better understand the role of CoA in NBIA pathology. 
 
2.  Further studies on pantothenate kinase 2 (PANK2). 
We have performed several studies to better characterize PANK2, the enzyme involved in the first 
step of CoA biosynthesis, to search for a correlation between defects in lipid metabolism, 
mitochondrial functionality and NBIA.  
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Main Results 
 
1. Identification and characterization of new disease genes involved in NBIA pathology. 
 
Molecular and biochemical results 
WES analysis of one subject affected by idiopathic NBIA resulted in the identification of a 
homozygous mutation in coenzyme A synthase (COASY), the gene coding for a bifunctional 
enzyme converting 4-phosphopantetheine into dephospho-CoA and then to coenzyme A, and we 
have considered this mutation as potentially relevant for the disease. This subject has shown a 
homozygous missense mutation, a c.1495C>T transition causing an amino acid change 
p.Arg499Cys (subject 1). 
Consequently, we have analyzed COASY in a cohort of 280 NBIA-affected individuals by using 
polymerase chain reaction and direct Sanger sequencing. By this analysis we identified a second 
Italian subject carrying COASY mutations. This subject turned out to be a compound heterozygote 
for the same mutation c.1495C>T (p.Arg499Cys) and for a c.175C>T transition, resulting in a 
premature p.Gln59* stop codon in the N-terminal regulatory region of the protein (subject 2). 
Segregation analysis in the parents demonstrated that the two mutations were localized on different 
alleles. 
The missense mutation p.Arg499Cys, affected the amino acid residue Arg499, which is highly 
conserved in all available animal, plant, and yeast species, and is localized in the nucleotide-binding 
site of the DPCK domain. 
Quantitative real-time PCR, performed on skin fibroblasts derived from the two patients, shown that 
in subject 1 the amount of mutant COASY transcript was similar to that of the control sample but it 
was reduced to 50% in subject 2, suggesting RNA decay. Immunoblot analysis revealed a 
significant reduction of the protein amount in the fibroblasts of the two patients. This suggests that 
the p.Arg499Cys change is associated with instability or accelerated degradation of COASY. 
To determine if COASY forms potential complexes with other proteins belonging to the CoA 
biosynthetic pathway, we performed co-immunoprecipitation (Co-IP) assay with PANK2 and PPCS 
and 2D-Blue Native gel analysis on HeLa cells. We observed that COASY did not co-
immunoprecipitate with PPCS and PANK2. A similar result was observed in the 2D-Blue Native 
gel: COASY did not seem to form a protein complex with the other enzymes involved in CoA 
biosynthesis (see Supplementary data- Figure S3). 
 Cellular localization studies 
COASY is a mitochondrial protein. To better determine the sub-mitochondrial localization of 
COASY, we have carried out immunoblot analysis of mitochondria and sub-mitochondrial fractions 
derived from HeLa cells, using a commercially available antibody. Immunoblotting revealed the 
presence of a band of the expected molecular weight in total lysate and intact mitochondria. We 
treated mitochondria with proteinase K (PK) and demonstrated COASY resistance to degradation. 
The protein was also found in mitoplasts and was resistant to PK digestion. Further fractionation of 
mitoplasts demonstrated that the protein was mainly present in the matrix, probably anchored to the 
inner mitochondrial membrane. 
 
Effect of p. Arg499Cys substitution 
To study the effect of the p.Arg499Cys substitution on the DPCK domain activity, we expressed 
mRNA corresponding to the wild-type and mutant DPCK in bacteria as His-tag fusion proteins. 
HPLC analysis was used to evaluate dephospho-CoA conversion into CoA after incubation of wild-
type and mutant DPCK domains with ATP and dephospho-CoA. The wild-type enzyme was able to 
completely convert dephospho-CoA into CoA, on the contrary, the DPCK-Arg499Cys mutant did 
not have this enzymatic activity and the peak corresponding to CoA was not observed. The same 
experiment was performed using the entire wild-type and mutant COASY proteins expressed in 
bacteria as His-tag fusion proteins. Wild-type COASY was able to synthesizes CoA, whereas 
mutant enzymes had an about 40-50% reduced activity compared to wild-type enzyme. The gain of 
functionality of the mutant COASY compared to the mutant DPCK domain, is not ascribable to the 
PPAT domain because wild-type PPAT is not able to synthesize CoA starting from 4-phospho-
pantetheine, the typical substrate of COASY (see Supplementary data- Figure S1, Figure S2). This 
finding suggests that CoA biosynthesis might be compromised in the presence of p.Arg499Cys 
change.  
Consequently, we analyzed CoA levels in fibroblasts derived from healthy and affected subjects by 
HPLC. We observed a general reduction of acetyl-CoA and total CoA in both affected individuals 
as compared to control. 
To examine whether skin fibroblasts from patients were able to synthesize CoA, we evaluated CoA 
biosynthesis in cell homogenates with 4-PP (4-phosphopantetheine) as substrate. HPLC analysis 
showed that dephospho-CoA and CoA were efficiently produced de-novo from 4-PP in control 
fibroblasts. We also observed residual de novo production of dephospho-CoA and CoA in skin 
fibroblasts from patients, but the level of CoA was approximately 20% of that produced by control 
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fibroblasts. These findings suggest the existence of an alternative pathway for CoA biosynthesis, or 
the possibility that the remaining COASY aberrant protein may still retain some catalytic activity. 
 
Studies in Saccharomyces cerevisiae 
Biosynthesis of CoA in Saccharomyces cerevisiae follows the same pathway described for 
mammalian cells: pantothenate is converted in CoA in five reactions catalyzed by enzymes encoded 
by CAB1 through CAB5. The only difference with human is that in yeast, the PPAT and DPCK 
activities reside on different proteins encoded by CAB4 and CAB5 genes, respectively. Sequence 
analysis indicated that Arg499 is highly conserved from yeast to human and corresponds to Arg146 
in the yeast Cab5.  
By using the plasmid shuffling method, we generated deletion strains expressing either the mutant 
alleles cab5
Arg146Cys
 and COASY
Arg499Cys
 or the CAB5 and COASY wild-type genes. The Δcab5 lethal 
phenotype was rescued by the re-expression of either human COASY wild-type or human 
COASY
Arg499Cys
 and yeast cab5
Arg146Cys
. We observed that the mutant strains cab5
Arg146Cys
 and 
COASY
Arg499Cys
 became auxotrophic for pantothenate and showed growth reduction: in the absence 
of pantothenate both strains failed to form colonies at the restrictive temperature of 37°C and a 
significant impairment of growth was observed at both 23°C and 28°C when compared with that of 
the strain expressing the wild-type alleles. This result supports the pathogenicity of the substitution 
p.Arg499Cys and suggests that the mutant enzyme requires a higher concentration of pantothenate 
to produce enough CoA to sustain yeast growth. 
We have also measured CoA level in mitochondria isolated from wild-type, COASY
Arg499Cys
, and 
cab5
Arg146Cys
 and we observed that the level of CoA was reduced to 40% in yeast transformed with 
the two mutant strains as compared to wild-type. Starting from this result, we searched if a defective 
CoA biosynthesis could lead to mitochondrial dysfunction. Serial dilutions of the strains 
cab5Δ/COASYArg499Cys and cab5Δ/COASY, were spotted on medium without pantothenate 
supplemented with either ethanol or glycerol, at 28°C. The oxidative growth of the 
cab5Δ/COASYArg499Cys mutant was partially affected compared to cab5Δ/COASY strain. 
To further analyze the respiratory deficiency, we measured oxygen consumption and activity of 
respiratory complexes. The oxygen consumption rate of the cab5Δ/COASYArg499Cys strain was 25% 
less than that of cab5Δ/COASY. The respiratory complex III and complex IV activities were 
reduced in the mutant strain respectively to 26% and 42% as compared to wild type. Altogether 
these results indicate a mitochondrial dysfunction associated to reduced CoA level. 
We have also studied the effect of a high iron content in yeast. We added FeSO4 to the medium and 
we demonstrated a clear growth defect in the mutant strain. We then performed a quantitative 
 determination of cellular iron level by a colorimetric assay and we obtained a two-fold increase in 
iron content in the cab5Δ/COASYArg499Cys mutant respect to the parental strain. 
Fe-S cluster is a marker of mitochondrial functionality linked to iron metabolism, we investigated 
whether the biosynthesis of the Fe-S cluster, was affected by COASY deficiency. We determined 
the activity of succinate dehydrogenase, a mitochondrial Fe-S cluster enzyme. SDH activity was 
decreased by about 50% in the mutant strain. 
Since an excess of iron causes an altered oxidative status, we exposed the mutant and the control 
strain to H2O2: wild type cells showed a viability of 10%, while mutant cells showed a viability of 
2% demonstrating that a COASY defect leads to oxidative stress susceptibility. 
Finally, since CoA is involved in biosynthesis of fatty acid and acetyl-CoA is necessary for the 
production of neutral lipids, important as a power reserve for the cell, we have evaluated lipid 
droplets content in the two strains. We have observed that the content of lipid droplets is decreased 
in the mutant strain cab5Δ/COASYArg499Cys.  
 
2.  Further studies on pantothenate kinase 2 (PANK2). 
 
Studies on PKAN patient-derived skin fibroblasts 
We have analysed skin fibroblasts from three PKAN patients: the first patient carried a homozygous 
c.569insA mutation in PANK2 that resulted in a premature stop codon at amino acid position 190 
(p.Y190X); the second and third patients are brothers and carried a homozygous c.1259delG 
mutation, resulting in a frame shift mutation with a creation of a stop codon (F419fsX472). In 
immunoblot analysis we have shown that PANK2 is virtually absent in all the three patients.  
We then have determined cellular oxidative status and its relationship with iron content in 
fibroblasts by treating control and PKAN fibroblasts with an iron chelator and by analyzing 
carbonylated proteins content. The content of carbonylated proteins in PKAN fibroblasts, not 
treated with the iron chelator, was incremented compared to control fibroblasts. Interestingly, 
treatment with the iron chelator, ameliorated the level of carbonylated proteins in PKAN 
fibroblasts, but it was completely ineffective in control fibroblasts. Then, we measured both total 
and reduced glutathione in fibroblasts and we observed a significant reduction in patient fibroblasts 
compared to controls. 
To verify whether the defect in PANK2 activity affected mitochondrial iron homeostasis, we have 
searched for the presence of potentially toxic free iron (LIP) in the mitochondrial compartment. 
After treatment with the iron chelator, the size of the mitochondrial LIP was statistically higher in 
PKAN fibroblasts than control cells in both basal growth conditions and with iron supplementation. 
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As labile iron can promote ROS formation, we have also measured their generation in basal growth 
conditions and after iron supplementation. We have observed that ROS production was significantly 
higher in PKAN fibroblast than in control in both conditions. To evaluate biosynthesis of heme, that 
represents an important iron-containing product in mitochondria, we have measured its content in 
fibroblasts and we have observed a significant reduction in heme content of PKAN fibroblasts. 
We further investigated the ability of mitochondria to maintain the cellular energy requirement. The 
mitochondrial membrane potential was evaluated on fibroblasts in the presence of an ATPase 
inhibitor. PKAN fibroblasts have shown lower membrane hyperpolarisation. Also mitochondrial 
network was compromised in patient-derived fibroblasts: it was more fragmented in PKAN 
patients. In line with this observation, we have observed a reduction in ATP levels in PKAN 
fibroblasts compared to control cells. 
 
Studies on induced neurons (iNs) from PKAN patient-derived skin fibroblasts 
Human neurons were generated from patient and control fibroblasts by direct neuronal 
reprogramming. 
We have analysed the amount of ROS specifically present in iNs and we have observed that PKAN 
iNs contained higher ROS levels than control iNs. We have also evaluated reduced glutathione 
content and we have seen that PKAN iNs contained significant lower reduced glutathione levels 
compared to control iNs. A similar approach was used to evaluate mitochondrial functionality in 
neuronal cells. We have measured mitochondrial membrane potential and we have observed that 
PKAN iNs had significantly lower membrane potentials compared to control iNs. 
 
Studies on Pank2 knockout (Pank2
-/-
) mouse model 
Pank2 knockout (Pank2
-/-
)
 
mice show reduced growth, retinal degeneration, male infertility and 
mitochondrial dysfunctions under standard diet conditions. 
Based on the role of CoA in several crucial cellular metabolic pathways, we have tested the 
hypothesis to stress the Pank2
-/- 
mouse model with a high-fat ketogenic diet. Ketone bodies 
produced by the ketogenic diet bypass glycolysis and enter the citric acid cycle to produce oxidative 
phosphorylation (OXPHOS) substrate. Mice on a ketogenic diet use mainly fatty acid oxidation and 
OXPHOS for ATP production as compared to mice on a standard diet. We have observed that only 
ketogenic diet-fed Pank2
-/- 
mice presented typical signs of neurological and motor impairment and 
neuropathological findings, like the phenotype observed in PKAN patients. In particular, Pank2
-/- 
mice under ketogenic treatment have shown progressive weight loss, kyphosis, feet clasping and 
dystonic limb positioning compared to control
 
mice. 
 Since a PANK2 knockout Drosophila melanogaster model has shown that the compound 
panthethine can bypass the block due to severe impairment of PANK2 and it is able to rescue brain 
degeneration, we have asked whether these signs could have been prevented by pantethine 
administration. We have observed that, with pantethine administration to mice fed a ketogenic diet, 
the weight of Pank2
-/- 
mice was similar to that of control
 
mice and no signs of kyphosis or feet 
clasping were present. Moreover, Pank2
-/- 
mice fed a ketogenic diet died after 2 months whereas the 
administration of pantethine prolonged their survival for up to 5 months. 
Pank2
-/- 
mice fed with ketogenic diet were lethargic and showed a significant reduction of 
spontaneous movements as compared with control mice fed with ketogenic diet, whereas no 
differences were observed when fed with standard diet. All of these abnormalities were recovered 
by pantethine treatment. 
We have performed a histological and immunohistochemical analysis of the whole brains and we 
have noticed the presence of small, scattered groups of neurons with round cytoplasmic inclusions 
positive for ubiquitin, in Pank2
-/- 
mice fed a ketogenic diet. Pantethine treatment led to the 
disappearance of these neuronal inclusions. 
Ultrastructural analysis was performed on basal ganglia and peripheral nerve of Pank2
-/- 
and control 
mice. In the basal ganglia, Pank2
-/- 
mice on standard diet have shown the presence of numerous 
mitochondria with abnormal and swollen cristae. These features were worsened by a ketogenic diet. 
Pank2
-/- 
animals fed a ketogenic diet also showed cytoplasmic deposits of lipofuscin. Pantethine 
administration completely rescued the mitochondrial morphology of Pank2
-/- 
animals on standard 
diet and ameliorated the morphology of ketogenic diet-fed Pank2
-/- 
mice. The analysis of peripheral 
nerve of Pank2
-/- 
mice on ketogenic diet has shown the presence of swollen mitochondria, 
characterized by cristae degeneration and by the presence of amorphous material in the matrix. 
Pantethine administration was able to completely rescue the mitochondrial morphology. 
We have also evaluated mitochondrial membrane potential in neurons derived from mice; neurons 
from Pank2
-/- 
mice treated with standard or ketogenic diet showed defective mitochondrial 
membrane potential. The same neurons, after addition of pantethine, showed instead preserved 
mitochondrial membrane potential.  
We have evaluated respiration with microscale oxygraphy on mitochondria isolated from brains of 
Pank2
-/- 
and control mice treated with pantethine and we have compared the results with untreated 
mice. We have measured basal oxygen consumption rate, and oxygen consumption rate after ADP 
addition, and after oligomycin addition. We have observed that pantethine was able to significantly 
increase oxygen consumption rate under all conditions tested in both Pank2
-/- 
and control 
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mitochondria. In particular, pantethine determines a doubling in oxygen consumption rate after 
ADP stimulation suggesting that respiration was tightly coupled with ATP production. 
We have performed cytochrome C oxidase (COX or complex IV of the respiratory chain) 
histochemical reaction on Pank2
-/- 
mice and on muscle biopsy derived from a PKAN patient 
carrying the PANK2 mutations N500I + IVS2-1G>A. We have found a very peculiar COX staining 
pattern suggestive of the presence of abnormal mitochondria. To further characterize these 
mitochondria we performed electron microscopy, which highlighted the presence of giant 
mitochondria spanning the sarcomere between two neighbouring Z-lines and showing irregularly 
shaped cristae. The histological alterations of the Pank2
-/- 
muscle were absent in pantethine-treated 
mice. 
Finally we have analyzed plasma derived from mice. Plasma analysis has shown an increase of 
cholesterol and triglycerides in mice on a ketogenic diet. Pantethine treatment was able to reduce 
the levels of both. 
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Conclusions and Future Perspectives 
 
We reported the second inborn error of CoA biosynthesis leading to a neurodegenerative disorder. 
The first defect discovered was due to PANK2 mutations, causing the most prevalent NBIA 
subtype, PKAN. We have identified mutations in the COASY gene in two subjects with clinical and 
MRI features typical of NBIA. We have proposed CoPAN, standing for COASY protein-associated 
neurodegeneration, as the acronym for NBIA caused by CoA synthase mutations to conform with 
the current nomenclature in use to classify these disorders. 
Both CoPAN patients identified, had a severe neurological disorder but they have survived up to the 
third decade of life, suggesting the presence of residual amount of CoA. The complete absence of 
CoA would be probably incompatible with life, and organisms have developed alternative strategies 
to counteract deleterious effects of mutations in CoA enzymatic pathway. Considering the 
ubiquitous presence of the enzymatic COASY activity, it remains unexplained why only the brain is 
affected and other organs are preserved. It is possible that a more severe impairment of CoA levels 
occurs in this organ. Moreover, it is relevant to notice that the mutations afflicting genes coding for 
pantothenate kinase and PPAT activity of CoA synthase are the two rate limiting steps in CoA 
biosynthesis. All together these factors could contribute to modulate the clinical presentation of 
individuals carrying COASY mutations. 
A yeast model for CoPAN disease was generated to better study CoA biosynthesis defects. In 
Saccharomyces cerevisiae the last two steps of CoA biosynthesis are catalyzed by two separate 
enzymes, namely the product of CAB4 and CAB5 genes. Since we have demonstrated that the 
lethality associated to deletion in CAB5 could be complemented by human COASY, we have further 
studied the human Arg499Cys substitution in yeast to support the pathogenic role of this mutation. 
The evaluation of the metabolic consequences of coenzyme A deficiency in yeast, revealed 
mitochondrial dysfunctions and a reduction of the activity of respiratory chain complexes. We also 
demonstrated that the growth of the mutant strain is not only strongly inhibited in the presence of 
iron but that the mutant strain showed iron accumulation. This result is consistent with the patient 
phenotype, with iron overload being a typical sign of PKAN and CoPAN. Since acetyl-CoA, one of 
the most important derivatives of CoA, is also required for the synthesis of fatty acids, we have 
analyzed the lipid droplets content in mutant yeast strain and observed it was 25% reduced. These 
results are in agreement with the hypothesis that low CoA perturbs lipid homeostasis. The 
 transcriptional analysis of key genes involved in lipid metabolism would help in elucidating the role 
of lipid metabolism in the pathology. 
Identification of mutations in COASY strongly reinforces the essential role of CoA biosynthetic 
pathway for the development and functioning of the nervous system. This also underlines the 
importance of further investigations on different subcellular pools of CoA available, because a 
specific mitochondrial pathway could exist considering that both PANK2 and COASY are 
mitochondrial enzymes. 
The reason why iron accumulates in human brain in CoPAN and PKAN disease is still unknown. A 
previous study demonstrated that PANK2 deficient fibroblasts showed an alteration of oxidative 
status in response to treatment with iron [Campanella et al., 2012]. As mitochondrial iron 
homeostasis and cytosolic iron homeostasis are strictly correlated, we hypothesize that iron 
mishandling could also occur in the mitochondria, thereby affecting organelle functionality. We 
have detected a larger mitochondrial labile iron pool (LIP) also under basal conditions, whereas the 
increase in the size of the cytosolic LIP was appreciable only after chronic iron supplementation. 
Nevertheless, the availability of high levels of mitochondrial iron did not appear to be properly 
utilized in iron sulphur cluster (ISC) and heme biosynthesis, thus they resulted defective in PKAN 
fibroblasts. A recent study on isolated mammalian mitochondria demonstrated that ISC biosynthesis 
requires, other than iron and sulphur, also GTP, NADH and ATP [Pandey et al., 2015]. A 
hypothesis could be that the impairment of the Krebs cycle due to CoA deficiency might result in 
lower production of GTP and NADH, with the consequent partial iron utilization in ISC 
biosynthesis. Moreover, other mitochondrial features appeared defective in PKAN cells, such as the 
mitochondrial membrane potential and mitochondrial morphology, suggesting a global organelle 
impairment, which can lead to energetic failure. We cannot exclude the possibility that the energetic 
impairment detected in PKAN fibroblasts, could also derive from membrane alterations due to CoA 
deficiency-induced defects in phospholipid synthesis; more detailed studies are needed to clarify 
this point. In fact, the partial mitochondrial swelling and depolarisation detected in PKAN 
fibroblasts suggest mitochondrial membrane damage. However, studies on isolated rat liver 
mitochondria reported that iron may catalyze lipids peroxidation in the mitochondrial inner 
membrane, which can result in a limited depolarisation [Gall et al., 2012]. 
Even if iron deregulation in PKAN may play a secondary role, its accumulation is harmful. Certain 
brain regions, such as the globus pallidus and the substantia nigra, have high iron content, which is 
necessary for the synthesis of neurotransmitters. These regions are particularly prone to the process 
of abnormal intracellular iron distribution, which may also contribute to the age-dependent iron 
accumulation. We approached this question obtaining human neurons starting from fibroblasts, and 
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we confirmed the presence of an altered oxidative status and mitochondrial function impairment in 
PKAN induced neurons. 
An altered mitochondrial membrane potential was also detected in neurons derived from a Pank2
-/- 
mouse model [Brunetti et al., 2012]. Based on the role of CoA in several metabolic pathways and 
considering the data obtained by a metabolomics approach in patients with PKAN, indicating the 
presence of impairment in lipid metabolism [Leoni et al., 2012], we tested the hypothesis to 
challenge the Pank2
-/- 
mouse model with a diet containing high fat levels. Ketogenic diet consists of 
a low glucose and high lipid content, stimulating lipid use by mitochondrial beta-oxidation and 
ketone body production in the liver. We demonstrate that the introduction of the ketogenic diet 
resulted in the onset of a severe phenotype in Pank2
-/- 
mice characterized by motor dysfunctions, 
neurological impairment with feet-clasping, and exacerbated mitochondrial alterations. It is reported 
that the compound pantethine can work as a precursor of CoA in PKAN model of Drosophila, even 
in the presence of severely reduced levels of functional pantothenate kinase and that it was able to 
rescue brain degeneration, mitochondrial dysfunction and locomotor disabilities [Rana et al., 2010]. 
In Pank2
-/- 
mice on a ketogenic diet, we have observed the rescue of the clinical phenotype 
including the movement disorder, the amelioration of the mitochondrial dysfunctions, and the 
extension of the lifespan after pantethine administration. Treatment with pantethine dramatically 
improved both the histological features of neurodegeneration and the ultrastructural mitochondrial 
damage in Pank2
-/- 
mice fed a ketogenic diet. We have also demonstrated that pantethine 
administration was able to rescue the mitochondrial phenotype in neurons derived from Pank2
-/- 
mice on a standard diet, indicating that its effectiveness was not dependent on or influenced by the 
ketogenic treatment. It is known that pantethine is rapidly converted into cysteamine and 
pantothenate by the vanin enzyme, also known as pantetheine hydrolase or pantetheinase [Kaskow 
et al., 2012]. Although pantethine is not able to cross the blood brain barrier, it was demonstrated 
that cysteamine can cross the blood brain barrier and can exert its positive effects [Bousquet et al. 
2010]. Cysteamine is able to upregulate the expression of the brain derived neurotrophic factor 
(BDNF). These neuroprotective effects of cysteamine have been hypothesized to reflect the positive 
actions of this compound in Parkinson’s disease [Sun et al., 2010; Gibrat and Cicchetti, 2011] and 
Huntington’s disease [Borrell-Pages et al., 2006]. In agreement with these data, we can hypothesize 
that the beneficial effects of pantethine in our model system were due to its conversion into 
pantothenate and cysteamine. Moreover, it is important to consider that environmental factors, such 
as food intake, together with genetic background could modulate the disease presentation by 
worsening or, on the contrary, stabilizing the progression of the symptoms. This could also explain 
the variability of the clinical presentation of the disease, with a spectrum of syndromes ranging 
 from rapid to slowly progressive. We finally suggest that pantethine administration to patients with 
PKAN should be considered as a possible, safe and non-toxic therapeutic approach. 
In conclusion, we have demonstrated that an altered lipid metabolism, as a result of CoA 
biosynthesis defect, could represent one of the main causes of NBIA disease. It is also possible, as 
demonstrated by the presence of mitochondrial alteration in mouse model, in the muscle and skin 
fibroblasts derived from PKAN patients and in CoPAN yeast model, that mitochondria play a 
relevant role or could be a concurrent cause in the pathogenic mechanism of NBIA.   
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Pantothenate kinase-associated neurodegeneration, caused by mutations in the PANK2 gene, is an autosomal recessive disorder
characterized by dystonia, dysarthria, rigidity, pigmentary retinal degeneration and brain iron accumulation. PANK2 encodes the
mitochondrial enzyme pantothenate kinase type 2, responsible for the phosphorylation of pantothenate or vitamin B5 in the
biosynthesis of co-enzyme A. A Pank2 knockout (Pank2/) mouse model did not recapitulate the human disease but showed
azoospermia and mitochondrial dysfunctions. We challenged this mouse model with a low glucose and high lipid content diet
(ketogenic diet) to stimulate lipid use by mitochondrial beta-oxidation. In the presence of a shortage of co-enzyme A, this diet
could evoke a general impairment of bioenergetic metabolism. Only Pank2/ mice fed with a ketogenic diet developed a
pantothenate kinase-associated neurodegeneration-like syndrome characterized by severe motor dysfunction, neurodegeneration
and severely altered mitochondria in the central and peripheral nervous systems. These mice also showed structural alteration of
muscle morphology, which was comparable with that observed in a patient with pantothenate kinase-associated neurodegen-
eration. We here demonstrate that pantethine administration can prevent the onset of the neuromuscular phenotype in mice
suggesting the possibility of experimental treatment in patients with pantothenate kinase-associated neurodegeneration.
Keywords: pantothenate kinase-associated neurodegeneration (PKAN); mitochondria; ketogenic diet; pantethine
Abbreviation: PKAN = pantothenate kinase-associated neurodegeneration
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Introduction
The common feature of a group of genetic disorders, termed
neurodegeneration with brain iron accumulation, is brain iron
overload identified by radiological and histopathological examin-
ations (Kruer et al., 2012). Different subtypes of neurodegenera-
tion with brain iron accumulation have been defined at the genetic
level but pantothenate kinase-associated neurodegeneration
(PKAN) syndrome is the most frequent form.
PKAN is caused by mutations in the PANK2 gene, which codes
for the mitochondrial enzyme pantothenate kinase 2. This enzyme
is involved in the co-enzyme A biosynthetic pathway, catalysing
the phosphorylation of vitamin B5 or pantothenate (Hayflick,
2003). PKAN usually manifests in childhood with gait disturbances
and rapidly progresses to a severe movement deficit with dystonia,
dysarthria and dysphagia. The hallmark of this disease is the eye-
of-the-tiger signal in the globus pallidus on T2-weighted MRI
(Hayflick et al., 2003; Gregory et al., 2009)
To date, the mechanistic connection linking PANK2 dysfunction,
neurodegeneration and alteration of iron homeostasis has not
been understood, thus preventing our comprehension of the
pathogenesis of the disease and the design of efficient therapeutic
strategies. It has been proposed that reduced PANK2 enzymatic
activity determines the accumulation of cysteine, which may che-
late iron thus promoting the formation of free radicals (Gregory
et al., 2008); alternatively, defects in co-enzyme A and, as a
consequence, in phospholipid metabolism may damage the mem-
branes and lead to increased oxidative stress, which may alter iron
homeostasis (Leonardi et al., 2007).
The mouse models of PKAN display incomplete phenotypes,
including hardly any brain iron accumulation. Pank2/ mice
show growth reduction, retinal degeneration, male infertility
because of azoospermia (Kuo et al., 2005), and mitochondrial
dysfunctions (Brunetti et al., 2012) under standard diet conditions.
Retinal degeneration (Kuo et al., 2005) was not confirmed in a
recent Pank2 knockout mouse (Garcia et al., 2012) and this
phenotype is uncertain. A movement disorder was present in
mice on a pantothenic acid-deficient diet (Kuo et al., 2007).
A Pank1 knockout mouse (Leonardi et al., 2010) displayed a
metabolic disorder characterized by altered fatty acid oxidation
and gluconeogenesis, causing mild hypoglycaemia. An additional
mouse model consisting of a double Pank1/Pank2 knockout
(Garcia et al., 2012) showed a severe phenotype characterized
by hypoglycaemia and hyperketonaemia leading to dysfunctional
post-natal development and premature death at 17 days.
Based on the role of co-enzyme A in several crucial cellular meta-
bolic pathways, we tested the hypothesis to stress the Pank2/
mouse model with a high-fat ketogenic diet. Ketone bodies pro-
duced by the ketogenic diet through fatty acid oxidation bypass
glycolysis and enter the citric acid cycle to produce oxidative phos-
phorylation (OXPHOS) substrate. Mice on a ketogenic diet use
mainly fatty acid oxidation and OXPHOS for ATP production as
compared to mice on a standard diet (Laffel, 1999). We observed
that only ketogenic diet-fed Pank2/ mice presented typical signs
of neurological and motor impairment, as well as neuropathological
findings, resembling the phenotype observed in patients with PKAN.
Moreover, these mice showed muscular dysfunctions with mito-
chondrial morphological alterations, which were also detected in
the muscle of a patient with PKAN.
Recently, a PANK2 knockout Drosophila model has shown that
panthethine can serve as a compound to bypass the block due to
severe impairment of pantothenate kinase and that it is able to res-
cue brain degeneration, mitochondrial dysfunction and locomotor
disabilities (Rana et al., 2010).
To determine if pantethine was able to counteract the disease
phenotype elicited in ketogenic diet-fed Pank2/ mice, we con-
tinuously administered pantethine in drinking water during the keto-
genic treatment. Our data indicated that pantethine treatment was
safe, with no side effects and was able to ameliorate both the ma-
jority of the symptoms in the nervous and muscular systems and the
morphological features of neuronal and mitochondrial damage.
Materials and methods
Animals and diets
Animal studies were approved by the Ethics Committee of the
Foundation IRCCS Neurological Institute C. Besta, in accordance
with guidelines of the Italian Ministry of Health: Project no. BT4/
2011. The use and care of animals followed the Italian Law D.L.
116/1992 and the EU directive 86/609/CEE.
Standard diet (Mucedola), ketogenic diet (E15149-30, ssniff
Spezialdiaten) and water were given ad libitum. Ketogenic diet compos-
ition: 79.2 % fat; 8% protein; 5% crude fibre; 4.5 % crude ash; 0.6%
starch; 0.7% sugar (31.6 MJ/kg), with multi-vitamin addition.
Pantethine (Sigma) was administered at a concentration of 15 mg/kg/
day in drinking water. The JM129/SvJ-C57BL/6 Pank2+ / mice used in
this study were kindly provided by Professor Hayflick (Kuo et al., 2005).
Animals were housed two or three in a cage, in a temperature-
controlled (21C) room with a 12 h light-dark cycle and 60% relative
humidity.
The experimental design included four groups of mice: (i) the
‘standard diet’ group composed of eight Pank2/ mice (four male
and four female) and nine Pank2+/+ (five male and four female) on a
standard diet for 2 months; (ii) the ‘standard diet + pantethine’ group
composed of eight Pank2/ mice (four male and four female) and 12
Pank2+ /+ (five male and seven female) on a standard diet with the
concomitant administration of pantethine for 2 months; (iii) the ‘keto-
genic diet’ group composed of 20 Pank2/ mice (nine male and 11
female) and 26 Pank2+ /+ (11 male and 15 female) on an ad libitum
ketogenic diet for 2 months; and (iv) the ‘ketogenic diet + pantethine’
group composed of 13 Pank2/ mice (five male and eight female)
and 16 Pank2+ /+ (five male and 11 female) on an ad libitum keto-
genic diet with the concomitant administration of pantethine.
Behavioural and motor skills analysis
The different groups were monitored weekly for onset of postural
abnormalities, loss of weight and general behavioural changes. We de-
tected spontaneous motor activity over a continuous period of 15 h (at
any time between 17:00 pm and 08:00 am) in an activity cage (Ugo
Basile) for four single-gender groups of 3-month-old Pank2+/+ and
Pank2/ mice, each comprising three mice of each genotype. In
total 12 Pank2+/+ and 12 Pank2/ mice were analysed.
2 | Brain 2013: Page 2 of 12 V. Tiranti et al.
 at Fondazione IRCCS Istituto N
eurologico Carlo Besta on D
ecem
ber 11, 2013
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
Measure of motor exercise endurance was evaluated using a tread-
mill apparatus (Columbus Instruments) counting the number of falls in
the motivational grid during a gradually accelerating program with
speed initially at 3.8 m/min and increasing by 3 m/min every 2 min.
The test was terminated by exhaustion, defined by 410 falls/min into
the motivational grid.
A footprint test was performed by painting hindlimbs with non-toxic
ink and placing mice at one end of an enclosed, dark tunnel on white
paper. Mice walked along a 28 cm long, 7 cm wide strip; stride length
and width of consecutive steps were measured. These tests were car-
ried out in 3-month-old mice to monitor the phenotype.
Histology, histochemistry and
immunohistochemistry
Histological, histochemical and immunohistochemical analyses were
performed on formalin-fixed and paraffin-embedded brain tissues
from the following treatment groups: standard diet Pank2+ /+
(n = 2); standard diet Pank2/ (n = 2); ketogenic diet Pank2+/+
(n = 4); ketogenic diet Pank2/ (n = 5); ketogenic diet + pantethine
Pank2+/+ (n = 3); ketogenic diet + pantethine Pank2/ (n = 3).
Briefly, whole formalin-fixed brains were cut in 2-mm thick slices
along the sagittal plane, and embedded in formalin. Five to 10-mm
thick serial sections were stained with haematoxylin-eosin, periodic
acid Schiff, Luxol fast blue and Perls’ stain. Immunohistochemistry
was performed using antibodies against amyloid precursor protein
(Abcam, 1:200), heavy molecular weight neurofilament (Abcam,
1:2000); ubiquitin (Dako, 1:50); phosphorylated tau (Abcam, 1:50),
alpha synuclein phospho specific (Covance, 1:200), NeuN (Millipore,
1:500), and glial fibrillary acidic protein (GFAP; Dako, 1:100).
Left quadricep skeletal muscle biopsies were performed in patients
according to a protocol approved by the Foundation IRCCS
Neurological Institute C. Besta. Morphological analysis in patient and
mouse skeletal muscle tissue was carried out on 8 mm cryostat sections
using standard histological and histochemical techniques (Dubowitz
et al. 1973). The reactions for COX and SDH were performed as
previously described (Sciacco and Bonilla, 1996). The following treat-
ment groups were analysed: standard diet Pank2+/+ (n = 2); standard
diet Pank2/ (n = 2); ketogenic diet Pank2+ /+ (n = 2); ketogenic
diet Pank2/ (n = 2); ketogenic diet + pantethine Pank2+ /+ (n = 2);
and ketogenic diet + pantethine Pank2/ (n = 2).
Evaluation of mitochondrial
bioenergetics
We analysed mitochondrial energy metabolism in isolated mitochon-
dria derived from brains of standard diet Pank2+/+ (n = 3); standard
diet Pank2/ (n = 3); standard diet + pantethine Pank2+/+ (n = 3);
and standard diet + pantethine Pank2/ (n = 3) mice, using an XF96
Extracellular Flux Analyzer (Seahorse Bioscience) as previously reported
(Brunetti et al., 2012).
Derivation of neurons from sciatic
nerve and analysis of mitochondrial
membrane potential
Detection of mitochondrial potential was performed using JC1 staining
kit on neurons derived from sciatic nerves isolated from adult mouse as
previously described (Brunetti et al., 2012).
Electron microscopy analysis
Sciatic nerve analysis was performed on the following treatment
groups: standard diet Pank2+/+ (n = 1); standard diet Pank2/
(n = 1); ketogenic diet Pank2+ /+ (n = 3); ketogenic diet Pank2/
(n = 3); ketogenic diet + pantethine Pank2+ /+ (n = 3); and ketogenic
diet + pantethine Pank2/ (n = 3). Sciatic nerves were surgically
removed and processed for epoxy resin embedding as previously
described (Brunetti et al., 2012). In particular, each sciatic nerve was
cut in proximal, middle and distal segments and dehydrated separately.
Ultrastructural analyses were conducted on each stump. Brain ultra-
structural analysis was performed on the following treatment groups:
standard diet Pank2+/+ (n = 1); standard diet Pank2/ (n = 1);
ketogenic diet Pank2+ /+ (n = 3); ketogenic diet Pank2/ (n = 3);
ketogenic diet + pantethine Pank2+ /+ (n = 3); and ketogenic diet +
pantethine Pank2/ (n = 3). Sagittally spliced brains were fixed by
immersion in glutaraldehyde (2.5% in phosphate buffer). After fix-
ation, serial sagittal slides of 1-mm thick were obtained. Selected
areas of interest were sampled, post-fixed in osmium tetroxide and
embedded in EponTM epoxy resin. Thin sections (80–90 nm) were
stained with uranyl acetate and lead citrate and examined with a
CM10 Philips electron microscope.
Patient and mouse muscle tissues were fixed in 2.5% glutaralde-
hyde, processed as previously described (Napoli et al., 2011) and
post-fixed in 2% osmium tetroxide for 1 h. After dehydration, the
specimens were embedded in epoxy resin. Ultrathin sections were
cut and stained with uranyl acetate and lead citrate, then examined
with a Zeiss electron microscope.
Results
Mice phenotyping
We constantly monitored the weight of Pank2+/+ and Pank2/
mice during the administration of standard or ketogenic diet. As
also previously reported (Kuo et al., 2005) Pank2/ mice under
standard diet showed a slight weight reduction as compared with
Pank2+/+ mice, whereas during ketogenic treatment Pank2/
mice showed a fast and progressive weight loss (Fig. 1A and B).
Moreover, only Pank2/ mice fed a ketogenic diet manifested
kyphosis with hunched position, (Fig. 1C), feet clasping (Fig. 1D),
whitening of the fur and rigidity of the tail (Fig. 1E), as well as
dystonic limb positioning (Fig. 1F).
We asked whether these signs could have been prevented by
pantethine administration. To this aim we treated a group of
Pank2+/+ and Pank2/ mice (‘ketogenic diet + pantethine’
group) with a ketogenic diet and the concomitant administration
of pantethine (15 mg/kg/day) in drinking water. This concentra-
tion was established based on a dosage of 900 mg/day in an adult
individual (n = 14) considering an average weight of 60 kg. We
also tested various concentrations of pantethine in mice over 3
weeks and determined that a dose of up to 480 mg/kg/day was
tolerated without any side effects on weight and drinking intake
(Supplementary Fig. 1).
We observed that, with pantethine administration to mice fed a
ketogenic diet, the weight of Pank2/ mice was similar to that of
Pank2+/+ mice (Fig. 1G), no signs of kyphosis or feet clasping were
present (Fig. 1H) and body size approached that of Pank2/ mice
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fed a standard diet (Fig. 1I). Most importantly, Pank2/ mice fed
a ketogenic diet died after 2 months whereas the administration of
pantethine prolonged their survival for up to 5 months (Fig. 1J). We
could not verify the recovery of retina degeneration as this initial
observation (Kuo et al., 2005) was not confirmed by our own in-
vestigations and also not reported in another Pank2 knockout
mouse model (Garcia et al., 2012). On the contrary, azoospermia
was confirmed in mice fed a standard diet and ketogenic diet but
was not rescued by pantethine treatment during the period of our
observation and with the dose used.
Motor performance evaluation
Pank2/ mice fed a ketogenic diet were lethargic and showed a
significant reduction of spontaneous movements as compared with
Pank2+ /+ mice fed a ketogenic diet, whereas no differences were
observed when fed a standard diet (Fig. 2A).
Quantitative motor tests revealed significantly lower activity in
Pank2/ mice on a ketogenic diet as compared with Pank2+ /+
mice; no differences were evident on a standard diet (Fig. 2B). The
footprint patterns were assessed quantitatively by measuring stride
length and hind base width. We found that Pank2/ mice on a
ketogenic diet exhibited shorter stride lengths and hind paw
width, and an irregular gait as compared with Pank2+ /+ mice
on a ketogenic diet (Fig. 2C). All of these abnormalities were re-
covered by pantethine treatment and Pank2/ mice behaved in
the same way as their control littermates (Fig. 2A–C).
Neuropathology of Pank2/ mice fed
a ketogenic diet
On histological and immunohistochemical analysis of the whole
brains we did not observe massive neural loss, gliosis or demye-
lination in Pank2/ mice on a standard diet or a ketogenic diet
(data not shown). However, we noticed the presence of small,
scattered groups of neurons with eosinophilic, periodic acid
Schiff-positive round cytoplasmic inclusions (Fig. 3A–C). These
features were observed only in Pank2/ mice on a ketogenic
diet, and were located mostly in the midbrain, putamen and
amygdala. On immunohistochemistry, the inclusions were sharply
positive for ubiquitin (Fig. 3D and F) and negative for amyloid
precursor protein, phosphorylated tau, -synuclein, and high mo-
lecular weight neurofilaments (not shown). In addition, ubiquitin
Figure 1 Mice phenotype. (A) Body weight of Pank2+/+ and Pank2/ mice fed a standard diet (SD). (B) Body weight of Pank2+/+
and Pank2/ mice on a ketogenic diet (KD). (C) Kyphosis with hunched position; (D) feet clasping in ketogenic diet-fed Pank2/
(arrow); (E) whitening of the fur and rigidity of the tail in ketogenic diet-fed Pank2/; (F) dystonic hindlimb position. (G) Body weight of
Pank2/ mice was similar to that of Pank2+/+ fed a ketogenic diet with pantethine administration (KD + P). (H) No sign of kyphosis or
feet clasping were present in Pank2/ mice on a ketogenic diet with pantethine administration (arrow). (I) Comparison of Pank2/
body size in mice on standard (SD), ketogenic (KD) and ketogenic + pantethine (KD + P) diets (J) Survival curves for different diet
conditions: Pank2/ mice fed a ketogenic diet died after 2 months (dotted green line); Pank2+/+ mice fed a ketogenic (dotted yellow
line); Pank2+/+ mice fed a ketogenic diet with pantethine (dotted pink line); Pank2/ mice fed a ketogenic diet with pantethine
administration prolonged their survival by up to 5 months (orange line); Pank2/ mice fed a standard diet (dotted brown line); and
Pank2+/+ mice fed a standard diet (blue line). In A, B and G, the red symbols indicate Pank2/; blue symbols indicate Pank2+/+ .
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stain highlighted finely granular cytoplasmic deposits in several
neurons, as well as large, ubiquitin positive degenerating neurons
(Fig. 3D and E). Iron deposits were not observed with Perl’s stain
(data not shown).
Pantethine treatment of Pank2/ mice on a ketogenic diet led
to the disappearance of neuronal cytoplasmic inclusion on haema-
toxylin-eosin and periodic acid Schiff stain. Ubiquitin was merely
detectable by immunohistochemistry after treatment (Fig. 3G) and
Figure 2 Motor performance evaluation. (A) Activity cage: no differences were observed in Pank2+/+ and Pank2/ mice on a standard
diet (SD) or with pantethine (SD + P); Pank2+/+mice were more active with pantethine treatment (*P50.05, two-tailed, unpaired
Student’s t-test). Pank2/ mice fed a ketogenic diet were lethargic and showed a significant reduction of spontaneous movements as
compared with Pank2+/+ mice on a ketogenic diet (**P50.001, two-tailed, unpaired Student’s t-test). Pantethine treatment (KD + P)
rescues the reduced movements. (B) Treadmill test: no differences in the distance travelled by Pank2+/+ and Pank2/ mice on a
standard diet (SD) or with pantethine (SD + P). Pank2/ mice on a ketogenic diet ran only 50 m as compared to 180 m of Pank2+ /+
mice (**P50.001, two-tailed, unpaired Student’s t-test). Pantethine treatment (KD + P) restored the running capability in Pank2/
mice and increased the performance in Pank2+/+ mice (*P50.05, two-tailed, unpaired Student’s t-test). (C) Footprint pattern:
Pank2/ mice fed a ketogenic diet showed shorter stride lengths and hind paw width, and an irregular gait as compared with Pank2+ /+
mice fed a ketogenic diet. Pantethine treatment (KD + P) abolishes the movement disorders. In A and B, the red bars indicate Pank2/
mice and blue bars indicate Pank2+ /+ mice, respectively.
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completely absent in ketogenic diet-Pank2+/+ mice brain
(Fig. 3H).
Ultrastructural features of central and
peripheral nervous systems
Ultrastructural analysis was performed on basal ganglia and periph-
eral nerve of Pank2/ and Pank2+/+ mice under different diet
conditions. In the basal ganglia, Pank2/ animals on a standard
diet showed the presence of numerous mitochondria with abnor-
mal, swollen cristae (Fig. 4). These features were worsened by a
ketogenic diet, which led to focal loss of cristae (Fig. 4). Pank2/
animals fed a ketogenic diet also showed cytoplasmic deposits of
lipofuscin (data not shown). Notably, pantethine administration
completely rescued the mitochondrial morphology of Pank2/ ani-
mals on a standard diet, which were indistinguishable from the
wild-type littermates (Fig. 4), and ameliorated the morphology of
ketogenic diet-fed Pank2/ mice (Fig. 4).
Ultrastructural analysis of peripheral nerve of Pank2/ animals
on a ketogenic diet showed the presence of swollen mitochondria,
characterized by cristae degeneration and by the presence of
amorphous material in the matrix (Fig. 5). Pantethine
Figure 3 Histology and immunohistochemistry of brains from Pank2/ mice fed a ketogenic diet and a ketogenic diet with pantethine.
The analysed animals were 3 months old. Round, eosinophilic, periodic acid Schiff-positive cytoplasmic inclusions were present in neurons
of Pank2/ mice fed a ketogenic diet (A–C, arrows in B and C). Cytoplasmic bodies are markedly positive on ubiquitin immunostain
(D and F, arrows). Scattered neurons showed a finely granular cytoplasmic stain for ubiquitin (D and E, asterisks). There were large
degenerating neurons with a diffuse positivity for ubiquitin (E, arrowhead). Ubiquitin stain was barely detected in neurons from Pank2/
mice fed a ketogenic diet with pantethine (G), which show histological and immunohistochemical features similar to their wild-type
littermates (H). Scale bars = 25 mm.
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administration was able to completely rescue the mitochondrial
morphology both in the PNS and CNS. No ultrastructural alter-
ations were observed in Pank2+/+ mice fed with standard or
ketogenic diets (Figs 4 and 5).
Pantethine restores mitochondrial
membrane potential of Pank2/
neurons
To evaluate mitochondrial membrane potential we used JC1
staining. As shown in Fig. 6, neurons derived from Pank2+ /+
animals treated with a standard or ketogenic diet presented red
fluorescent aggregates indicating the preservation of the mito-
chondrial membrane potential. On the contrary, neurons derived
from Pank2/ mice treated with a standard or ketogenic diet
presented with a diffuse green fluorescence (Fig. 6) confirming
the presence of a defective mitochondrial membrane potential.
Interestingly, neurons derived from Pank2/ mice under
Figure 5 Electron microscopy of peripheral nerve in Pank2+ /+
and Pank2/ mice under different diet conditions. The ana-
lysed animals were 3 months old. Sciatic nerve axons of
Pank2+ /+ mice on a standard diet (SD), standard diet + pan-
tethine (SD + P), ketogenic diet (KD) and ketogenic diet +
pantethine (KD + P) contain morphologically normal mito-
chondria. Sciatic nerve axons of Pank2/ mice on a standard
diet and ketogenic diet show swollen mitochondria with altered
cristae (arrows). Sciatic nerve axons of Pank2/ mice on a
standard diet + pantethine and ketogenic diet + pantethine
show a high prevalence of normally-shaped mitochondria
with regular cristae organization (arrowheads). Scale
bars = 500 mm.
Figure 4 Electron microscopy of basal ganglia in Pank2+ /+ and
Pank2/ mice under different diet conditions. The analysed
animals were 3 months old. Pank2+ /+ mice on a standard diet
(SD), a standard diet + pantethine (SD + P), ketogenic diet (KD)
and ketogenic diet + pantethine (KD + P) show normal mito-
chondria. Pank2/ mice on a standard diet show mitochondria
with swollen cristae (asterisks and insert). With a ketogenic diet
the mitochondrial morphology is worsened with focal loss of
cristae (arrow and insert). Pank2/ mice on standard diet with
pantethine were similar to wild-type littermates; with a keto-
genic diet with pantethine there is a prevalence of mitochondria
with normal cristae morphology, although a few mitochondria
still showed swollen cristae.
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standard and ketogenic treatment plus the addition of pantethine
in drinking water, showed predominantly red fluorescence aggre-
gates indicating that the mitochondrial membrane potential was
preserved.
Pantethine improves mitochondrial
respiration
We evaluated respiration with microscale oxygraphy on mitochon-
dria isolated from brains of Pank2+/+ and Pank2/ mice
treated with pantethine and we compared the results with
untreated mice. Measurement was not performed in mitochondria
derived from mice under ketogenic treatment because of tech-
nical difficulties, probably due to the presence of increased fat
levels in the brain. We measured basal oxygen consumption
rate, and oxygen consumption rate after ADP addition,
and after oligomycin addition. We observed that pantethine was
able to significantly increase oxygen consumption rate under all
conditions tested in both Pank2+/+ and Pank2/ mitochondria
(Fig. 7). In particular, pantethine determines a doubling in oxygen
consumption rate after ADP stimulation suggesting a tightly
coupled respiration with ATP production.
These differences were statistically significant as
demonstrated by an unpaired, two-sided Student’s t-test, assum-
ing unequal variance. Values for statistical significance were set at
P5 0.05.
Comparison of muscle derived from
Pank2/ mice on a ketogenic diet
versus a patient with pantothenate
kinase-associated neurodegeneration
COX histochemical reaction of the muscle derived from Pank2/
mice fed a ketogenic diet revealed a peculiar staining pattern, likely
because of the presence of abnormal mitochondria (Fig. 8A). We
had the opportunity to study the muscle biopsy of a 6-year-old
patient with PKAN (PANK2 mutations: N500I + IVS2-1G4A).
We did not observe any defects in the respiratory chain enzymatic
activities apart from a succinate dehydrogenase (SDH) activity
below the lower control value (not shown), but we found the
same COX staining pattern (Fig. 8B) observed in mice. To charac-
terize these mitochondria further we performed electron micros-
copy, which highlighted the presence of giant mitochondria
spanning the sarcomere between two neighbouring Z-lines and
showing irregularly shaped cristae (Fig. 8C).
The histological alterations of the Pank2/ muscle highlighted by
both trichrome and COX staining were absent in pantethine-treated
mice (Fig. 9). Moreover, no histological abnormalities were evident in
standard diet or ketogenic diet Pank2+/+ muscle (Fig. 9).
Plasma analysis
Plasma analysis showed an increase of cholesterol (Supplementary
Fig. 2A) and triglycerides (Supplementary Fig. 2B) in mice on a
Figure 6 Membrane potential in Pank2+ /+ and Pank2/ neurons derived from mice under different diet conditions. Neurons derived
from Pank2+ /+ animals treated with a standard (SD) or ketogenic diet (KD), with or without pantethine (P) presented red fluorescent
aggregates indicating the preservation of the mitochondrial membrane potential. Neurons derived from Pank2/ mice treated with a
standard or ketogenic diet presented with a diffuse green fluorescence confirming the presence of a defective mitochondrial membrane
potential. Neurons derived from Pank2/ mice with standard and ketogenic treatment plus the addition of pantethine, showed
predominantly red fluorescence aggregates, indicating preservation of mitochondrial membrane potential. Scale bars = 100 mm.
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ketogenic diet. As expected, pantethine was able to reduce the
levels of both (Supplementary Fig. 2A and B). A decrease of glu-
cose levels was detected in mice fed a ketogenic diet and a keto-
genic + pantethine diet (Supplementary Fig. 2C). Ketosis was
observed in mice fed a ketogenic diet and was maintained
during pantethine administration (Supplementary Fig. 2D).
Discussion
The Pank2/ mouse model did not recapitulate the clinical and
neuropathological features of the human condition (Kuo et al.,
2005; Brunetti et al., 2012). Based on the role of co-enzyme A
in several crucial metabolic pathways and considering the data
obtained by a metabolomics approach in patients with PKAN,
indicating the presence of impairment in lipid metabolism, we
tested the hypothesis to challenge this mouse model with a diet
containing high fat levels. Ketogenic diet consists of a low glucose
and high lipid content, stimulating lipid use by mitochondrial beta-
oxidation and ketone body production in the liver. Ketone bodies
are high-energy-content compounds that can be used as an
energy source by the brain, heart and skeletal muscle. We admin-
istered a low carbohydrate high-fat ketogenic diet to 2-month-old
Pank2/ and Pank2+ / + mice and evaluated the clinical and
biochemical phenotype.
We demonstrate here that the introduction of the ketogenic diet
resulted in the onset of a severe phenotype in Pank2/ mice
characterized by motor dysfunctions, neurological impairment
with feet-clasping, and exacerbated mitochondrial alterations,
which were also present in the brain and PNSs of 12-month-old
Pank2/ mice on a standard diet (Brunetti et al., 2012).
Moreover, this diet caused the premature death of Pank2/
mice.
Pank2/ mice fed a ketogenic diet did show the clinical signs
present in patients with PKAN, namely more severe movement
disorder and neurodegeneration. Importantly, these animals
showed histological and immunohistochemical features of neuro-
degeneration, with cytoplasmic accumulation of abnormal, ubiqui-
nated proteins as observed in the brains of patients with PKAN
(Kruer et al., 2011). However, the exact nature of the ubiquiti-
nated proteins in our model remains to be elucidated. As observed
in humans, cytoplasmic inclusions in Pank2/ mice were nega-
tive for -synuclein, confirming that PKAN neuropathological
findings are different from other forms of neurodegeneration
with brain iron accumulation.
We did not observe iron accumulation in Pank2/ mice on a
ketogenic diet, in contrast to that observed in human PKAN
brains. We cannot exclude that iron levels could be below the
detection level for the histological technique or that iron accumu-
lates over a period of time beyond our observation. These aspects
are still to be clarified and require further investigation.
The induction of a PKAN-like phenotype in Pank2/ mice fed
with a ketogenic diet, allowed us to have a model in which to test
therapeutic compounds. Recently, in the Drosophila dPANK/fbl
mutants it was shown that panthethine can work as a precursor
of co-enzyme A, even in the presence of severely reduced levels of
Figure 8 Muscle COX (cytochrome c oxidase) histochemical reaction and electron microscopy. (A) Pank2/ mice on a ketogenic diet.
(B) Patient with PKAN revealed the same peculiar staining pattern as mice fed a ketogenic diet. (C) Electron microscopy highlighted
the presence of giant mitochondria spanning the sarcomere between two neighbouring Z-lines and showing irregularly shaped cristae
(20 000).
Figure 7 Evaluation of mitochondrial bioenergetics status.
Oxygen consumption rate (OCR) in mitochondria isolated from
brains of Pank2+ /+ and Pank2/ mice treated with pantethine
and compared with untreated mice. We measured basal oxygen
consumption rate (OCR-B) after ADP addition (OCR-ADP), and
after oligomycin addition (OCR-O). Pantethine was able to
significantly increase oxygen consumption rate in both
Pank2+/+ and Pank2/ mitochondria, especially ADP-induced
respiration. Black, white and grey histograms indicate OCR-B, -
ADP, and -O, respectively. Bars indicate the standard deviation
(SD). **P50.01; *** P50.001 (unpaired, two-tail Student’s
t-test). WT = wild-type; KO = knock-out.
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functional pantothenate kinase and that it was able to rescue brain
degeneration, mitochondrial dysfunction and locomotor disabilities
(Rana et al., 2010). By reasoning on these data we decided to
administer pantethine to mice under ketogenic treatment and, as
an internal control, to mice on a standard diet. In Pank2/ mice
on a ketogenic diet, we observed the rescue of the clinical pheno-
type including the movement disorder, the amelioration of the
mitochondrial dysfunctions, and the extension of the lifespan as
previously demonstrated in Drosophila (Rana et al., 2010).
Treatment with pantethine dramatically improved both the histo-
logical features of neurodegeneration and the ultrastructural mito-
chondrial damage in Pank2/ mice fed a ketogenic diet. We did
not observe rescue of the azoospermic phenotype in mice. Fertility
was not thoroughly investigated in patients with PKAN because of
the severity of their clinical presentation and shortened lifespan.
However, analysis of sperm samples in two affected individuals
showed aberrant morphology and altered motility (Gregory and
Hayflick, 2005).
We also demonstrated that pantethine administration was able
to rescue the mitochondrial phenotype in neurons derived from
Pank2/ mice on a standard diet, indicating that its effectiveness
was not dependent on or influenced by the ketogenic treatment.
It is known that pantethine is rapidly converted into cysteamine
and pantothenate by the vanin enzyme, also known as pan-
tetheine hydrolase or pantetheinase (Kaskow et al., 2012).
Although pantethine is not able to cross the blood–brain barrier,
Bousquet et al. (2010) demonstrated that cysteamine can cross
the blood–brain barrier and in so doing can exert positive effects
on the striatum and substantia nigra (Gibrat and Cicchetti, 2011).
Cysteamine is able to enhance the expression of tyrosine hydro-
xylase protein and of the Nurr1 gene (now known as Nr4a2), and
to upregulate the expression of the Brain Derived Neurotrophic
Factor (BDNF). These neuroprotective effects of cysteamine and
of its dimer cystamine have been hypothesized to reflect the posi-
tive actions of this compound in Parkinson’s disease (Sun et al.,
2010; Gibrat and Cicchetti, 2011) and Huntington’s disease
(Borrell-Pages et al., 2006).
It has been observed that cysteamine and pantethine in drinking
water have beneficial effects in MPTP-induced mouse models of
Parkinson’s disease (Cornille et al., 2010; Sun et al., 2010) and
Figure 9 Gomori trichrome (TG) and COX histochemical reactions in muscle of Pank2+ /+ and Pank2/ mice under different diet
conditions. No alterations were present in Pank2+/+ mice. Ketogenic diet (KD) induced muscle histological abnormalities in Pank2/
mice (see also Fig. 8A) characterized by the presence of enlarged mitochondria. These alterations were rescued by pantethine adminis-
tration (KD + P). Magnification  400. SD = standard diet.
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would prevent neuronal degeneration in animal models of
Parkinson’s disease (Stack et al., 2008; Gibrat and Cicchetti,
2011). Moreover, in animal models of Huntington’s disease,
cysteamine exerts its neuroprotective effects by prolonging life-
span and decreasing motor symptoms (Dedeoglu et al., 2002;
Karpuj et al., 2002).
In agreement with these data, we can hypothesize that the
beneficial effects of pantethine in our model system were due to
its conversion into pantothenate and cysteamine. In fact, pan-
tethine is rapidly hydrolyzed to pantothenic acid and cysteamine
as it could not be detected in plasma after oral administration
(Wittwer et al., 1985). Cysteamine, the reduced form of cysta-
mine (2-aminoethanethiol) is approved by the FDA for the treat-
ment of cystinosis, a childhood disorder, which causes renal failure
through cystine intracellular accumulation (Dohil et al., 2010) and
in 2006 a small trial with this compound was initiated in patients
with Huntington’s disease (Dohil et al., 2010).
However, cysteamine causes side effects (Corden et al., 1981)
whereas pantethine has low toxicity (Knott et al., 1957; Schwartz
and Bagdon, 1964) and might act as a neutral systemic carrier that
would target cysteamine into the brain, avoiding toxicity and max-
imizing its efficacy.
The metabolism of cysteamine generates several intermediates
including hypotaurine and taurine. In addition to being the major
bile salt, in the form of taurocholate (Bouckenooghe et al., 2006),
taurine crosses the blood–brain barrier and is involved in brain
physiological activities such as inhibitory neurotransmission and
long-term potentiation (Muramatsu et al., 1978; Pasantes-
Morales et al., 1981). Recently, we observed a reduction of the
bile acids tauro and glycol cholate (Leoni et al., 2012) and an
alteration of lipid metabolism in plasma derived from patients
with PKAN, likely because of co-enzyme A shortage causing,
among others, dysfunctional fat assimilation.
Together with the data obtained in mice fed a high-fat diet,
these observations suggest that it is possible to trace a parallel
between patients with PKAN and Pank2/ mice under stressful
conditions. Moreover, it is important to consider that environmen-
tal factors, such as food intake, together with genetic background
could modulate the disease presentation by worsening or, on the
contrary, stabilizing the progression of the symptoms. This could
also explain the variability of the clinical presentation of the dis-
ease, with a spectrum of syndromes ranging from rapid to slowly
progressive.
Interestingly, we have analysed for the first time the muscle
histology of a genetically defined patient with PKAN. The first
neuromuscular examination was performed by Malandrini et al.
(1995) in two adult cases of clinically-defined Hallerworden-
Spatz disease, which showed the presence of subsarcolemmal
myeloid structures, features characteristic of inflammatory
myopathies.
In our study we demonstrated that the muscle of a 6-year-old
patient with PKAN showed giant mitochondria with a mild alter-
ation of the cristae and was histologically comparable with the
muscle of Pank2/ mice fed a ketogenic diet. These alterations
were rescued in mice after pantethine administration. This is a
relevant observation when considering the option of pantethine
administration to patients, as muscle analysis could represent the
quantitative read-out to evaluate the effect of the compound with
a minimal invasive procedure.
Taken together, these data strongly suggest that pantethine ad-
ministration to patients with PKAN should be considered as a pos-
sible, safe and non-toxic therapeutic approach. Moreover, our
data clearly demonstrate that an altered lipid metabolism, as a
result of co-enzyme A shortage, could represent one of the under-
lining causes of the disease. It is also possible, as demonstrated by
the presence of mitochondrial alteration in the mouse model and
in the muscle of a patient with PKAN, that mitochondria play a
relevant role or could be a concurrent cause in the pathogenic
mechanism of the disease. Interestingly, the presence of giant
mitochondria in muscle, although with slight morphological differ-
ences, resembles the picture present in another human disorder
caused by mutations in the CHKB gene and mainly characterized
by muscular dystrophy and mental retardation (Quinlivan et al.,
2013). CHKB encodes an enzyme catalysing the first step in de
novo phosphatidylcholine synthesis (Mitsuhashi et al., 2013).
CHKB and PANK2 are clearly part of different metabolic pathways
but they converge on phospholipid biosynthesis. It is tempting to
speculate that dysfunction of lipid metabolism is indeed the
common culprit of the generation of mitochondrial muscle alter-
ation observed in both disorders (Lamari et al., 2013).
We believe that the modulation of the diet composition in
Pank2 knockout mice has generated a useful model system in
which to test not only pantethine, but also additional compounds,
which could be beneficial for patients.
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Exome Sequence Reveals Mutations in CoA Synthase
as a Cause of Neurodegeneration
with Brain Iron Accumulation
Sabrina Dusi,1 Lorella Valletta,1 Tobias B. Haack,2,3 Yugo Tsuchiya,4 Paola Venco,1
Sebastiano Pasqualato,5 Paola Goffrini,6 Marco Tigano,6 Nikita Demchenko,4 Thomas Wieland,3
Thomas Schwarzmayr,3 Tim M. Strom,2,3 Federica Invernizzi,1 Barbara Garavaglia,1 Allison Gregory,7
Lynn Sanford,7 Jeffrey Hamada,7 Conceic¸a˜o Bettencourt,8 Henry Houlden,8 Luisa Chiapparini,9
Giovanna Zorzi,10 Manju A. Kurian,11,12 Nardo Nardocci,10 Holger Prokisch,2,3 Susan Hayflick,7
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Neurodegeneration with brain iron accumulation (NBIA) comprises a clinically and genetically heterogeneous group of disorders with
progressive extrapyramidal signs and neurological deterioration, characterized by iron accumulation in the basal ganglia. Exome
sequencing revealed the presence of recessivemissensemutations in COASY, encoding coenzyme A (CoA) synthase in one NBIA-affected
subject. A second unrelated individual carrying mutations in COASY was identified by Sanger sequence analysis. CoA synthase is a
bifunctional enzyme catalyzing the final steps of CoA biosynthesis by coupling phosphopantetheine with ATP to form dephospho-
CoA and its subsequent phosphorylation to generate CoA. We demonstrate alterations in RNA and protein expression levels of CoA
synthase, as well as CoA amount, in fibroblasts derived from the two clinical cases and in yeast. This is the second inborn error of
coenzyme A biosynthesis to be implicated in NBIA.Introduction
The common pathological feature of a group of genetic
disorders termed ‘‘neurodegeneration with brain iron
accumulation’’ (NBIA) is brain iron overload.1 Distinct
subclasses of early-onset neurodegeneration with auto-
somal-recessive transmission are defined by mutations in
specific genes: PANK2 (MIM 606157) causes pantothenate
kinase-associated neurodegeneration (PKAN);2,3 PLA2G6
(MIM 256600) causes phospholipase A2-associated neuro-
degeneration (PLAN, also known as INAD);4 FA2H (MIM
611026) causes fatty acid hydroxylase-associated neurode-
generation (FAHN);5 and C19orf12 (MIM 614297) causes
mitochondrial membrane protein-associated neurodegen-
eration (MPAN).6,7 More recently, a distinctive form of
NBIA with X-linked dominant de novo mutations in
WDR45 (MIM 300894), coding for a protein with a puta-
tive role in autophagy, was reported.8,9
These genes account for ~70% of subjects with NBIA,
leaving a significant fraction without an identified genetic
defect. For this reason we performed exome sequence
investigation in one individual with clinical presentation
and neuroimaging suggestive of NBIA but without muta-
tions in previously associated genes. By applying this1Unit of Molecular Neurogenetics – Pierfranco and Luisa Mariani Center for th
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Theapproach we identified a homozygous missense mutation
in COASY, coding for CoA synthase. We then performed
traditional Sanger sequence analysis of a larger cohort of
idiopathic NBIA cases, and we found a second individual
harboring mutations in the same gene. CoA synthase is a
bifunctional enzyme possessing 40PP adenyltransferase
(PPAT) and dephospho-CoA kinase (DPCK) activities, cata-
lyzing the last two steps in the CoA biosynthetic
pathway.10 The enzyme is encoded by a single gene in
mammals and Drosophila,11,12 although two different
genes code for PPAT and DPCK activities in yeast and
bacteria.13 In human there are three splice variants:
COASY alpha is ubiquitously expressed and has a molecu-
lar weight of 60 kDa; COASY beta is predominantly
expressed in the brain and possesses a 29 aa extension at
the N terminus;14 and COASY gamma is predicted to
code for C-terminal region of CoA synthase corresponding
to DPCK domain. Several studies have investigated the
subcellular compartmentalization of the CoA biosynthetic
pathway and have demonstrated that both PANK2, defec-
tive in themost commonNBIA disorder, and CoA synthase
alpha and beta are mitochondrial enzymes. PANK2 is
mainly located in the intermembrane space2,15,16 whereas
CoA synthase alpha and beta are anchored to the outere study of Mitochondrial Disorders in Children, IRCCS Foundation Neuro-
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localized within the mitochondrial matrix.18 We here
demonstrate that COASY is mainly located in the mito-
chondrial matrix and that the identified amino acid
substitution causes instability of the protein with altered
function of its enzymatic activity.Subjects and Methods
Exome and Sanger Sequencing
Informed consent for participation in this study was obtained
from all individuals involved and from their parents, in agreement
with the Declaration of Helsinki, approved by the ethics commit-
tee of the Fondazione IRCCS (Istituto di Ricovero e Cura a Carat-
tere Scientifico) Istituto Neurologico C. Besta (Milan, Italy) and
by the ethics committees of the other institutes participating in
the screening (Germany, UK, USA).
Exome sequencing and variant filtering was performed as
described previously.8 In brief, exonic DNA fragments were
enriched with the SureSelect 50 Mb kit from Agilent and
sequenced as 100 bp paired-end reads on a HiSeq 2500 system
from Illumina. For sequencing statistics details see Table S1 avail-
able online. We predicted that causal mutations would be very
rare and would alter the protein. We therefore searched for nonsy-
nonymous variants with a frequency <0.1% in 2,700 control
exomes analyzed in Munich and public databases that, given the
reported consanguinity of the parents, were anticipated to be
homozygous. This analysis left a total of 12 candidate genes (Table
S2). The detailed list of these 12 genes is reported in Table S3. We
first excluded the following genes because of the presence of addi-
tional subjects with compound heterozygous or homozygous
mutations related with different clinical phenotypes: HRNR,
ADAM8, BZRAP1, C17orf47, LRP1B, EVC2, KIAA1797, and
CACNB1. Moreover, variants in HRNR, CACNB1, C17orf47, and
KIAA1797 were predicted to be benign by PolyPhen. Four remain-
ing genes (GUCA2A, FBXO47, COASY, and IFNW1) were poten-
tially good candidates carrying deleterious mutations.
By performing segregation analysis of the c.265G>T homozy-
gous variant in GUCA2A, we found that also the healthy mother
(subject I-2 of family 1) and one of the healthy sisters (subject
II-4 of family 1) carried this variant.
Segregation analysis of c.490A>G in IFNW1 showed that this
change was present in homozygous state in the healthy mother
(subject I-2 of family 1) and in two healthy sisters (subjects II-4
and II-5 in family 1). Altogether, this observation excluded both
GUCA2Aand IFNW1aspotential candidategenes (seealsoTable S3).
FBXO47wasmainly expressed in kidney, liver, and pancreas and
it was suggested to act as a tumor-suppressor gene in renal carci-
noma and possibly other malignancies.19 However, because this
gene carries a splice sitemutation, we decided to perform sequence
analysis in a subgroup of 56 NBIA-affected individuals. We did not
identify any pathogenic mutation in this cohort of subjects.
Based on these data and because COASY coded for an enzyme
involved in Coenzyme A biosynthesis as PANK2, we concentrated
our efforts on the analysis of this gene.RNA Extraction and Real-Time PCR
Total RNAwas isolated from fibroblasts (80% confluence) with the
RNeasy Mini Kit (QIAGEN). RNA quantity was measured with the
Nanodrop instrument (Nanodrop Technologies). RNA was used as2 The American Journal of Human Genetics 94, 1–12, January 2, 2014a template to generate complementary DNA (cDNA) by GoScript
Reverse Transcriptase protocol (Promega). Reverse transcriptase
products were used in real-time PCR to evaluate the expression
level of COASY with the Power SYBR Green PCR Master Mix
(Applied Biosystems) system. The housekeeping gene used for
data normalization was GAPDH. Primer sequences are as follows:
COASY, forward 50-AGTTGCGGTTTCTCCGTTAG-30 and reverse
50-ATCCTGGGAGGGGGAAAT-30; GAPDH, forward 50-CTCTG
CTCCTCCTGTTCGAC-30 and reverse 50-ACGACCAAATCCGTT
GA-30.
Expression and Purification of Recombinant hDPCK
in Bacteria
mRNA coding for human DPCK domain (COASY amino acid
sequence from 355 to 564) was expressed with the N-terminal
histidine-tag from pET30-a(þ) (Novagen) at 37C in E. coli strain
BL21 (DE3), after induction with 0.2 mM IPTG.
Cells were lysed by a French press in 50 mM Tris-HCl (pH 8),
0.5MNaCl, 1% Triton X-100, 20mM imidazole, 1 mM phenylme-
thylsulfonyl fluoride (PMSF), 10 mM b-mercaptoethanol, and
Roche Complete EDTA-free protease inhibitor cocktail. After
clearing, the lysate was loaded on a Ni-NTA beads (QIAGEN)
column. Bound proteins were eluted with an imidazole gradient.
Fractions containing His-hDPCK were pooled, desalted, and
loaded onto an anion-exchange (AE) Resource-S column (GE
Healthcare) equilibrated in 50 mM Tris-HCl (pH 7.4), 2.5% glyc-
erol, 20 mM b-mercaptoethanol. The protein was eluted with a
NaCl gradient, concentrated by ultrafiltration, and further sepa-
rated by size exclusion chromatography (SEC) on a Superdex-
200 column (GE Healthcare) equilibrated in 10 mM Tris-HCl
(pH 7.4), 0.15 M NaCl, 2.5% glycerol, 0.1 mM EDTA, and 1 mM
DTT. The entire purification scheme was carried out at 4C.
Mitochondria and Mitoplast Isolation from Cultured
Cells
Isolatedmitochondria from cultured cells were obtained according
to the protocol described by Ferna´ndez-Vizarra.20
For mitoplast purification, mitochondria were dissolved in 1 ml
Buffer A (MOPS 20mM, sucrose 0.25M [pH 7.4]). A total of 1 ml of
200 mg/ml digitonin in Buffer A was added to each sample. Sam-
ples were mixed and incubated on ice 5 min, then centrifuged
3 min at 8,000 rpm at 4C. Supernatant was discarded and pellet
dissolved in 1 ml Buffer B (MOPS 20 mM, sucrose 0.25 M, EDTA
Na4 1 mM [pH 7.4]). Samples were incubated on ice for 5 min,
then centrifuged at 12,000 rpm at 4C for 3min. Separate fractions
of mitochondria and mitoplasts were also treated with 0.04 mg of
proteinase K (PK) for 15 min at 4C or 37C; PK digestion was
blocked with PMSF. In some samples of mitochondria and mito-
plasts, 0.1% Triton X-100 was added followed by incubation for
15 min at 37C.
Immunoblot Analysis
Approximately 1 3 106 fibroblasts, grown in DMEM (EuroClone)
were trypsinized, centrifuged at 1,200 rpm for 3 min, and solubi-
lized in 200 ml of RIPA buffer (50 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 1% NP40, 0.5% NaDOC, 5 mM EDTA) with 13 Complete
Mini Protease Inhibitor Cocktail Tablets (Roche) for 40 min at
4C. 30 mg of proteins were used for each sample in denaturing
sodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Immunoblot analysis was performed as described21 with
the ECL-chemiluminescence kit (Amersham).
Please cite this article in press as: Dusi et al., Exome Sequence Reveals Mutations in CoA Synthase as a Cause of Neurodegeneration with
Brain Iron Accumulation, The American Journal of Human Genetics (2014), http://dx.doi.org/10.1016/j.ajhg.2013.11.008Antibodies
A rabbit monoclonal anti-COASY antibody was used at 1:1,000
dilution (EPR8246-Abcam). Amousemonoclonal anti-b-TUBULIN
antibody was used at a final concentration of 1 mg/ml (Sigma-
Aldrich). Secondary anti-rabbit and anti-mouse antibodies were
used at 1:2,000 and 1:7,000 dilution, respectively.HPLC Analysis of Dephospho-CoA, CoA, and
AcetylCoA
HPLC analysis was performed on recombinant wild-type and
mutant DPCK proteins, on fibroblast lysates derived from control
and subjects carrying COASY variants, and on isolated yeast mito-
chondria.
The method employed a column (Kinetex 5u C18 100A New
Column 250 3 4.6 mm from Phenomenex) eluted with
100 mmol/l NaH2PO4 and 75 mmol/l CH3COONa (pH was
adjusted to 4.6 by the addition of concentrated H3PO4)-acetoni-
trile (94:6, v/v) at a flow rate of 1.0 ml/min. The ultraviolet (UV)
detector was set at 259 nm. To obtain standard solutions of
5 mM, dephospho-CoA and CoA were dissolved in 50 mmol/l
KH2PO4-K2HPO4 buffer (pH 7.0). CoA and dephospho-CoA stan-
dards were eluted at approximately 4.5 and 8 min, respectively,
and CoA compounds were quantified by comparison of peak areas
with those of authentic standards.
In Vitro DPCK Activity
1 mg of purified wild-type or mutant protein was incubated for 2 hr
at 37C in 50 ml of reaction mixture containing 50 mM Tris-HCl
(pH 8), 5 mM MgCl2, 1 mM ATP, and 0.1 mM dephospho-CoA.
After incubation, sample was treated with perchloric acid (PCA)
3%, vortexed, and centrifuged at 13,000 rpm at 4C. Trietanol-
amine was added to the supernatant to a final concentration of
100 mM, and then the sample was neutralized with 5 M K2CO3.
Fibroblast Analysis
Fibroblasts, grown on 10 cm plates (approx. 80%–90% confluent),
were washed with PBS and collected by trypsinization. 40 ml of ice-
cold PCA (5%) was added to cells and samples were vortexed and
centrifuged at 18,000 3 g for 5 min at 4C. The supernatant was
collected and triethanolamine was added to a final concentration
of 100 mM. The pH was adjusted to 6.5 with 5 M K2CO3 before
centrifuging again at 18,0003 g for 3 min at 4C to remove potas-
sium perchlorate. Neutralized PCA extract was made up to 100 ml
with Na2H2PO4 (150 mM), Tris-(2-carboxyethyl) phosphine
hydrochloride (TCEP) (10 mM), EDTA (5 mM), and methanol
(9%) and filtered through a 0.2 mm PVDF filter, and 50 ml was
injected for HPLC analysis of CoA compounds.
In Vitro PPAT/DPCK Assay of Cell Homogenates
Fibroblasts grown on 10 cm plates (approx. 80%–90% confluent)
were washed with PBS and collected by trypsinization. Cells
were homogenized in 150 ml buffer containing 50 mM Tris/HCl
(pH 7.5), 150 mM NaCl, 10 mM 2-glycerophosphate, 1 mM
EDTA, 0.5mMTCEP, and protease inhibitor cocktail (Roche). Total
protein concentration in the homogenate was measured by
Bradford assay. 65 mg of homogenate protein was incubated with
2 mM ATP, 5 mM MgCl2, and 5 mM 4-phosphopantetheine in
a total volume of 50 ml at 30C for 1 hr. 4-phosphopantetheine
was prepared by phosphorylating pantetheine with bacterially
expressed pantothenate kinase 1b. For control incubation, ATP
and MgCl2 were added to homogenate, but 4-phospho-
pantetheine was omitted. After the incubation, PCA (3.5% final)
was added to the reaction mixtures before centrifugation at
18,000 3 g for 5 min at 4C. The pH of the PCA-soluble fractionThewas adjusted to 6.5 with TEA/K2CO3 and CoA compounds formed
were analyzed by HPLC as described above.
Yeast Mitochondria Analysis
Mitochondrial suspensions were diluted to obtain about 0.5 mg/ml
in a final volume of 150 ml of 5% 5-sulfosalicylic acid containing
50 mmole/l DTT and vortexed. The homogenates were centrifuged
at 12,000 3 g for 10 min at 4C. The supernatant was passed
through a 0.45 mm filter (Millipore) and the filtrate (40 ml) was
injected directly into the HPLC system. We loaded equal amount
of yeast mitochondrial proteins (40 mg) and we performed CoA
quantification by evaluating peak’s areas as compared to known
concentration of internal standard.
Yeast Strains and Media
Yeast strains used in this study were W303-1B (MATaade2-1 leu2-
3,112 ura3-1 his3-11,15 trp1-1 can1-100) ade2-1 leu2-3,112 ura3-1
trp1-1 his3-11,15, its isogenic strain cab5::KanMx4 that harbors
plasmid pFl38-CAB5 or pFl39-CAB5, and the strain cab5::KanMx4
that harbors plasmid pYEX-BX-COASY (see below). Cells were
cultured in minimal medium 40 supplemented with appropriate
amino acids and bases for auxotrophy as previously described.22
To obtain medium lacking pantothenate (40-Pan), a mixture of
vitamins without pantothenate was prepared. Various carbon
sources (Carlo Erba Reagents) were added at the indicated con-
centration. YP medium contained 1% Bacto-yeast extract and
2% Bacto-peptone (ForMedium). Media were solidified with 20
g/l agar (ForMedium) and strains were incubated at 23C, 30C,
or 37C.
Cloning Procedures and Plasmid Vectors
pFL38-CAB5 was obtained by PCR amplification of CAB5,
including the upstream and the downstream regions, from
genomic DNA of strain W303-1B with primers as follows.
For CAB5 (forward 50-GGGGGGATCCCCATTGCTTAGAA
TGGGCGG-30 and reverse 50-CCGCGGTACCGAGAACCCATA
GAATTCGAC-30), the oligos were modified at 50 end in order to
insert restriction sites for cloning in the centromeric plasmid
pFL38 carrying the URA3 marker.23 pFL39-CAB5 was obtained by
subcloning CAB5 into pFL39 vector carrying the TRP1 marker.23
Human COASY and human COASYArg499Cys were amplified by
PCR from pcDNA3.1 constructs, containing wild-type andmutant
cDNA, respectively, with primers described below.
For COASY (forward 50-GGGGGGATCCATGGCCGTATT
CCGGTCG-30 and reverse 50-CCGCGTCGACTCAGTCGAGGG
CCTGATGAGTC-30), the oligonucleotides contained appropriate
restriction sites to allow cloning in the BamHI-SalI-digested
pYEX plasmid under the control of CUP1 promoter. All cloned
fragments were sequenced to check the absence of mutations. Re-
striction-enzyme digestions, Escherichia coli transformation, and
plasmid extractions were performed with standard methods.24
Site-Directed Mutagenesis and Generation of Yeast
cab5 Strains
The conserved human arginine 499 residue (RefSeq accession
number NM_025233.6), which is replaced by a cysteine in human
COASY, corresponds to arginine 146 (RefSeq NM_001180504.3) in
the yeast protein. The CAB5 mutant allele was obtained by site-
directed mutagenesis (QuikChange II Site-Directed Mutagenesis
Kit Stratagene) by introducing an AGA>TGT codon substitution,
resulting in p.Arg146Cys amino acid change. The corresponding
modified primers used to generate mutated allele are as follows.American Journal of Human Genetics 94, 1–12, January 2, 2014 3
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TGTTTAATGACAAGAAATCCTG-30 and reverse 50-CAGGATTTC
TTGTCATTAAACATTCTAGTTGCAATTCTTGCG-30), mutagenized
insert was verified by sequencing of both strands.
The pFL38 plasmid-borne CAB5 was transformed in the W303-
1B by the lithium-acetate method25 to allow cell viability and the
resident CAB5 was deleted with the KanMX4 cassette amplified
from plasmid pCXJKan by primers described below.
For CAB5-Kan (forward 50-CAGATAGCCACAATTAAAATAT
GCTGGTAGTGGGATTGACAGGTCGTACGCTGCAGGTCGAC-30
and reverse 50-GTAATTATAAGATATCAACCTTATACCCGCTGAA
GACTTTTTATTTTGAAGATCGATGAATTGAGCTCG-30), both of
them contained a 50 complementary stretch for an internal
sequence of CAB5 ORF and a 30 complementary stretch (under-
lined in the sequences) for the extremities of the KanMX4 cassette.
Strains with engineered CAB5 were selected on YP supplemented
with 200 mg/ml geneticin and gene rearrangement was confirmed
by PCR. Transformation of cab5::KanR/pFLl38CAB5 strain with
pfl39-CAB5 and pFL39-CAB5Arg146Cys constructs and plasmid
shuffling on media supplemented with 5-FOA in order to select
spontaneous events of Uraþ constructs loss were finally per-
formed. Similarly, cab5::KanR/pFL39CAB5 strain was transformed
with pYEX-BX-COASY and pYEX-BX-COASYArg499Cys constructs;
loss of Trpþ plasmids was induced by growing the transformants
with tryptophan in the medium.
Yeast Mitochondria Isolation
Mitochondria were purified as previously reported.26 In brief, cells
cultured at 28C in the 40 medium supplemented with 0.6%
glucose were collected and washed. Spheroplasts were obtained
after Zymoliase20T digestion (Nacalai Tesque) and disrupted
with a glass-teflon potter homogenizer. Mitochondria were puri-
fied by differential centrifugation. Total protein concentrations
were quantified according to Bradford (Bio-rad).Results
Molecular and Biochemical Investigations
Exome-NGS analysis of one individual (subject II-3, family
1, Figure 1) affected by idiopathic NBIA resulted in the
identification of 12 genes (Table S3) that carried variants
potentially relevant for the disease. However, as described
in detail in the Subjects and Methods section, several of
these genes were not investigated further because (1) the
identified variants were present in additional individuals
and associated with other clinical phenotypes; (2) genetic
segregation analysis was not compatible with clinical pre-
sentation of the subjects of family 1; or (3) gene function
and tissue-specific expression could hardly explain the
neurological presentation. The homozygous mutation in
COASY, coding for a bifunctional enzyme converting 40-
phosphopantetheine into dephospho-CoA and then to
Coenzyme A, was considered as potentially relevant for
the disease and further investigated. By Sanger sequencing
we confirmed the presence of the homozygous missense
COASY mutation in the affected individual (Figure 1: sub-
ject II-3, family 1). The family had no history of neurolog-
ical disorders and this subject was the youngest and the
only affected of five siblings. She was born to consanguin-4 The American Journal of Human Genetics 94, 1–12, January 2, 2014eous parents after an uneventful pregnancy and normal
delivery. Birth weight was 3,850 g. There was no history
of perinatal complications and she attained normal early
developmental milestones. From 24 months of age, par-
ents reported gait difficulties and persistent toe walking.
At age 6, when she started primary school, she showed
poor academic ability. At age 15, general physical examina-
tion was normal. Neurological evaluation showed mild
oro-mandibular dystonia with dysarthria and also spastic
dystonic paraparesis, but she was still able to walk unaided.
Neuropsychological evaluation demonstrated cognitive
impairment (total IQ¼ 49). The disease continued to prog-
ress slowly and at the age of 20 she became unable to
ambulate independently. During themost recent examina-
tion at age 25, the clinical picture was dominated by a
severe spastic bradykinetic-rigid syndrome associated
with mild dystonia and with distal areflexia in the lower
limbs. There were no clinical or psychometric data suggest-
ing mental deterioration but behavioral disturbances with
obsessive-compulsive symptoms and depression was
evident. Funduscopic examination and visual evoked
potential studies were normal and on electroretinogram
there were no signs of retinopathy. Electromyographic
and nerve conduction studies were consistent with a
mild motor axonal neuropathy. Serial brain MRI showed
bilateral hypointensity in the globi pallidi associated
with a central region of hyperintensity in the antero-
medial portion (Figure 1).
Identification of one Italian subject carrying COASY
mutation prompted us to analyze the nine exons of this
gene in a cohort of 280 NBIA-affected individuals of
different ethnicity by using polymerase chain reaction
and direct Sanger sequencing. Primer sequences and PCR
conditions are described in Table S4. By this analysis we
identified a second Italian case carrying COASY mutations
(Figure 1: subject II-2, family 2). He is 20 years old and he
was born at term of uneventful pregnancy from healthy
nonconsanguineous parents. Psychomotor development
was normal in the first year of life, but he was delayed in
walking as a result of instability and toe walking. At age 3
the neurological picture was characterized by spastic tetra-
paresis with moderate mental and language impairment.
The disease was progressive, with worsening of the motor
signs in the lower limbs and progressive involvement of
the upper limbs and oro-mandibular region. He lost inde-
pendent ambulation at age 15. At age 17, the neurological
examination showed mild oro-mandibular dystonia with
dysarthria, spastic-dystonic tetraparesis with prevalent
involvement of lower limbs, and parkinsonian features
(rigidity and abnormal postural reflexes). Distal amyo-
trophia and areflexia with pes cavus were also evident.
Cognitive impairment was severe (total IQ < 40) with
obsessive-compulsive behavior and complex motor tics.
On follow-up, 2 years later, the neurological picture was
unchanged. Nerve conduction study and electromyog-
raphy detected a motor axonal neuropathy more promi-
nent in the lower limbs. There was no retinal or optic nerve
Figure 1. Genetics and MRI of Subjects Carrying COASY Mutations
(A) Pedigrees of family 1 (left) and family 2 (right). II-3, affected individual in family 1; II-2, affected individual in family 2. The presence
of homozygous or compound heterozygous mutation is indicated by /; wild-type sequence by þ/þ; heterozygous mutation by þ/.
(B) Electropherograms show sequence variations in individual II-3 of family 1 (left) and in individual II-2 of family 2 (right).
(C) Left: MRI of individual II-3 of family 1 at 11 years of age (a–c). Axial MR (1.5 T) proton density and T2-weighted images (a, b) show
bilateral low signal intensity in the globi pallidi (clearly visible in b) with a central region of high signal intensity located in the antero-
medial portion of the nuclei (‘‘eye-of-the-tiger’’ sign) and with a large central spot of low signal intensity. Axial CT (c) shows bilateral
hyperdensities consistent with calcifications and corresponding to the central spot visible on MRI. Six years later (d), no changes
were found. The hypointensity in the medial portion of the substantia nigra was also unchanged. Right: MRI of individual II-2 of family
2 at 9 years of age (e, f) and at age 19 (g, h). Axial T2-weighted 1.5 T MR images (e, f) reveal hypointensity in the pallida. Both caudate
nuclei and putamina are swollen and hyperintense. Slight hyperintensity is also present in both medial and posterior thalami (arrows).
Axial T2-weighted MR image (g) confirms bilateral symmetric low signal intensity and atrophy in the pallida. Both putamina and
caudate nuclei are still slightly hyperintense with minimal swelling. Coronal FLAIR image (h) demonstrates low signal in both pallida
and in the medial portion of the substantia nigra (arrowheads).
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evoked potential studies.
The first brain MRI performed at age 5 demonstrated
hyperintensity and swelling of both caudate nuclei and
putamina and mild hyperintensity in both thalami. Globi
pallidi were normal. At ages 9 and 19, hypointensity in the
globi pallidi was evident and no significant changes were
found in the caudate nuclei, putamina, and thalami
(Figure 1).
Subject II-3 of family 1 (Figure 1) carried a homozygous
missense mutation, a c.1495C>T transition causing anTheamino acid change p.Arg499Cys (referral sequence
NM_025233.6; numbering starts from the first methio-
nine). Segregation analysis performed in family 1 indicated
heterozygous state in the parents (Figure 1), and the four
healthy sisters showed wild-type sequence (Figure 1).
Subject II-2 of family 2 (Figure 1) turned out to be a com-
pound heterozygote for the same mutation, c.1495C>T
(p.Arg499Cys), identified in subject II-3, and for a
c.175C>T transition, resulting in a premature p.Gln59*
stop codon in the N-terminal regulatory region of the
protein. Segregation analysis in the parents demonstratedAmerican Journal of Human Genetics 94, 1–12, January 2, 2014 5
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Figure 2. COASY: Conserved Domains,
Phylogenetic Conservation, and Crystal
Structure
(A) Schematic domain organization of hu-
man CoA synthase and location of point
mutations. Abbreviations are as follows:
MLS, mitochondrial localization signal;
NRD, N terminus regulatory domain;
PPAT, 40PP adenylyltransferase domain;
DPCK, dephospho-CoA kinase domain.
(B) Amino acid sequence alignment
showing conservation of Arg499 across
species.
(C) Crystal structure of E. coliDPCK (CoaE)
(PDB ID 1VHL) showing the position of
Arg140 (equivalent to Arg499 in human
DPCK) in the nucleotide-binding site.
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Brain Iron Accumulation, The American Journal of Human Genetics (2014), http://dx.doi.org/10.1016/j.ajhg.2013.11.008that the two mutations were on different alleles: one in-
herited from themother and one from the father (Figure 1).
The healthy brother was not available for genetic testing.
Themissense substitution affected an amino acid residue
Arg499, which is highly conserved in all available animal,
plant, and yeast species, including S. cerevisiae, and is local-
ized in the nucleotide-binding site of the DPCK domain
(Figure 2). Furthermore, mutational analysis of Arg140,
equivalent to Arg499, in the mycobacterial dephospho-
CoA kinase (CoaE) revealed the importance of this residue
in ATP binding and phosphotransfer reaction.27,28
The substitution was predicted to be pathogenic by
in silico analysis according to Polyphen2 (p ¼ 1) and
MutPred (p ¼ 0.909). Frequency of the mutation derived
from the Exome Variant Server and calculated on Euro-
pean, American, and African population was 1 out of
13,005 analyzed cases.
To evaluate the impact of the two mutations on the
stability of the transcript, we extracted mRNA from fibro-
blasts of subjects II-3 (family 1) and II-2 (family 2) and
reverse transcribed it into cDNA. Quantitative real-time
PCR showed that although in individual II-3 the amount
of mutant COASY transcript was similar to that of the
control sample (Figure 3A), it was reduced to 50% in indi-
vidual II-2, suggesting RNA decay.
Next, we analyzed COASY level in total cell lysates
obtained from both mutants and control fibroblasts by
using a monoclonal anti-COASY antibody. We first tested
the antibody specificity by verifying its cross-reactivity
with the 62 kDa COASY alpha in vitro translation product
(Figure 3B).
Immunoblot analysis revealed the presence of a normal
protein content in three different control fibroblasts
whereas a significant reduction of the protein amount
was detected in fibroblasts of subject II-2 (family 2)
carrying the premature stop codon and the missense
p.Arg499Cys (Figure 3B). Interestingly, we also observed a
minimally detectable immunoreactive band correspond-
ing to COASY in subject II-3 (family 1) carrying the homo-
zygous p.Arg499Cys substitution (Figure 3B). This suggests
that the p.Arg499Cys change is associated with instability
or accelerated degradation of the protein. Immunoblot6 The American Journal of Human Genetics 94, 1–12, January 2, 2014analysis of fibroblasts derived from subject I-2 of family 1
and from both parents of family 2 (Figure 3B) showed a
partial reduction of the protein level. As reported in
Figure 3C, protein amount quantified by densitometry
analysis with three different controls as standard resulted
to be around 50% in subject I-2 of family 1 and in the
parents of family 2 and less than 5% in both affected indi-
viduals.
Submitochondrial Localization of COASY
To better determine submitochondrial localization of
COASY, we carried out immunoblot analysis of mitochon-
dria and submitochondrial fractions derived from HeLa
cells, using a commercially available antibody (see Subjects
and Methods).
Immunoblotting of different cellular fractions revealed
the presence of a band of the expected molecular weight
in total lysate and intact mitochondria (Figure 4A). To
determine whether the protein was present on the outer
mitochondrial membrane, we treated mitochondria with
proteinase K (PK) and demonstrated COASY resistance to
degradation (Figure 4A). Efficiency of PK activity was
demonstrated by treating mitochondria with Triton
X-100, which dissolves the membranes and makes the
protein accessible to PK digestion (Figure 4A). This result
was further supported by hybridizing the same filter with
control antibodies against proteins such as CORE1 or
ETHE1, which are located in the inner mitochondrial
membrane and in the mitochondrial matrix, respectively,
or against VDAC1, which is located in the outer mitochon-
drial membrane (Figure 4A) facing the intermembrane
space. We observed that COASY was also present in total
lysates and not enriched in the mitochondrial fraction,
suggesting that its localization might not be exclusively
in mitochondria.
The protein was found in mitoplasts and was resistant
to PK digestion. Further fractionation of mitoplasts
demonstrated that the protein was mainly present in the
matrix, probably anchored to the inner mitochondrial
membrane (Figure 4B). The presence of trans-membrane
domains was predicted by TMpred and PSIPRED software.
We also observed the presence of VDAC in mitoplasts,
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Figure 3. COASY mRNA Expression and
Protein Accumulation in Skin Fibroblasts
(A) Quantification of COASY mRNA levels
by real-time PCR in fibroblasts of subject
II-3 and II-2 relative to the expression of
glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH). The amount of COASY
transcript is reduced in subject II-2 versus
control samples (CT), indicating mRNA
decay. Data are represented as mean 5
SD. Statistically significant differences
with CT were determined by the Student’s
t test; **p < 0.02.
(B) Immunoblot analysis of COASY in
fibroblasts derived from three healthy
subjects (CT 1, CT 2, CT 3), individual I-2
(family 1), individuals I-1 and I-2 (family
2), and affected subjects (II-3 and II-2).
The same amount of protein (30 mg) was
loaded. b-tubulin was used as a loading
control. As a control, COASY in vitro trans-
lation product (COASY peptide) was
loaded.
(C) Relative quantification of the
protein amount: mean 5 SD of three
controls (CT); of individual I-2 (family 1);
of individuals I-1 and I-2 (family 2); and
of affected subjects II-3 and II-2. Histogram
shows COASYamount quantified by densi-
tometry and normalized on b-tubulin
level.
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not completely removed. However, VDAC was partially
digested with PK and, most importantly, it was completely
absent in the mitochondrial matrix.
HPLC Assays on Recombinant Protein and Fibroblasts
Derived from Affected Subjects
To assess the effect of the p.Arg499Cys substitution on the
DPCK activity, we expressed mRNA corresponding to the
wild-type and mutant DPCK domain in bacteria as His-
tag fusion proteins. Recombinant proteins were purified
by NTA chromatography and 1 mg of each protein was
loaded on an SDS-PAGE and stained with Coomassie blue
(Figure 5A, top). To demonstrate that the recombinant
proteins were recognized by the anti-COASY antibody,
the gel was blotted and incubated with the specific anti-
body (Figure 5A, bottom). Activities of wild-type DPCK
and of the mutant DPCK-Arg499Cys were measured
in vitro by HPLC analysis via 1 mg of recombinant proteins.
This analysis evaluates dephospho-CoA conversion into
CoA after incubation of wild-type and mutant DPCK
proteins with ATP and dephospho-CoA. As indicated by
the chromatogram in Figure 5B, the wild-type enzyme
was able to completely convert dephospho-CoA into
CoA, as demonstrated by the coincidence of the reaction
mixture peak with that of CoA standard. On the contrary,
the DPCK-Arg499Cys mutant did not have this enzymatic
activity and the peak corresponding to CoA was not
observed (Figure 5C). This finding suggests that CoA
biosynthesis might be abolished in the presence of the
p.Arg499Cys change.TheWe then analyzed CoA levels in fibroblasts derived from
healthy and affected subjects by HPLC, but we did not
observe a significant difference. However, a general reduc-
tion of acetyl-CoA and total CoA was observed in both
affected individuals as compared to control, and this differ-
ence was statistically significant for acetyl-CoA in subject
II-3 of family 1 (Figure 6A).
To examine whether skin fibroblasts from affected
individuals were able to synthesize CoA, we performed
an in vitro assay to evaluate CoA biosynthesis in cell
homogenates with 40PP (40-phosphopantetheine) as
substrate. HPLC analysis of reaction mixtures showed
that dephospho-CoA and CoA were efficiently produced
de novo from 40PP in control fibroblasts (Figure 6B). We
also observed residual de novo production of dephospho-
CoA and CoA in skin fibroblasts from affected subjects,
although the level of CoA was approximately 20% of
that produced by control fibroblasts (Figure 6B). These
findings suggest the existence of an alternative as yet un-
characterized pathway for CoA biosynthesis. However,
we cannot exclude the possibility that the remaining
COASY aberrant protein present in fibroblasts may still
retain some catalytic activity.
Studies in Yeast Saccharomyces cerevisiae
To further test the pathogenic role of the COASY missense
mutation, we used the yeast Saccharomyces cerevisiae.
Biosynthesis of CoA in S. cerevisiae follows the same
pathway described for mammalian cells: pantothenate,
formed de novo from several amino acids or taken up
from outside the cell, is converted in CoA in five reactionsAmerican Journal of Human Genetics 94, 1–12, January 2, 2014 7
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Figure 4. Mitochondrial Localization of
COASY
(A) Immunoblot analysis on mitochondria
and different submitochondrial fractions
derived from HeLa cells. Mitochondria
were treated for 15 min at 4C or 37C
with proteinase K (PK) in presence or
absence of triton. The filter was incubated
with anti-COASY, anti-CORE1, anti-
ETHE1, and anti-VDAC1 antibodies. As
a control, COASY in vitro translation
product (COASY peptide) was loaded.
(B) Immunoblot analysis on mitoplasts,
matrix, and inner membrane isolated
from HeLa cells. Mitoplasts were treated
for 15 min at 4C or 37C with PK in pres-
ence or absence of triton. The filter was
sequentially incubated with anti-COASY,
anti-ETHE1, anti-CORE1, and anti-VDAC
antibodies.
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With the exception of CAB1, the other genes of the
pathway have been identified because of sequence similar-
ity and their function in CoA biosynthesis assessed by
heterologous complementation with bacterial genes. The
only difference with human is that in yeast, as in E. coli,
the PPAT and DPCK activities reside on different proteins
encoded by CAB4 and CAB5 genes, respectively. Deletion
of each CAB gene results in a lethal phenotype, indicating
an essential role for this pathway in yeast.
Sequence analysis indicated that Arg499 is highly
conserved from yeast to human and corresponds to
Arg146 in the yeast Cab5p (see also Figure 2). By using
the plasmid shuffling method, deletion strains express-
ing either the mutant alleles cab5Arg146Cys and
COASYArg499Cys or the CAB5 and COASY wild-type genes
were generated. The Dcab5 lethal phenotype was rescued
by the re-expression of either human COASY wild-type or
human COASYArg499Cys and yeast cab5Arg146Cys. No major
defects of growth on different substrates or at different
temperatures were observed (data not shown).
However, we noticed that the mutant cab5Arg146Cys as
well as the strain expressing COASYArg499Cys became
auxotrophic for pantothenate and showed growth reduc-
tion. In fact, wild-type yeast can form colonies regardless
of the presence of pantothenate at all tested temperatures
(Figure 7A); by contrast, in the absence of pantothenate
both mutants cab5Arg146Cys and COASYArg499Cys failed to
form colonies at 37C and a significant impairment of
growth was observed at both 23C and 28C when
compared with that of the strain expressing the wild-
type alleles (Figure 7B). This result supports the pathoge-
nicity of the substitution p.Arg499Cys and suggests that
the mutant enzyme requires a higher concentration of
pantothenate to produce enough CoA to sustain yeast
growth.
Because Cab5p as COASY is located into the mitochon-
dria,30 we measured the level of CoA in mitochondria
isolated from wild-type, COASYArg499Cys, and cab5Arg146Cys8 The American Journal of Human Genetics 94, 1–12, January 2, 2014transformed yeasts grown in complete medium at 28C
with 0.6% glucose. We first verified, by immunoblot
analysis, that COASYArg499Cys was expressed in yeast at a
comparable level as in the wild-type enzyme (not shown).
We could not verify cab5Arg146Cys expression because the
available antibody did not cross-react with the yeast
protein. We observed that the level of CoA was reduced
to 40% in yeast transformed with both the human
COASYArg499Cys and yeast cab5Arg146Cys mutant versions
as compared to wild-type (Figure 8).Discussion
We here report the second inborn error of CoA synthesis
leading to a neurodegenerative disorder. The first defect
discovered was due to PANK2 mutations, causing the
most prevalent NBIA subtype, PKAN.2
Coenzyme A (CoA) is a crucial cofactor in all living
organisms and is involved in several enzymatic reactions.
It is a key molecule for the metabolism of fatty acids,
carbohydrates, amino acids, and ketone bodies. Its biosyn-
thesis proceeds through a pathway conserved from
prokaryotes to eukaryotes, involving five enzymatic steps,
which utilize pantothenate (vitamin B5), ATP, and
cysteine.
In the first step, catalyzed by pantothenate kinase,
the product of PANK2, pantothenic acid is phosphorylated
to generate 40-phosphopantothenic acid. Then, this inter-
mediate is converted into 40-phosphopantothenoyl-
cysteine, which is subsequently decarboxylated to
40-phosphopantetheine. The last two steps are carried
out by the bifunctional enzyme CoA synthase, which
converts 40-phosphopantetheine into dephospho-CoA
and then CoA.31
We have identified mutations in the COASY in two
subjects with clinical and MRI features typical of NBIA.
They displayed a strikingly similar phenotype, more severe
in subject II-2 of family 2, presenting with early-onset
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Figure 5. HPLC Analysis of CoA Produc-
tion by Wild-Type and Mutant DPCK
Recombinant Proteins
(A) Top: equal amount of purified wild-
type and mutant DPCK proteins were
loaded on a 12% SDS page and stained
with Coomassie blue. Bottom: immuno-
blot analysis on the same gel showing
that anti-COASY antibody is able to recog-
nize both the wild-type and the mutant
protein.
(B) Chromatogram showing the peak cor-
responding to the reaction product (green)
obtained from incubation of wild-type
DPCK recombinant protein with ATP and
dephospho-CoA.
(C) Chromatogram showing the peak cor-
responding to the reaction product (green)
obtained from incubation of mutant
DPCK-Arg499Cys recombinant protein
with ATP and dephospho-CoA. Red peak,
CoA standard; blue peak, dephospho-CoA
standard.
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parkinsonian features, cognitive impairment, and pro-
nounced obsessive-compulsive disorder. The disease was
slowly progressive with loss of ambulation during adoles-
cence and adulthood. This phenotype overlaps with other
NBIA disorders, including the presence of an axonal
neuropathy, which is commonly reported in phospholi-
pase A2-associated neurodegeneration (PLAN) and also in
mitochondrial membrane protein-associated neurodegen-
eration (MPAN) cases.32
In subject II-3 of family 1, MR images are reminiscent of
the ‘‘eye-of-the-tiger’’ sign even if with subtle features,
which differentiate it from the typical appearance present
in PKAN.33,34 In subject II-2 of family 2, an isolated
involvement of neostriatum, which usually hallmarks a
metabolic rather than degenerative disorder, preceded
the evidence of the typical increase of pallida iron content.
Such features have not been previously reported, expand-
ing the MR spectrum of NBIA disorders.0 
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statistically significant. A reduction of total CoA was observed in bo
(B) De novo synthesis of CoA and dephosphoCoA (dpCoA) in primar
two affected individuals (II-3, family 1; II-2, family 2). CoA (white bar
tified by HPLC after deproteinization of reaction mixture with PCA
independent experiments. Statistically significant differences with C
TheBoth individuals presented with a severe neurological
disorder but they have survived up to the third decade
of life, suggesting the presence of residual amount of
CoA as observed in cultured fibroblasts. The complete
absence of CoA would be probably incompatible with
life, and organisms have developed alternative strategies
to counteract deleterious effects of mutations in CoA
enzymatic pathway. For instance, mammals possess four
closely related PANK isoforms,2 1a, 1b, 2, and 3, which
exhibit a tissue-specific pattern of expression. This redun-
dancy could explain why PKAN patients can survive into
the first or second decade of life. Probably, the different
isoforms can compensate each other to maintain
adequate CoA level. This was clearly demonstrated in
mice by the simultaneous knockout of two different
Pank genes.35
COASY has been reported to code for three transcript
variants resulting in tissue-specific isoforms.14 The exis-
tence and functional significance of these variants are* 
II-3 
(family 1) 
II-2 
(family 2) 
Figure 6. HPLC Analysis of CoA and CoA
Derivatives in Fibroblasts
(A) CoA (white bar), acetyl-CoA (black bar),
and total CoA (gray bar) levels in primary
skin fibroblasts derived from a healthy
control (CT) and from the two affected
individuals (II-3, family 1; II-2, family 2).
Results shown are mean 5 SEM of four
independent experiments. Statistically
significant differences in acetyl-CoA
amount between CT and subject II-3 (fam-
ily 1) were determined by the Student’s
t test; *p < 0.05. This subject also shows
a reduction in acetyl-CoA, which is not
th affected individuals, although not statistically significant.
y skin fibroblasts derived from a healthy control (CT) and from the
) and dpCoA (gray bar) produced from 40PP as substrate were quan-
(3% final). Results shown are mean 5 SEM of values from three
T were determined by the Student’s t test; **p < 0.02.
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Figure 7. Growth of Yeast Strains in Presence or Absence of
Pantothenate
The strain Dcab5 was transformed with pFL39 plasmid carrying
the wild-type CAB5 and the mutant allele cab5Arg146Cys (A) or
with pYEX-BX plasmid carrying COASY and COASYArg499Cys (B).
Equal amounts of serial dilutions of cells from exponentially
grown cultures (105, 104, 103, 102, 101 cells) were spotted onto
minimum medium 40 plus 2% glucose, with or without panto-
thenate 1 mg l1. The growth was scored after 3 days of incuba-
tion at 23C, 28C, or 37C. Each experiment of serial dilution
grow test was done in triplicate starting from independent yeast
cultures.
Figure 8. HPLC Analysis of CoA in Yeast Mitochondria
CoA level in mitochondria isolated from Dcab5 yeast transformed
with wild-type (WT) or mutant (p.Arg146Cys) yeast CAB5 (A), and
with wild-type or mutant (p.Arg499Cys) human COASY (B). Equal
amount of mitochondrial proteins (40 mg) were used in each assay.
Results shown are mean 5 SD of values from three independent
experiments. Values of mutant samples are expressed as percent-
age of values obtained in wild-type samples taken as 100%. Statis-
tically significant differences were determined by the Student’s
t test; *p < 0.05; **p < 0.02.
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study affect the protein sequence common to isoforms
alpha and beta, predicting overall impairment of COASY
function. Considering the ubiquitous presence of the
enzymatic COASY activity, it remains unexplained why
only the brain is affected and other organs are preserved.
It is possible that a more severe impairment of CoA levels
occurs in this organ, thus explaining the prevalence of
neurological symptoms. At the cellular level CoA
concentration is regulated by numerous factors, including
hormones, glucocorticoids, nutrients, and cellular metabo-
lites,36,37 and a link between the complex signaling mTOR
pathway, which is implicated in numerous metabolic and
signaling processes, and CoA biosynthesis has been pro-
posed.38 Moreover, it is relevant to notice that the muta-
tions targeted genes coding for pantothenate kinase39
and PPAT activity of CoA synthase36 are the two rate-
limiting steps in CoA biosynthesis. All together these fac-
tors could contribute to modulate the clinical presentation
of individuals carrying COASY mutations.
It is still unknown how mutations in genes involved in
Coenzyme A enzymatic pathway cause neurodegeneration10 The American Journal of Human Genetics 94, 1–12, January 2, 201with iron accumulation in specific areas of the brain but
whereas for PANK2 it was hypothesized that cysteine accu-
mulation may chelate iron and catalyze free radical forma-
tion,40 a different mechanism could be involved in case of
COASY mutations.
In Drosophila it has been demonstrated that abolishing
the different genes of CoA biosynthetic pathway including
the fumble/PANK2 and PPAT-DPCK activities causes a
neurological phenotype characterized by brain vacuoliza-
tion without iron accumulation.12
Identification of mutations in CoA synthase strongly
reinforces the essential role of CoA biosynthetic pathway
for the development and functioning of the nervous
system. This also underlines the importance of further
investigations on different subcellular pools of CoA avail-
able, because a specific mitochondrial pathway could exist
considering that both PANK2 and CoA synthase are mito-
chondrial enzymes.16–18 At present it is not understood
whether CoA can pass from cytosol to mitochondria,
even if a CoA-specific carrier has been identified in the
inner mitochondrial membrane.41 Moreover, it is not clear
whether the regulation of the different pools is coordi-
nated and whether the utilization could be modulated in
response to different physiological or pathological condi-
tions.
In conclusion, we have demonstrated that COASY
mutations cause a distinctive NBIA subtype. This finding
will require further investigation to understand the
connection linking CoA metabolism to neurodegenera-
tion, iron accumulation, and mitochondrial bioenergetics.
We propose CoPAN, standing for COASY protein-associ-
ated neurodegeneration, as the acronym for NBIA caused
by CoA synthase mutations to conform with the current
nomenclature in use to classify these disorders.4
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1b TCCCATACAGGCCTCTGCC GGCCTTAGCACCAATTGAGTG 
AmpliTaq 
Gold® 
60°C 
2 TGCTTGCCTGTTTCTTCACCT CGGGCAAACTGAGAACCAGTT GoTaq® Flexi 59°C 
3 GGAGCCTGGGTAGGAAGGG CTCAGCCTCATGCCTGGG GoTaq® Flexi 60°C 
4 CCTGGCAATGCTGGAGAGTAG GGCCTGGCTAGCTCCTCACT GoTaq® Flexi 60°C 
5 GGCCTCTGTGCTCAGTTGTCT GCAAGGTGGTGTTGGGAACA GoTaq® Flexi 60°C 
6 CCCAGAATGCCATTTCCATT GACGTTCTCCCAGGCAGAAC GoTaq® Flexi 59°C 
7 GAGGATGGCAACAGCTAAGGG TTTGTCAGGAAGAATTCCAGCTC GoTaq® Flexi 59°C 
8 CCCCCCACACCATCCCTAC GATGAGTCTTGGGAATGCGCT GoTaq® Flexi 60°C 
9 TACTGCCTGACCCTGCCCT AAAGCTCGCCTCTGGCTAGC 
AmpliTaq 
Gold® 
60°C 
GoTaq® Flexi DNA Polymerase (Promega); AmpliTaq Gold® (Life Technologies) were used. PCR 
conditions were: 94°C, 1min (1 cycle); 94°C 30sec, annealing time was 30sec at the indicated 
temperatures, 72°C 1min (30 cycles). 
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Induced neuronsPantothenate kinase-associated neurodegeneration is an early onset autosomal recessive movement disorder
caused by mutation of the pantothenate kinase-2 gene, which encodes a mitochondrial enzyme involved in coen-
zymeAsynthesis. The disorder is characterisedbyhigh iron levels in thebrain, although thepathologicalmechanism
leading to this accumulation is unknown. To address this question,we tested primary skinﬁbroblasts from three pa-
tients and three healthy subjects, as well as neurons induced by direct ﬁbroblast reprogramming, for oxidative sta-
tus, mitochondrial functionality and iron parameters. The patients' ﬁbroblasts showed altered oxidative status,
reduced antioxidant defence, and impaired cytosolic and mitochondrial aconitase activities compared to control
cells. Mitochondrial iron homeostasis and functionality analysis of patient ﬁbroblasts indicated increased labile
iron pool content and reactive oxygen species development, alteredmitochondrial shape, decreasedmembrane po-
tential and reduced ATP levels. Furthermore, analysis of induced neurons, performed at a single cell level, conﬁrmed
some of the results obtained inﬁbroblasts, indicating an altered oxidative status and signs ofmitochondrial dysfunc-
tion, possibly due to iron mishandling. Thus, for the ﬁrst time, altered biological processes have been identiﬁed
in vitro in live diseased neurons. Moreover, the obtained induced neurons can be considered a suitable human neu-
ronal model for the identiﬁcation of candidate therapeutic compounds for this disease.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Neurodegeneration with brain iron accumulation (NBIA) is a hetero-
geneous group of genetic disorders characterised by radiological evidence
of focal accumulation of iron in the brain, usually in the basal ganglia and
extrapyramidal dysfunction (Schneider et al., 2013; Levi and Finazzi,
2014). These disorders are characterised by early or late onset, with the
main symptoms associated with problems in movement, spasticity and, deferoxamine; DHR-123,
inducedneurons; IRP1, ironreg-
ationwith brain iron accumula-
egeneration; PIH, pyridoxal
es; RPA, rhodamine B-[(1,10-
rhodamine B-[(phenanthren-9-
ine methyl ester.
University and San Raffaele
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ect.com).
. This is an open access article under
t al., Mitochondrial iron and en
robiol. Dis. (2015), http://dx.cognitive impairment. Approximately 50% of cases of NBIA can be ex-
plained by mutations in the PANK2 gene that cause an autosomal–reces-
sive form of the disease, termed pantothenate kinase-associated
neurodegeneration (PKAN or NBIA type I; OMIM 234200) (Hayﬂick,
2014). Magnetic resonance imaging (MRI) is particularly useful for
distinguishing the cases of PKAN from other NBIA forms. In the majority
of PKAN patients, the T2-weighted images show a hyperintense lesion
of the globus pallidus, surrounded by a hypointense area (Angelini et al.,
1992). This combination of hyper- and hypointense areas in the globus
pallidus gives rise to a pattern deﬁned as the “eye of the tiger”, which is
almost pathognomonic of the disease. The brain regions inwhich iron ac-
cumulates at pathological levels are the globus pallidus and substantia
nigra, where iron-positive spheroidal bodies are visible, usually in the vi-
cinity of swollen axons. Other neuropathological signs include demyelin-
ation, neuronal loss and gliosis (Kruer et al., 2011).
PANK2 codes for the pantothenate kinase-2 (PANK2), amitochondrial
enzyme that catalyses theﬁrst limiting step of the de novo biosynthesis of
coenzymeA(CoA). CoA is a key factor in several cellular processes, includ-
ing mitochondrial energy metabolism, anabolism and catabolism of fatty
acids, as well as protein biosynthesis (Leonardi et al., 2005). In humans, 4the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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localisation. Mutations in PANK2, which is located on chromosome 20,
are spread over all 7 exons and include missense, nonsense, frameshift
and splicing sitemutations (Hartig et al., 2006).Mutations in PANK2 result
in enzyme deﬁciency, leading to insufﬁciency of the ﬁnal product and ac-
cumulation of upstream substrates, such as N-pantotenoil-cysteine and
pantetheine, which are potentially toxic (Leoni et al., 2012). In particular,
cysteine is a potent iron chelator, and it has been proposed that high local
levels of cysteine are the basis of the subsequent accumulation of iron,
resulting in increased oxidative stress (Perry et al., 1985). The other hy-
pothesis to explain the observed iron accumulation suggests that alter-
ations in phospholipid metabolism due to CoA-deﬁciency may injure
the membranes, with consequent oxidative stress that leads to iron dys-
homeostasis (Leonardi et al., 2007). Different animal disease-models
have been developed using Drosophila melanogaster andMus musculus.
Drosophila PKAN models partially recapitulate the human phenotype,
showing locomotor dysfunction and neurodegeneration (Rana et al.,
2010). In addition, a Pank2 KO mouse model does not fully recapitulate
the human phenotype (Kuo et al., 2005), unless particular dietary condi-
tions are used (Brunetti et al., 2014). The double knock-out of more than
one Pank in mice produces a very drastic phenotype resembling a meta-
bolic syndrome (Garcia et al., 2012). However, these models do not
show iron accumulation in the brain and are not useful for studying the
pathogenetic mechanism leading to iron imbalance, which is hallmark
sign in the brains of patients. Two in vitro studies on cellular models
have attempted to explain the relationship between PANK2 deﬁciency
and iron deregulation. In HeLa, HepG2 and SH-SY5Y cells, the speciﬁc
siRNA silencing of PANK2 affects cell proliferation, induces cellular iron
deﬁciency and increases the expression of the iron exporter ferroportin
(Poli et al., 2010). PKAN ﬁbroblasts, maintained in chronic iron supple-
mentation, showed disturbed iron sensor protein iron regulatory protein
1 (IRP1) activity, resulting in deregulation of ferritin and transferrin re-
ceptor1 (TfR1), as well as a larger intracellular bioactive labile iron pool
(LIP). This effect results in higher reactive oxygen species (ROS) develop-
ment and leads to increased cellular oxidative status (Campanella et al.,
2012).
Mitochondria are the main sites of iron utilisation in the cell (Levi
and Rovida, 2009). This organelle employs the metal to sustain the bio-
synthesis of the iron sulphur cluster (ISC) and heme cofactors,which are
prosthetic groups ofwidespread proteins involved in key biological pro-
cesses, such as electron transfer, DNA synthesis and repair, metabolic
and regulatory processes (Stehling et al., 2014). Thus, mitochondria
play a central role in cell life, not only for energy supply but also for cel-
lular iron handling. This important role is highlighted by the fact that
defects in mitochondrial iron homeostasis lead to pathological pheno-
types and cell death (Levi and Rovida, 2009). Here, we evaluated mito-
chondrial functionality in terms of iron handling and energetic proﬁle to
investigatewhether the iron-dependent oxidative status alteration, pre-
viously revealed in PKAN patients' ﬁbroblasts (Campanella et al., 2012),
also affects themitochondrial compartment. Furthermore, by taking ad-
vantage of the recently developed technology (Amamoto and Arlotta,
2014; Caiazzo et al., 2011) that allows neurons to be directly
transdifferentiated from ﬁbroblasts, we generated induced neurons
(iNs) from PKAN patients to establish a suitable disease model in
which to study the consequences of PANK2 dysfunction.
Material and methods
Cell culture
We used primary skin ﬁbroblasts from three unaffected subjects
(controls 1, 2 and 3, two neonatals and one adult) purchased from
ATCC and from three PKAN patients selected from theMovement Disor-
ders Bio-Bank available at theNeurogeneticsUnit of theNeurological In-
stitute ‘Carlo Besta’ (INCB), Milan, Italy. Two PKAN patients (marked
F419fsX472(a) and F419fsX472(b), biopsy was made at the age of twoPlease cite this article as: Santambrogio, P., et al., Mitochondrial iron and e
pantothenate kinase-associated neuro..., Neurobiol. Dis. (2015), http://dx.and four years old) (Campanella et al., 2012)were brothers who are ho-
mozygous for the same frame shift mutation that results in a truncated
PANK2 protein (F419fsX472). The third, Y190X (Hartig et al., 2006),was
homozygous for amutation that produced a truncated amino acid chain.
The ﬁbroblasts were grown in DMEM (Lonza) supplemented with 10%
FBS (Lonza), 100 mg/ml streptomycin, 100 U/ml penicillin and 4 mM
L-glutamine (Sigma).Generation of iNs from human ﬁbroblasts by direct reprogramming
Human ﬁbroblasts from patients and controls were grown in medi-
um for ﬁbroblasts (DMEM, FBS, nonessential amino acids, sodium pyru-
vate, and penicillin/streptomycin) plated onto Matrigel-coated 24-well
plates (5 × 104 cells/well). For the immune-histochemical analysis,
some of these cells were plated onto Matrigel-coated glass coverslips.
On the second day, the ﬁbroblasts were infected by lentivirus in which
cDNAs for transcription factors (Mash1, Nurr1, and Lmx1a) had been
cloned (Caiazzo et al., 2011) under the control of a tetracycline-
responsive promoter. Sixteen to twenty hours after infection, the cells
were switched into fresh ﬁbroblast medium containing doxycycline
(2mg/ml), and after a further 48 h, themediumwas replacedwith neu-
ronal inducing medium (DMEM F12, 25 μg/ml insulin, 50 μg/ml trans-
ferrin, 30 nM sodium selenite, 20 nM progesterone, and 100 nM
putrescine and penicillin/streptomycin) containing doxycycline (all
from Sigma). The medium was changed every 2–3 days for a further
20 days.Immunoblotting
Soluble cellular extracts for immunoblotting were obtained by lys-
ing cells in 20mMTris–HCl, pH7.4, 1% TritonX-100, and protease inhib-
itor cocktail (Roche) followed by centrifugation at 16,000 g for 10 min.
Fifteen micrograms of total proteins was separated by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), and immu-
noblotting was performed using speciﬁc antibodies: anti-citosolic
aconitase (cAco) (Campanella et al., 2012) was used at a dilution of
1:500; anti-mitochondrial aconitase (mAco) (Antibody Verify) was
used at a ﬁnal concentration of 1 μg/ml; the anti-β-actin antibody
(Sigma) was used at a dilution of 1:6000; the mouse monoclonal anti-
PANK2 (Origene) antibody was used at a dilution of 1:2000; and the
mouse monoclonal anti-SDH (70 kDa subunit) (MitoScience) was
used at a ﬁnal concentration of 0.1 μg/ml, followed by peroxidase-
labelled secondary antibodies (Sigma-Aldrich). Band intensity was re-
vealed by the ECL-chemiluminescence kit (GE Healthcare). The total
protein contents were measured using the BCA protein assay (Thermo
Fisher Scientiﬁc) calibrated with bovine serum albumin.Determination of aconitase activity
Aconitase activity was in-gel assayed as described in Tong and
Rouault (2006). The patient and control ﬁbroblasts were grown in
DMEM, harvested, washed in PBS and lysed in 20 mM Tris–HCl buffer,
pH 7.4, 1% Triton X-100, protease inhibitor cocktail, 2 mM citrate,
0.6 mM MnCl2, and 40 mM KCl. Soluble extracts (40 μg) in 25 mM
Tris–HCl, pH 8.0, 10% glycerol, bromophenol blue, were loaded on
PAGE gels containing 8% acrylamide, 132mMTris base, 132mMborate,
and 3.6mMcitrate in the separating gel; and 4% acrylamide, 67mMTris
base, 67mMborate, 3.6mMcitrate in the stacking gel. The runwas per-
formed at 180 V for 2.5 h at 4 °C. Aconitase activity was determined in
the dark at 37 °C by incubating the gel in 100 mM Tris–HCl, pH 8.0,
1 mM NADP, 2.5 mM cis-aconitic acid, 5 mM MgCl2, 1.2 mM MTT,
0.3 mM phenazine methosulfate, and 5 U/ml isocitrate dehydrogenase.
The quantiﬁcation of the signal was performed using the NIH image
software ImageJ.nergetic dysfunction distinguish ﬁbroblasts and induced neurons from
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Heme content was measured in ﬁbroblasts from patients and con-
trols as previously described (Santambrogio et al., 2011). Brieﬂy, the
cells were washed with phosphate-buffered saline and dissolved in
0.25 ml of 98% formic acid and incubated for 15 min. The heme content
was evaluated by analysing the clear supernatant at 400nm,with an ex-
tinction coefﬁcient of 1.56 × 105 ×M−1 × cm−1. The datawere normal-
ised to protein content as determined by the BioRad Protein Assay
(BioRad).
Oxidised protein detection
Oxidised proteins were detected using the OxyBlot Protein Oxida-
tionDetection Kit (Millipore) following themanufacturer's instructions.
Brieﬂy, 10 μg of the soluble cellular extracts was derivatised to 2,4
dinitrophenylhydrazone, and 5 μg was loaded on a 12% SDS-PAGE gel,
blotted and incubated with an anti-DPN antibody. The bound activity
was revealed by a ECL-chemiluminescence kit (GE Healthcare).
Glutathione measurement
Fibroblasts, treated or not with 1 mM TCEP (tris[2-
carboxyethyl]phosphine) for 30 min at 37 °C, were incubated with
20 μM ThiolTracker Violet (Invitrogen) for 30 min at 37 °C, washed
with PBS and ﬁxed in 4% paraformaldehyde in PBS for 20 min at
room temperature. The images were acquired by Zeiss Axiovert 135
TV ﬂuorescence microscope, and the ThiolTracker Violet signal was
quantiﬁed by ImageJ software. iNs were incubated with 20 μM
ThiolTracker Violet (Invitrogen) for 30 min at 37 °C, washed with
PBS and ﬁxed in 4% paraformaldehyde in PBS for 20min at room tem-
perature. The cells were then permeabilised for 3min in PBS contain-
ing 0.1% Triton X100 and 10% normal goat serum. Next, the cells were
incubated with Alexa Fluor 647 mouse anti-human CD56 (N-CAM,
BD Biosciences, diluted 1:40) for 1 h at 37 °C, and with 2 μg/ml
Hoechst for 2 min. After washing, the cells were analysed by IN Cell
Analyzer 1000 system (GE Healthcare). The ThiolTracker Violet ﬂuo-
rescence in N-CAM-positive cells was collected to compare relative
glutathione contents.
Determination of LIP
LIP was measured using the iron-sensitive ﬂuorescent probe RPA
(rhodamine B-[(1,10-phenanthrolin-5-yl)-aminocarbonyl]benzyl ester)
(Squarix Biotechnology). Control of ﬂuorescence probe incorporation
was performed with RPAC (rhodamine B-[(phenanthren-9-yl)-
aminocarbonyl]-benzylester), an analogue of RPA but without iron bind-
ing capacity and subsequent quenching. Brieﬂy,ﬁbroblastswere plated in
96-well plates and incubated with or without 100 μM FAC and 200 μM
ascorbic acid (Sigma) for 18 h. The cells were incubated in HBSS supple-
mented with 10 mM glucose and 2 μM RPA or RPAC for 15 min at 37 °C.
After two washes with HBSS, the cells were maintained in HBSS supple-
mented with 10 mM glucose. Basal ﬂuorescence was measured using a
Victor3Multilabel Counter (Wallac, Perkin Elmer) at 530 nm (excitation)
and 590 nm (emission). The quenching of RPA by ironwas revealed after
the addition of the speciﬁc iron chelator PIH (ﬁnal concentration: 2 mM)
for 30 min. The results were normalised for protein content.
Determination of ROS
Fibroblasts were incubated with 30 μM dihydrorhodamine-123
(DHR-123, Molecular Probes) for 15 min at 37 °C and then washed
with PBS and maintained in HBSS supplemented with 10 mM glucose.
The ﬂuorescence was determined using the Victor3 Multilabel Counter
(PerkinElmer) at 485 and 535 nm for excitation and emission,Please cite this article as: Santambrogio, P., et al., Mitochondrial iron and en
pantothenate kinase-associated neuro..., Neurobiol. Dis. (2015), http://dx.respectively. The cells were incubated in HBSS for 30 min at 37 °C
with 0.3 M H2O2, and ﬂuorescence was determined as above.
iNs generated from ﬁbroblasts were incubated with Alexa Fluor 647
mouse anti-human CD 56 (anti-N-CAM; BD Biosciences) for 1 h, with
20 μM of 2′,7′-dichlorodihydroﬂuorescein diacetate (H2DCFDA; Molec-
ular Probes) for 15 min and with 2 μg/ml of Hoechst 33342 for 2 min.
All of these incubationswere performed at 37 °C. The cells werewashed
and analysed using an IN-Cell Analyzer 1000 system (GE Healthcare).
The ﬂuorescence of DCF from N-CAM-positive cells was collected to
compare the relative ROS contents.
Determination of mitochondrial membrane potential
Fibroblasts were incubated with 4 μg/ml of oligomycin (Sigma) for
1 h at 37 °C and with 2 μg/ml of Hoechst 33342 for 2 min. Then,
20 nM of tetramethylrhodamine methyl ester (TMRM; Molecular
Probes) was added, and its incorporation was followed by analysis
with the IN-Cell Analyzer 1000 system for 2 h. Next, 4 μg/ml of FCCP
(Sigma) was added to depolarise the mitochondrial membrane, and
TMRM signal followed for other 10 min.
iNs generated from ﬁbroblasts were incubated with Alexa Fluor 488
mouse anti-human CD 56 (anti-N-CAM; BD Biosciences) for 1 h, with
20 μM of TMRM (Molecular Probes) for 15 min, and with 2 μg/ml of
Hoechst 33342 for 2 min. All of these incubations were performed at
37 °C. The cells were washed and analysed by the IN-Cell Analyzer
1000 system (GE Healthcare). The ﬂuorescence of TMRM from N-
CAM-positive cells was collected to compare the relative mitochondrial
membrane potential.
Analysis of mitochondrial network and Shape Factor
The cells were plated on 35-mm glass-bottom dishes in complete
DMEM. After 24 h, Mitotracker Red (Invitrogen) was added at a ﬁnal
concentration of 10 nM for 30min at 37 °C. The cells were then washed
three times with PBS, and a medium with 25 mM HEPES and without
Phenol Red was added. Fluorescence was visualised on an Axiovert
200 epiﬂuorescence inverted microscope (Zeiss, Germany) equipped
with a 40× ﬂuorite objective using a CARV II Confocal Imager (BD Bio-
sciences). The images were acquired using a CCD camera (Roper Scien-
tiﬁc, USA). All of the imaging data were collected and analysed using
MetaMorph acquisition/analysis software (Universal Imaging Corp.,
Downingtown, PA, USA).
The amount of mitochondrial fragmentation was evaluated using
the Shape Factor function of the MetaMorph software. Shape Factor
evaluates the circular shape of an object and attributes a score near 0
in the case of a ﬂattened object and a score near 1 for a perfect circle.
We deﬁned three shape factor groups to classify the different morphol-
ogies of the mitochondrial networks: Group I: shape factor 0–0.3
consisted of cells with a ﬁlamentous mitochondrial network; Group II:
shape factor 0.3–0.6 consisted of cells with ﬁlamentous network but
with the presence of round-shaped mitochondria; and Group III:
shape factor 0.6–1 consisted of cells with high fragmentation with
only round-shaped mitochondria. For each cell type, a total of 100 im-
ages, collected in four different experiments, were used to calculate
the percentage of the different shape factors.
ATP evaluation
Fibroblasts were plated at 8000 cells/well in 96-well plates. The
next day, total cellular ATP was measured using the ATPlite kit
(PerkinElmer Life Sciences) according to the manufacturer's proce-
dure. This method is based on the mono-oxygenation of luciferin,
which is catalysed by luciferase in the presence of Mg2+, ATP, and
oxygen, resulting in a luminescent signal that is proportional to the
ATP concentration. The plate was read on a Victor plate reader
(Perkin Elmer) in luminescence mode. The cell numbers wereergetic dysfunction distinguish ﬁbroblasts and induced neurons from
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normalised for cell number.Statistical analyses
The data, except where otherwise indicated, are reported as the
mean+/− SD values or as representative of at least three independent
experiments with similar results. Statistically signiﬁcant differences be-
tween controls and patients were determined in all the experiments by
one-way ANOVA analyses with Bonferroni's post-test and by Student's
t-test; *, ** and *** indicated p b 0.05, p b 0.01 and p b 0.001, respectively.
A p value b0.05 was considered statistically signiﬁcant. Both analyses
gave similar signiﬁcance except where speciﬁed.Results
PKAN ﬁbroblasts show altered iron dependent oxidative status
We analysed ﬁbroblasts from three PKAN patients and healthy
subjects. One PKAN patient carried a homozygous c.569insA mutation
that resulted in a premature stop codon at amino acid position 190
(p. Y190X) (Hartig et al., 2006); the other two patients are brothers
and carried a homozygous c.1259delG mutation, producing a frame
shift mutation resulting in the substitution of 53 amino acids and the
creation of a stop codon (F419fsX472) (Campanella et al., 2012; Zorzi
et al., 2011). As shown bywestern-blot analysis in Fig. 1A, PANK2 is vir-
tually absent in all three patients, whilst a normal level of the protein is
present in the controls. We then determined cellular oxidative status
and its relationship with iron content in these cells by treating control
and PKAN ﬁbroblasts with the iron-chelator deferoxamine (DFO) for
18 h. The content of carbonylated proteins in the DFO-treated and un-
treated cellular extractswas then evaluated byOxyblot (Fig. 1B). The re-
sults conﬁrmed that untreated PKAN ﬁbroblasts showed increased
carbonylated protein levels compared to control cells (Fig. 1B, DFO−).
Interestingly, whilst DFO treatment ameliorated the level of
carbonylated proteins in PKAN ﬁbroblasts, it was completely ineffective
in control ﬁbroblasts (Fig. 1B, DFO+). Moreover, by monitoring
ThiolTracker Violet intensity, we observed a signiﬁcant reduction in
levels of both total and reduced glutathione in PKAN ﬁbroblasts com-
pared to controls (Fig. 1C).Fig. 1. PKAN ﬁbroblasts show altered oxidative status. (A) The determination of the PANK2 p
(47 kDa) and to SDH70 used as loading control. The other lower band, present in patients an
not with 100 μM deferoxamine (DFO) for 18 h, and the levels of carbonylated proteins in solu
experiments is shown. (C) Measurements of total and reduced glutathione content in ﬁbroblas
quired by ﬂuorescence microscopy, and the quantiﬁed signal, relative to controls, was plott
**p b 0.01, ***p b 0.001.
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Toverifywhether the defect in PANK2 activity affectedmitochondri-
al iron homeostasis, we tested for the presence of potentially toxic free
iron (LIP) in themitochondrial compartment using the iron sensingmi-
tochondrial target-speciﬁc ﬂuorescent probe (rhodamine B-[(1,10-
phenanthrolin-5-yl)-aminocarbonyl]benzyl ester, RPA). This probe has
been largely used with success in previous works to speciﬁcally mea-
sure the mitochondrial LIP (Cabantchik, 2014; Ma et al., 2015; Rauen
et al., 2007). Rhodamine B-[(phenanthren-9-yl)-aminocarbonyl]-
benzylester (RPAC), an analog of RPA but without iron binding capacity
and subsequent quenching, was used to monitor the incorporation of
the probe driven by mitochondrial-membrane-potential in the control
and patients' cells. The cells were incubated with or without 100 mM
ferric ammonium citrate (FAC) for 18 h. The RPAC ﬂuorescence was
measured and the results indicated that the amount of incorporated
probe was similar in control and patients' cells in all the conditions
(not shown). Then, RPA ﬂuorescence was measured before and after
the addition of the iron chelator PIH (pyridoxal isonicotinoyl
hydrazone) (Rauen et al., 2007). The result indicated that the size of
the mitochondrial LIP was statistically higher in PKAN ﬁbroblasts than
in control cells in both basal growth conditions (Fig. 2A) and with iron
supplementation (not shown). As labile iron can promote ROS forma-
tion, we measured their generation using the ROS sensitive mitochon-
drial probe dihydrorhodamine 123 (DHR-123) in basal growth
condition and after iron supplementation (Campanella et al., 2009).
The ﬂuorescence intensity was signiﬁcantly higher in PKAN ﬁbroblasts
than in controls under basal growth conditions (Fig. 2B) and after iron
addition (not shown). In PKAN cells only, this difference further in-
creased after incubation with 0.3 mMH2O2 both in basal growth condi-
tion (Fig. 2C) and after iron supplementation (not shown). To test the
efﬁciency of ISC biosynthesis, we evaluated the in-gel enzymatic activi-
ty of cAco and mAco, two ISC-containing proteins, after separation on
non-denaturing PAGE (Fig. 2D, upper panel), a higher sensible method
with respect to the one previously used (Campanella et al., 2012). Den-
sitometric analysis of the bands showed a reduced enzymatic activity of
both aconitase forms (Fig. 2D, lower panels). However, the amount of
aconitase proteins as evaluated by western blotting with speciﬁc anti-
bodies was similar between PKAN and control ﬁbroblasts (not
shown). Furthermore, we evaluated heme biosynthesis that, other
than depending on the ISC-containing ferrochelatase, represents the
other major iron-containing product in mitochondria. We measuredrotein content in ﬁbroblast soluble extracts. The arrows point to PANK2 mature peptide
d controls, is a non-speciﬁc reaction of the antibody. (B) The ﬁbroblasts were treated or
ble cell extracts were then analysed by Oxyblot. One representative of three independent
ts evaluated using the speciﬁc ﬂuorescent probe ThiolTracker Violet. The images were ac-
ed as the mean and standard deviation of three independent experiments in triplicate.
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Fig. 2. PKANﬁbroblasts show alteredmitochondrial iron handling. (A) The evaluation of themitochondrial LIP in untreatedﬁbroblasts by the speciﬁc probe RPA. Themean and SDof three
independent experimentsmade in quadruplicate, and the bars indicate statistically signiﬁcant differences, * p b 0.05. (B and C) The cells were treated or not with 0.3mMH2O2 for 30min,
and the mitochondrial ROS generation was evaluated on untreated B or treated C ﬁbroblasts using the ﬂuorescent probe DHR-123. The mean and SD of three independent experiments
made in quadruplicate, *p b 0.05, **p b 0.01. (D) The enzymatic activity of aconitase was evaluated on soluble cell homogenates that were separated on non-denaturing PAGE gels. The
arrows indicate the position ofmitochondrial aconitase (mAco), of cytosolic aconitase (cAco) and of the protein band stainedwith Coomassie blue used for loading control. The histograms
show the densitometry of aconitase bands relative to controls, with the mean and SD of three independent experiments, *p b 0.05, **p b 0.01, ***p b 0.001. (E) The evaluation of heme
content in untreated ﬁbroblasts by absorbance at 400 nm of the soluble cell lysates. The mean and SD of six independent experiments, *p b 0.05, ***p b 0.001.
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tracts from cells lysed in formic acid at 400 nm. We observed a signiﬁ-
cant difference in heme content, corresponding to a 25% reduction in
PKAN compared to the control ﬁbroblasts (Fig. 2E).
PKAN ﬁbroblasts show energetic mitochondrial dysfunction
We further investigated the ability of mitochondria to maintain the
cellular energy requirement. The mitochondrial membrane potential
was evaluated with the mitochondria-speciﬁc ﬂuorescent probe
tetramethylrhodamine methyl ester (TMRM) on ﬁbroblasts in thePlease cite this article as: Santambrogio, P., et al., Mitochondrial iron and en
pantothenate kinase-associated neuro..., Neurobiol. Dis. (2015), http://dx.presence of the ATPase inhibitor oligomycin. The kinetics of TMRM incor-
porationwas followed for 2 h bymonitoring theﬂuorescence of the probe
using the IN-Cell Analyzer 1000 system. Starting from 30 min, the mean
kinetics of the controls was statistically higher than for PKAN patient ﬁ-
broblasts (Fig. 3A, *p b 0.05). These data indicated that the PKAN ﬁbro-
blasts incorporated less probe compared to control cells, suggesting
lowermembrane hyperpolarisation.We investigatedmitochondrialmor-
phology after loading cellswithMitotracker Red and examinationbyﬂuo-
rescencemicroscopy. Theﬁbroblastswere scored into different categories
on the basis of mitochondrial morphology. Representative images of
these classes of mitochondrial morphology are shown in Fig. 3B. A totalergetic dysfunction distinguish ﬁbroblasts and induced neurons from
doi.org/10.1016/j.nbd.2015.02.030
Fig. 3. PKAN ﬁbroblasts show alteredmitochondrial functionality. (A) The ﬁbroblasts were incubatedwith 4 μg/ml of oligomycin for 1 h, and the mitochondrial-speciﬁc ﬂuorescent probe
TMRMwas then added. Its incorporationwas followed using the IN-Cell Analyzer 1000 system for 2 h. Plots, normalised on starting points, show the kinetics of TMRM incorporation,with
themean and SEM of three independent experiments, * p b 0.05 from 30minwith the exception of patient Y190X that resulted signiﬁcant only from 60min by one-way ANOVA analyses
with Bonferroni's post-test. The arrow indicates the time of FCCP addition. (B) Fibroblasts were incubated with MitoTracker Red ﬂuorescent probe. The evaluation of the mitochondrial
shape factor was performed on images obtained by ﬂuorescence microscopy. The histogram shows the percentage of cells with the indicated shape factor, with the mean and SD of
four independent experiments, **p b 0.01, ***p b 0.001. (C) Evaluation of ATP content in ﬁbroblasts. Total ATP levels were evaluated by the ATPlite kit. The data are presented as the
mean of two controls (reported as a single bar) and three patients, reported separately, with the mean and SD of three independent experiments. *p b 0.05, ***p b 0.001.
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The amount of mitochondrial fragmentation was evaluated using the
Shape Factor function of MetaMorph software. This function evaluates
the circular shape of an object and attributes a score near 0 in the case
of a ﬂattened object and a score near 1 for a perfect circle. The Shape Fac-
tor average of PKAN patients' ﬁbroblasts was closer to 1 than in the con-
trol subjects. The mitochondrial network of PKAN patients with loss-of-
functionmutationswasmore fragmented than controls, indicating an im-
paired bioenergetic proﬁle. The difference between these two samples
was statistically signiﬁcant (Fig. 3B upper panel; *p b 0.05; **p b 0.01).
In line with this observation, we observed a reduction in ATP levels in
PKAN ﬁbroblasts compared to control cells (Fig. 3C; *p b 0.05; **p b 0.01).
Generation and characterisation of induced neurons from PKAN ﬁbroblasts
Human neurons were generated from patient and control ﬁbroblasts
by direct neuronal reprogramming (Caiazzo et al., 2011; Cozzi et al.,
2013). Lentiviruses expressing the transcription factor combination
Ascl1, Nurr1 and Lmx1a were used to transduce ﬁbroblasts to generate
iNs, whichwere thenmaintained in a neurobasal medium supplemented
with a cocktail of growth factors and inducing molecules (see the
Material andmethods section). iNs were identiﬁed in the reprogrammed
cell culture by immunostainingwith the speciﬁc neuronalmarker class III
β-tubulin (TuJ1), N-CAM andMAP2, as well as the dopaminergic-speciﬁc
enzyme tyrosine hydroxylase (TH) (Fig. 4A and data not shown). At least
50% of the TuJ1-positive cells were also positive for TH. We used TuJ1-
positive cells to evaluate neuronal reprogramming efﬁciency, which
was approximately 5% and comparable between PKAN and control cells
(Fig. 4B). We then used iNs to evaluate several parameters, including
the oxidative status and mitochondrial functionality. Due to the lowPlease cite this article as: Santambrogio, P., et al., Mitochondrial iron and e
pantothenate kinase-associated neuro..., Neurobiol. Dis. (2015), http://dx.efﬁciency of direct cellular reprogramming, we developed a method for
in vivo analysis at single cell level by selecting the live neurons using
the speciﬁc neuronal membrane marker N-CAM.
PKAN induced neurons show altered oxidative status
First, we analysed the amount of ROS speciﬁcally present in iNs
grown in basal conditions. The cellswere incubatedwith theﬂuorescent
ROS-sensitive dichloroﬂuorescein (DCF), and the images were acquired
by the IN-Cell Analyzer 1000 system. The identity of iNs was veriﬁed by
the expression of the neuronal speciﬁc marker N-CAM, and only the N-
CAM-positive cells were utilised to calculate the ﬂuorescence of the DCF
(Fig. 4C). The quantiﬁcation of ﬂuorescent intensity speciﬁc to iNs indi-
cated that PKAN iNs contained higher ROS levels than control iNs
(Fig. 4D). Moreover, an analysis of ThiolTracker Violet treated cells re-
vealed that PKAN iNs contained signiﬁcant lower reduced glutathione
levels compared to control iNs (Fig. 4E).
PKAN induced neurons show alterations in mitochondrial membrane
potential
A similar approachwas used to evaluatemitochondrial functionality
in neuronal cells. We measured mitochondrial membrane potential by
quantifying the TMRM signal 15 min after treatment with the probe;
the images were collected as above. As previously described, only N-
CAM-positive cells were utilised to calculate the TMRM ﬂuorescence
(Fig. 4F). The quantiﬁcation of TMRM intensity showed that PKAN iNs
had signiﬁcantly lower membrane potentials compared to control iNs
(Fig. 4G).nergetic dysfunction distinguish ﬁbroblasts and induced neurons from
doi.org/10.1016/j.nbd.2015.02.030
Fig. 4. Characterisation of induced neurons obtained from PKAN ﬁbroblasts by direct reprogramming. (A) The induced neuronswere stained for neuronal class III beta tubulin (α-Tuj1, top
panels in red) and tyrosine hydroxylase (α-TH,middle panels in green). Hoechst was used to stain cell nuclei (in blue), and the lower panels show themerged images, scale bar=100 μm.
Tuj1, a neuronal marker, was used to calculate the reprogramming efﬁciency, and the results are plotted in panel B. (C) Live cells stainedwith the ROS-sensing ﬂuorescent probe DCF (top
panels in green) andwith the neuron-speciﬁc anti-N-CAMantibody (middle panels in red); merged images are shown in the lower panels, with the nuclei stainedwith Hoechst. Theﬂuo-
rescencewas analysedusing the INCell Analyser 1000 System, scale bar=100 μm. (D) TheDCFﬂuorescence signal fromN-CAM-positive cells (frompanel C)were quantiﬁed, and thedata
are shown in the plots as themean and SDof three independent experiments (at least 50 neurons per type), *p b 0.05. (E) The ThiolTracker Violetﬂuorescence signal fromN-CAM-positive
cells was quantiﬁed (experiments were performed as in panel C, with ThiolTracker in place of DCF), and the data are shown in the plots as the mean and SD of three independent exper-
iments (at least 50 neurons per type), *p b 0.05, **p b 0.01. (F) Live cells were stainedwith themitochondrial membrane potential sensible ﬂuorescent probe TMRM (middle panels in red)
andwith theneuron-speciﬁcα-N-CAMantibody (toppanels in green). Themerged images are shown in the lower panels,with nuclei stainedwithHoechst. Theﬂuorescencewas analysed
using an IN-cell analyser, scale bar=100 μm. (G) The TMRM ﬂuorescence signal fromN-CAM-positive cells (from panel F)was quantiﬁed, and the data are shown in the plots as themean
and SD of three independent experiments (at least 50 neurons per type), **p b 0.01, ***p b 0.001.
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PKAN is a severe and disabling neurodegenerative disorder, the
pathogenic mechanisms of which are largely unknown (Zhou et al.,
2001). The low amount of CoA due to the PANK2 enzymatic defect has
a devastating impact on many biological processes. CoA is utilised as a
cofactor in approximately 4% of all known enzymes; thus, its imbalance
inhibits awide range of enzymatic pathways (Leonardi et al., 2005). This
effectwas highlighted by the studies of PKANdiseasemodels inﬂies and
mice. These analyses revealed different types of CoA-deﬁciency related
phenotype, such as the following: sterility (Afshar et al., 2001; Kuo
et al., 2005); abnormal locomotor function, neurodegeneration, and re-
duced life span (Bosveld et al., 2008); mitochondrial impairment
(Brunetti et al., 2012; Rana et al., 2010); altered cytoskeleton function
(Siudeja et al., 2012); protein acetylation (Siudeja et al., 2011);
disrupted circadian locomotor patterns and a unique transcriptional sig-
nature (Pandey et al., 2013). However, all of these investigations have
not clariﬁed the mechanism of one of the major features of the human
disease, brain iron accumulation, which has not been reported neither
in ﬂies nor in mice (Brunetti et al., 2012; Rana et al., 2010).
To approach this question, we previously examined iron metabolism
in PKAN ﬁbroblasts, demonstrating an abnormal behaviour of PANK2 de-
ﬁcient cells in response to treatment with iron and the consequent alter-
ation of oxidative status (Campanella et al., 2012). In the previous study,
we concentrated our attention on cytosolic iron handling. As mitochon-
drial iron homeostasis and cytosolic iron homeostasis are strictly interre-
lated, we hypothesised that iron mishandling could also occur in the
mitochondria, thereby affecting organelle functionality. For this reason,
we extended our analysis to mitochondria to determine whether and
howmitochondrial iron alteration could impact on the cell's bioenergetic
proﬁle. Interestingly, we detected a larger mitochondrial LIP also under
basal conditions, whereas the increase in the size of the cytosolic LIP
was appreciable only after chronic iron supplementation (Campanella
et al., 2012). Nevertheless, the availability of high levels of mitochondrial
iron did not appear to be properly utilised in ISC and heme biosynthesis,
thus they resulted defective in PKANﬁbroblasts. The reasonswhy this oc-
curs and how the PANK2 deﬁciency is involved are still obscure. Very re-
cent data, obtained on isolated mammalian mitochondria, demonstrated
that ISC biosynthesis requires, other than iron and sulphur, also GTP,
NADH and ATP (Pandey et al., 2015). A very reliable hypothesis could
be that the impairment of the Krebs cycle due to CoA deﬁciencymight re-
sult in lower production of GTP and NADH, with the consequent partial
iron utilisation in ISC biosynthesis.
Moreover, LIP and ROS are tightly controlled in cell and large varia-
tions are not expected. In fact, the detected increased size of the LIP re-
sulted in a slight increase inmitochondrial ROS production, which plays
a central role in the regulation of ISC enzyme activity and, in particular,
in Acos enzyme functions. Both the cAco and mAco contain [4Fe–4S]
clusters that are responsible for their catalytic activity, which is regulat-
ed by reversible oxidation (Bulteau et al., 2003). The main role of mAco
is to control cellular ATP production via the regulation of intermediate
ﬂux in the Krebs cycle. cAco has two different functions: in the ISC-
containing form, it operates as an enzyme, whereas in the oxidised
form, it is involved in the control of iron–protein translation as IRP1
(Lushchak et al., 2014). Thus, the reduction of their activities, caused
by their higher oxidation produced by ROS or by diminished production
of ISC, has an effect both on ATP production and iron homeostasis,
which we demonstrated to be altered in PKAN ﬁbroblasts.
In addition, other mitochondrial features appeared defective in pa-
tients' cells, such as the mitochondrial membrane potential and mito-
chondrial morphology, suggesting a global organelle impairment,
which can lead to energetic failure. Interestingly, a mitochondrial mor-
phology alteration was also recently reported in the muscles of a PKAN
patient with a deﬁned genetic mutation (Brunetti et al., 2014), indicat-
ing that variation of mitochondrial morphology can also be detected
in vivo in different patient cell types. An altered mitochondrialPlease cite this article as: Santambrogio, P., et al., Mitochondrial iron and e
pantothenate kinase-associated neuro..., Neurobiol. Dis. (2015), http://dx.membrane potential was also detected in neurons derived from a
Pank2 KO mouse model (Brunetti et al., 2012).
Obviously, we cannot exclude the possibility that the energetic im-
pairment detected in PKAN ﬁbroblasts could also derive frommembrane
alterations due to CoA deﬁciency-induced defects in phospholipid syn-
thesis; more detailed studies are needed to clarify this point. In fact, the
partial mitochondrial swelling and depolarisation detected in PKAN ﬁ-
broblasts suggestmitochondrialmembrane damage. However, as report-
ed by previous studies on isolated rat liver mitochondria, iron may
catalyse the peroxidation of lipids in themitochondrial inner membrane,
which can result in a limited depolarisation (Gall et al., 2012). Mitochon-
drial membrane depolarisation is a strong stimulus for opening themito-
chondrial permeability transition pore (Bernardi et al., 1992; Gogvadze
et al., 2003), which is considered one of the causative events of neuronal
injury (Crompton, 2004). The opening of the pore may facilitate mito-
chondrial iron import from the cytosolic compartment, further increasing
the size of themtLIP, not utilised by the intra-mitochondrial biosynthetic
pathways, thus exacerbating the injury.
Extensive studies on Saccharomyces cerevisiaedemonstrated that the
cells respond to reduced ISC synthesis with increased cellular iron up-
take and intracellular iron re-distribution, resulting in mitochondrial
iron accumulation until themetal precipitates as an amorphousmineral
(Lill andMuhlenhoff, 2008). These pathologic events have also been de-
scribed to occur in human disorders, such as Friedreich's ataxia
(Koeppen et al., 2007; Vaubel and Isaya, 2013) and Parkinson disease
(Horowitz and Greenamyre, 2010a; Mastroberardino et al., 2009) as
well as during the physiological ageing process (Isaya, 2014). In fact,
in recent times, there has been growing evidence of the role of mito-
chondrial iron dysfunction in the pathogenesis of commonneurodegen-
erative diseases (Horowitz and Greenamyre, 2010b). Overall, the data
indicate that defects in mitochondrial ISC biogenesis seem to represent
a common primary mechanism, which triggers abnormal intracellular
iron distribution. This effect results in cytosolic iron starvation and mi-
tochondrial iron accumulation, oxidative phosphorylation deﬁcits and
oxidative stress (Isaya, 2014; Nunez et al., 2012).
To clarify whether this abnormal iron distribution has a primary or a
secondary etiopathological role or is simply an epiphenomenon, more
work on different disease models is necessary. In any case, even if iron
dysregulation in PKAN may play a secondary role, its accumulation is
harmful and can aggravate the damage observed in the basal ganglia,
thus possibly justifying the iron chelation treatment proposed in pa-
tients (Zorzi et al., 2011). Certain brain regions, such as the globus
pallidus and the substantia nigra, have high iron contents, which are
necessary for the synthesis of neurotransmitters. These regions are par-
ticularly prone to the process of abnormal intracellular iron distribution,
which may also contribute to the age-dependent iron accumulation
(Isaya, 2014; Urrutia et al., 2013). We approached this question
employing direct neuronal cell reprogramming technology (Amamoto
and Arlotta, 2014; Caiazzo et al., 2011), which allowed us to obtain
human neurons starting from ﬁbroblasts. Although this technique has
an overall low efﬁciency in neuronal generation, we succeeded in
obtaining enough neurons from PKAN and healthy subject ﬁbroblasts
for an in depth analysis. Our data indicate that it is feasible to generate
human neuronal cells, even in cases of genetic alterations that lead to
mitochondrial impairment, as in the case of PKAN. In addition, as previ-
ously determined in ﬁbroblasts, our results conﬁrm, for the ﬁrst time in
PKAN induced neurons, the presence of an altered oxidative status in
basal conditions and the impairment of mitochondrial functions. iN
technology represents a very powerful system to investigate disease-
relevant pathogenetic mechanisms. However, this technology does not
currently allow the generation of striatal neurons, which represent the
most affected neuronal population in PKAN. Considering how fast direct
neuronal reprogramming technologies have been developing, we pre-
dict that an even more appropriate human neuronal model will be
soon available to further investigate PKAN pathogenetic mechanisms.
Nevertheless, our approach has enabled the identiﬁcation of alterednergetic dysfunction distinguish ﬁbroblasts and induced neurons from
doi.org/10.1016/j.nbd.2015.02.030
9P. Santambrogio et al. / Neurobiology of Disease xxx (2015) xxx–xxxbiological processes that are relevant in diseased neurons; therefore, the
present results are more relevant than the analyses of other cell types.
Our results indicate that PANK-iNs might also represent a suitable sys-
tem for establishingmedium-scale drug screenings to identify new can-
didate therapeutic compounds for this disease.
Conﬂict of interested statement
None declared.
Acknowledgements
The ﬁnancial support of Telethon-Italia (Grant no. GGP11088) is
gratefully acknowledged (to SL and VT), of AISNAF to SL, of TIRCONpro-
ject of the European Commission's Seventh Framework Programme
(FP7/2007–2013, HEALTH-F2-2011, grant agreement No. 277984) to
VT and of the European Research Council (AdERC #340527) to VB are
gratefully acknowledged.
The authorswish to thankDr. Alberto Locca for experimental support,
Dr. Des Richardson for providing us the iron chelators, and Dr. Alessandro
Campanella for critical reading of the manuscript. Part of this work was
carried out in ALEMBIC, an advanced microscopy laboratory established
by the San Raffaele Scientiﬁc Institute and the Vita-Salute San Raffaele
University. The authors would also like to thank the Cell lines and DNA
Bank of Paediatric Movement Disorders and Neurodegenerative Diseases
of the Telethon Genetic Biobank Network, which is supported by
TELETHON Italy (project n. GTB09003) and the Bank for the Diagnosis
and Research of Movement Disorders (MDB) of the EuroBiobank.
References
Afshar, K., Gonczy, P., DiNardo, S., Wasserman, S.A., 2001. Fumble encodes a pantothenate
kinase homolog required for proper mitosis and meiosis in Drosophila melanogaster.
Genetics 157, 1267–1276.
Amamoto, R., Arlotta, P., 2014. Development-inspired reprogramming of the mammalian
central nervous system. Science 343, 1239882.
Angelini, L., Nardocci, N., Rumi, V., Zorzi, C., Strada, L., Savoiardo, M., 1992. Hallervorden–
Spatz disease: clinical and MRI study of 11 cases diagnosed in life. J. Neurol. 239,
417–425.
Bernardi, P., Vassanelli, S., Veronese, P., Colonna, R., Szabo, I., Zoratti, M., 1992. Modulation
of the mitochondrial permeability transition pore. Effect of protons and divalent cat-
ions. J. Biol. Chem. 267, 2934–2939.
Bosveld, F., Rana, A., van der Wouden, P.E., Lemstra, W., Ritsema, M., Kampinga, H.H.,
Sibon, O.C., 2008. De novo CoA biosynthesis is required to maintain DNA integrity
during development of the Drosophila nervous system. Hum. Mol. Genet. 17,
2058–2069.
Brunetti, D., Dusi, S., Morbin, M., Uggetti, A., Moda, F., D'Amato, I., Giordano, C., et al., 2012.
Pantothenate kinase-associated neurodegeneration: altered mitochondria mem-
brane potential and defective respiration in Pank2 knock-out mouse model. Hum.
Mol. Genet. 21, 5294–5305.
Brunetti, D., Dusi, S., Giordano, C., Lamperti, C., Morbin, M., Fugnanesi, V., Marchet, S., et al.,
2014. Pantethine treatment is effective in recovering the disease phenotype induced
by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse
model. Brain 137, 57–68.
Bulteau, A.L., Ikeda-Saito, M., Szweda, L.I., 2003. Redox-dependent modulation of
aconitase activity in intact mitochondria. Biochemistry 42, 14846–14855.
Cabantchik, Z.I., 2014. Labile iron in cells and body ﬂuids: physiology, pathology, and
pharmacology. Front. Pharmacol. 5, 45.
Caiazzo, M., Dell'Anno, M.T., Dvoretskova, E., Lazarevic, D., Taverna, S., Leo, D., Sotnikova,
T.D., et al., 2011. Direct generation of functional dopaminergic neurons from mouse
and human ﬁbroblasts. Nature 476, 224–227.
Campanella, A., Rovelli, E., Santambrogio, P., Cozzi, A., Taroni, F., Levi, S., 2009. Mitochon-
drial ferritin limits oxidative damage regulating mitochondrial iron availability: hy-
pothesis for a protective role in Friedreich ataxia. Hum. Mol. Genet. 18, 1–11.
Campanella, A., Privitera, D., Guaraldo, M., Rovelli, E., Barzaghi, C., Garavaglia, B., et al.,
2012. Skin ﬁbroblasts from pantothenate kinase-associated neurodegeneration pa-
tients show altered cellular oxidative status and have defective iron-handling proper-
ties. Hum. Mol. Genet. 21, 4049–4059.
Cozzi, A., Santambrogio, P., Privitera, D., Broccoli, V., Rotundo, L.I., Garavaglia, B., Benz, R.,
et al., 2013. Human L-ferritin deﬁciency is characterized by idiopathic generalized sei-
zures and atypical restless leg syndrome. J. Exp. Med. 210, 1779–1791.
Crompton, M., 2004. Mitochondria and aging: a role for the permeability transition?
Aging Cell 3, 3–6.
Gall, J., JJr, Skrha, Buchal, R., Sedlackova, E., Verebova, K., Platenik, J., 2012. Induction of the
mitochondrial permeability transition (MPT) by micromolar iron: liberation ofPlease cite this article as: Santambrogio, P., et al., Mitochondrial iron and en
pantothenate kinase-associated neuro..., Neurobiol. Dis. (2015), http://dx.calcium is more important than NAD(P)H oxidation. Biochim. Biophys. Acta 1817,
1537–1549.
Garcia, M., Leonardi, R., Zhang, Y.M., Rehg, J.E., Jackowski, S., 2012. Germline deletion of
pantothenate kinases 1 and 2 reveals the key roles for CoA in postnatal metabolism.
PLoS ONE 7, e40871.
Gogvadze, V., Walter, P.B., Ames, B.N., 2003. The role of Fe2+-induced lipid peroxidation
in the initiation of the mitochondrial permeability transition. Arch. Biochem. Biophys.
414, 255–260.
Hartig, M.B., Hortnagel, K., Garavaglia, B., Zorzi, G., Kmiec, T., Klopstock, T., Rostasy, K., et
al., 2006. Genotypic and phenotypic spectrum of PANK2 mutations in patients with
neurodegeneration with brain iron accumulation. Ann. Neurol. 59, 248–256.
Hayﬂick, S.J., 2014. Defective pantothenate metabolism and neurodegeneration. Biochem.
Soc. Trans. 42, 1063–1068.
Horowitz, M.P., Greenamyre, J.T., 2010a. Gene–environment interactions in Parkinson's
disease: the importance of animal modeling. Clin. Pharmacol. Ther. 88, 467–474.
Horowitz, M.P., Greenamyre, J.T., 2010b. Mitochondrial iron metabolism and its role in
neurodegeneration. J. Alzheimers Dis. 20 (Suppl. 2), S551–S568.
Isaya, G., 2014. Mitochondrial iron–sulfur cluster dysfunction in neurodegenerative dis-
ease. Front. Pharmacol. 5, 29.
Koeppen, A.H., Michael, S.C., Knutson, M.D., Haile, D.J., Qian, J., Levi, S., Santambrogio, P.,
Garrick, M.D., Lamarche, J.B., 2007. The dentate nucleus in Friedreich's ataxia: the
role of iron-responsive proteins. Acta Neuropathol. 114, 163–173.
Kruer, M.C., Hiken, M., Gregory, A., Malandrini, A., Clark, D., Hogarth, P., Grafe, M., Hayﬂick,
S.J., Woltjer, R.L., 2011. Novel histopathologic ﬁndings in molecularly-conﬁrmed pan-
tothenate kinase-associated neurodegeneration. Brain 134, 947–958.
Kuo, Y.M., Duncan, J.L., Westaway, S.K., Yang, H., Nune, G., Xu, E.Y., Hayﬂick, S.J., Gitschier,
J., 2005. Deﬁciency of pantothenate kinase 2 (Pank2) in mice leads to retinal degen-
eration and azoospermia. Hum. Mol. Genet. 14, 49–57.
Leonardi, R., Zhang, Y.M., Rock, C.O., Jackowski, S., 2005. Coenzyme A: back in action. Prog.
Lipid Res. 44, 125–153.
Leonardi, R., Zhang, Y.M., Lykidis, A., Rock, C.O., Jackowski, S., 2007. Localization and reg-
ulation of mouse pantothenate kinase 2. FEBS Lett. 581, 4639–4644.
Leoni, V., Strittmatter, L., Zorzi, G., Zibordi, F., Dusi, S., Garavaglia, B., Venco, P., et al., 2012.
Metabolic consequences of mitochondrial coenzyme A deﬁciency in patients with
PANK2 mutations. Mol. Genet. Metab. 105, 463–471.
Levi, S., Finazzi, D., 2014. Neurodegeneration with brain iron accumulation: update on
pathogenic mechanisms. Front. Pharmacol. 5, 99.
Levi, S., Rovida, E., 2009. The role of iron inmitochondrial function. Biochim. Biophys. Acta
1790, 629–636.
Lill, R., Muhlenhoff, U., 2008. Maturation of iron–sulfur proteins in eukaryotes: mecha-
nisms, connected processes, and diseases. Annu. Rev. Biochem. 77, 669–700.
Lushchak, O.V., Piroddi, M., Galli, F., Lushchak, V.I., 2014. Aconitase post-translational
modiﬁcation as a key in linkage between Krebs cycle, iron homeostasis, redox signal-
ing, and metabolism of reactive oxygen species. Redox Rep. 19, 8–15.
Ma, Y., Abbate, V., Hider, R.C., 2015. Iron-sensitive ﬂuorescent probes: monitorino intra-
cellular iron pools. Metallomics 7 (2), 212–222.
Mastroberardino, P.G., Hoffman, E.K., Horowitz, M.P., Betarbet, R., Taylor, G., Cheng, D., Na,
H.M., et al., 2009. A novel transferrin/TfR2-mediated mitochondrial iron transport
system is disrupted in Parkinson's disease. Neurobiol. Dis. 34, 417–431.
Nunez, M.T., Urrutia, P., Mena, N., Aguirre, P., Tapia, V., Salazar, J., 2012. Iron toxicity in
neurodegeneration. Biometals 25, 761–776.
Pandey, V., Turm, H., Bekenstein, U., Shifman, S., Kadener, S., 2013. A new in vivomodel of
pantothenate kinase-associated neurodegeneration reveals a surprising role for tran-
scriptional regulation in pathogenesis. Front. Cell. Neurosci. 7, 146. http://dx.doi.org/
10.3389/fncel.2013.00146. eCollection 2013.
Pandey, A., Pain, J., Ghosh, A.K., Dancis, A., Pain, D., 2015. Fe–S cluster biogenesis in isolat-
ed mammalian mitochondria: coordinated use of persulﬁde sulfur and iron and re-
quirements for GTP, NADH, and ATP. J. Biol. Chem. 290 (1), 640–657.
Perry, T.L., Norman, M.G., Yong, V.W., Whiting, S., Crichton, J.U., Hansen, S., Kish, S.J., 1985.
Hallervorden–Spatz disease: cysteine accumulation and cysteine dioxygenase deﬁ-
ciency in the globus pallidus. Ann. Neurol. 18, 482–489.
Poli, M., Derosas, M., Luscieti, S., Cavadini, P., Campanella, A., Verardi, R., Finazzi, D.,
Arosio, P., 2010. Pantothenate kinase-2 (Pank2) silencing causes cell growth
reduction, cell-speciﬁc ferroportin upregulation and iron deregulation.
Neurobiol. Dis. 39, 204–210.
Rana, A., Seinen, E., Siudeja, K., Muntendam, R., Srinivasan, B., van der Want, J.J., Hayﬂick,
S., et al., 2010. Pantethine rescues a Drosophila model for pantothenate kinase-
associated neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 107, 6988–6993.
Rauen, U., Springer, A., Weisheit, D., Petrat, F., Korth, H.G., de Groot, H., Sustmann, R., 2007.
Assessment of chelatable mitochondrial iron by using mitochondrion-selective ﬂuo-
rescent iron indicators with different iron-binding afﬁnities. Chembiochem 8,
341–352.
Santambrogio, P., Erba, B.G., Campanella, A., Cozzi, A., Causarano, V., Cremonesi, L., Gallì,
A., et al., 2011. Over-expression ofmitochondrial ferritin affects the JAK2/STAT5 path-
way in K562 cells and causes mitochondrial iron accumulation. Haematologica 96,
1424–1432.
Schneider, S.A., Zorzi, G., Nardocci, N., 2013. Pathophysiology and treatment of neurode-
generation with brain iron accumulation in the pediatric population. Curr. Treat. Op-
tions Neurol. 15, 652–667.
Siudeja, K., Srinivasan, B., Xu, L., Rana, A., de Jong, J., Nollen, E.A., Jackowski, S., et al., 2011.
Impaired coenzyme Ametabolism affects histone and tubulin acetylation in Drosoph-
ila and human cell models of pantothenate kinase associated neurodegeneration.
EMBO Mol. Med. 3, 755–766.
Siudeja, K., Grzeschik, N.A., Rana, A., de Jong, J., Sibon, O.C., 2012. Coﬁlin/Twinstar phos-
phorylation levels increase in response to impaired coenzyme a metabolism. PLoS
ONE 7, e43145.ergetic dysfunction distinguish ﬁbroblasts and induced neurons from
doi.org/10.1016/j.nbd.2015.02.030
10 P. Santambrogio et al. / Neurobiology of Disease xxx (2015) xxx–xxxStehling, O., Wilbrecht, C., Lill, R., 2014. Mitochondrial iron–sulfur protein biogenesis and
human disease. Biochimie 100, 61–77.
Tong,W.H., Rouault, T.A., 2006. Functions of mitochondrial ISCU and cytosolic ISCU inmam-
malian iron–sulfur cluster biogenesis and iron homeostasis. Cell Metab. 3, 199–210.
Urrutia, P., Aguirre, P., Esparza, A., Tapia, V., Mena, N.P., Arredondo, M., Gonzalez-Billault,
C., Nunez,M.T., 2013. Inﬂammation alters the expression ofDMT1, FPN1 and hepcidin,
and it causes iron accumulation in central nervous system cells. J. Neurochem. 126,
541–549.
Vaubel, R.A., Isaya, G., 2013. Iron–sulfur cluster synthesis, iron homeostasis and oxidative
stress in Friedreich ataxia. Mol. Cell. Neurosci. 55, 50–61.Please cite this article as: Santambrogio, P., et al., Mitochondrial iron and e
pantothenate kinase-associated neuro..., Neurobiol. Dis. (2015), http://dx.Zhou, B., Westaway, S.K., Levinson, B., Johnson, M.A., Gitschier, J., Hayﬂick, S.J., 2001. A
novel pantothenate kinase gene (PANK2) is defective in Hallervorden–Spatz syn-
drome. Nat. Genet. 28, 345–349.
Zorzi, G., Zibordi, F., Chiapparini, L., Bertini, E., Russo, L., Piga, A., Longo, F., et al., 2011. Iron-
related MRI images in patients with pantothenate kinase-associated neurodegenera-
tion (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov. Disord. 26,
1756–1759.nergetic dysfunction distinguish ﬁbroblasts and induced neurons from
doi.org/10.1016/j.nbd.2015.02.030
  
 
 
OPEN ACCESS | www.microbialcell.com 126 Microbial Cell | April 2015 | Vol. 2 No. 4 
www.microbialcell.com 
Research Article 
ABSTRACT  Mutations in nuclear genes associated with defective coenzyme A 
biosynthesis have been identified as responsible for some forms of neuro-
degeneration with brain iron accumulation (NBIA), namely PKAN and CoPAN. 
PKAN are defined by mutations in PANK2, encoding the pantothenate kinase 
2 enzyme, that account for about 50% of cases of NBIA, whereas mutations in 
CoA synthase COASY have been recently reported as the second inborn error 
of CoA synthesis leading to CoPAN. As reported previously, yeast cells ex-
pressing the pathogenic mutation exhibited a temperature-sensitive growth 
defect in the absence of pantothenate and a reduced CoA content. Additional 
characterization revealed decreased oxygen consumption, reduced activities 
of mitochondrial respiratory complexes, higher iron content, increased sensi-
tivity to oxidative stress and reduced amount of lipid droplets, thus partially 
recapitulating the phenotypes found in patients and establishing yeast as a 
potential model to clarify the pathogenesis underlying PKAN and CoPAN dis-
eases. 
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INTRODUCTION 
In all living cells Coenzyme A (CoA) is the major carrier of 
acetyl and acyl groups playing a central role in basic cellu-
lar functions such as lipids metabolism, Krebs cycle and 
aminoacid biosynthesis. CoA biosynthesis proceeds 
through a highly conserved pathway, involving five enzy-
matic steps: pantothenic acid (vitamin B5) phosphorylation, 
cysteine conjugation, decarboxylation, conjugation to an 
adenosyl group and phosphorylation.  
Whereas in mammals the last two steps are catalyzed 
by Coenzyme A synthase (COASY), a mitochondrial bifunc-
tional enzyme possessing both 4’-phospho-pantetheine 
adenylyltransferase (PPAT) and dephospho-CoA kinase 
(DPCK) activities [1, 2], in other organisms, such as yeast, 
PPAT and DPCK activities reside in two different enzymes, 
Cab4 and Cab5, the products of the essential genes CAB4 
and CAB5 [3] whose compartmentalization is not well un-
derstood. 
Recently, it has been reported that dysfunctions of CoA 
biosynthetic pathway may play a role in the pathogenesis 
of neurodegeneration with brain iron accumulation (NBIA), 
a wide spectrum of clinically and genetically heterogene-
ous diseases characterized by progressive neurodegenera-
tion and high iron content in specific brain region [4, 5, 6].  
This concept is supported by the fact that mutations in 
PANK2, encoding the first enzyme in the CoA synthesis, 
approximately account for 50% of NBIA cases, classified as 
PKAN (Pantothenate Kinase Associated Neurodegenera-
tion) [7, 8]. Moreover COASY gene has been identified as a 
novel NBIA-associated gene and these NBIA cases have 
been termed CoPAN (COASY Protein-Associated Neuro-
degeneration)[9]. 
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Neurodegenerative diseases are often characterized by 
mitochondrial dysfunctions, altered lipid metabolism and 
iron accumulation [10, 11, 12] and several evidences link-
ing PKAN and CoPAN to these metabolic alterations have 
been reported [8, 13, 14, 15, 16]. 
The development of cellular and animal models is cru-
cial for advancing our understanding of the pathophysiolo-
gy of these diseases. In the last decade, the yeast Saccha-
romyces cerevisiae has been used as in vivo model system 
to gain insights into the molecular basis of mitochondrial 
pathologies and neurodegenerative disorders [17, 18]. 
Despite their simplicity, yeast cells possess most of the 
basic cellular machinery including pathways required for 
energy metabolism and protein homeostasis. Moreover, 
many of the genes and biological systems that function in 
yeast iron homeostasis are conserved throughout eukary-
otes [19]. 
To investigate if defective CoA metabolism could un-
derlie a more general disequilibrium of lipid metabolism 
and mitochondrial dysfunctions and its relationship with 
brain iron accumulation, we have performed phenotypic 
and biochemical investigation in a recently developed 
yeast model expressing the pathogenic missense mutation 
COASY
R499C
 found in NBIA patients [9].  
The results obtained in this study showed that yeast 
mutant defective in CoA biosynthesis recapitulates the 
most important phenotypes found in patients and validat-
ed this system to model CoPAN in order to help elucidating 
important cellular and biochemical aspects of mitochon-
drial, lipid and iron homeostasis underpinning this disease.  
 
RESULTS 
Cellular localization of yeast Cab5 protein 
Proteomics studies [20] and in silico analysis using the 
PSORT and MITOPROT programs [21, 22], which allows the 
prediction of protein localization, suggest for Cab5 a mito-
chondrial localization. Moreover human CoA synthase is a 
mitochondrial enzyme and the human gene is able to com-
plement the cab5Δ mutation. To confirm experimentally 
the mitochondrial localization of Cab5p, a carboxyl-
terminal fusion of HA epitope to Cab5 was constructed. 
The cab5Δ lethal phenotype was rescued by the re-
expression of the tagged wild type allele, indicating that 
the addition of HA did not disrupt targeting and function of 
the Cab5 protein. Equivalent amounts of mitochondrial 
pellet (M) and supernatant (PMS) fractions from cells ex-
pressing HA tagged Cab5 (Cab5-HA) were subjected to SDS-
PAGE and Western blotting to identify the indicated pro-
tein. The great majority of Cab5-HA co-fractionated with 
the mitochondrial membrane protein porin, while only a 
small amount remained in the supernatant with the solu-
ble cytoplasmic protein phosphoglycerate kinase (PGK), 
indicating that Cab5 behaves as a mitochondrial associated 
protein (Fig. 1A). We further investigated the mitochondri-
al localization of Cab5p by performing a protease protec-
tion assay of intact mitochondria. Cab5-HA exhibited a 
significant increase in proteinase K sensitivity treatment in 
respect to both porin, which is only partially exposed on 
the surface, and to the inner membrane protein Core1 (Fig. 
1B). The mitochondria were then treated with 0.1 M 
Na2CO3, pH 11, and supernatant and pellet fractions were 
generated by centrifugation. As depicted in Fig. 1C the 
amount of Cab5 associated with mitochondria was signifi-
cantly reduced but the amount of porin was not altered. 
Taken together these results suggest that Cab5 is an extrin-
sic outer membrane protein. 
 
Characterization of mitochondrial functions 
We have previously demonstrated by HPLC analysis that in 
the strain expressing the human COASY
R499C 
or
 
the yeast 
cab5
R146C 
mutant versions the level of CoA in mitochondria 
was reduced by 40% compared to wild-type [9]. Given that 
defective CoA biosynthesis could lead to a variety of meta-
bolic defects we looked for evidence of mitochondrial dys-
function. 
In order to reveal a possible respiratory growth defect, 
serial dilutions of the strains were spotted on mineral me-
dium without pantothenate supplemented with either 
ethanol or glycerol, at 28°C. As shown in Fig. 2A the 
OXPHOS growth of the cab5Δ/COASY
R499C 
mutant was par-
tially affected compared to COASY wild type expressing 
strain. To confirm the growth delay we determined the cell  
 
 
FIGURE 1: Localization of Cab5p. (A) Equal amounts (20 mg) of 
the mitochondrial fraction (M) and post mitochondrial fraction 
(PMS) were resolved by SDS-PAGE and analyzed by immunoblot-
ting with HA, PGK1 (cytosolic marker), PORIN (mitochondrial 
outer membrane marker) antibodies. (B) Mitochondria were 
treated for 60 min at 4°C with proteinase K (prot K) (1 mg/ml). 
The filter was incubated with anti-HA, anti-CORE1, and anti-
PORIN antibodies. Core1 was used as an inner membrane protein 
control. (C) 150 µg of mitochondrial proteins were treated with 
TEGN buffer or TEGN and 0.1M NaCO3. The insoluble pellet (P) 
and supernatant (S) fractions were resolved by SDS-PAGE and 
analyzed by immunoblotting with HA and PORIN antibodies. 
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FIGURE 2: Characterization of mitochondrial functions. (A) Oxidative growth phenotype. The strain W303-1B cab5Δ was transformed with a 
pYEX-BX plasmid carrying the wild-type COASY or the mutant allele COASY
R499C
. Equal amounts of serial dilutions of cells from exponentially 
grown cultures (10
5
,
 
10
4
, 10
3
, 10
2
, 10
1
) were spotted onto mineral medium (40) plus 2% glucose, 2% ethanol or 2% glycerol without panto-
thenate. The growth was scored after 5 days of incubation at 28°C. (B) Cell yield. Cell yield was calculated by growing cells on liquid medium 
containing ethanol or glycerol and measuring the optical density at 600 nm after 48h of growth (COASY black columns and COASY
R499C
 grey 
columns). Values are mean of three independent experiments. * P < 0.05; **P < 0.01 (unpaired two-tailed t-test). (C) Oxygen consumption 
rates. Respiration was measured in cells grown in mineral medium (40) plus 0.2% glucose and 2% galactose without pantothenate at 28°C. 
The values observed for the COASY mutant strain are reported as percentage of the respiration obtained in cells expressing the wild-type 
COASY gene. (D) NADH-cytochrome c oxidoreductase (NCCR) and cytochrome c oxidase (COX) activities were measured in mitochondria 
extracted from cells grown exponentially at 28°C in mineral medium (40) plus 0.2% glucose and 2% galactose without pantothenate. The 
values of the COASY mutant are expressed as percentage of the activities obtained in the wild type strain. (E) Steady state level of cIII and cIV 
subunits in cells carrying the wild-type COASY and the mutant allele. The filter was incubated with specific antibodies against Core1, Rip1, 
CoxII, CoxIV and Porin. The signals were normalized according to the control signal (porin) and taken as 1.00 the signal of the cab5∆/COASY 
(wild-type) strain. 
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yield for each yeast strain grown on ethanol or glycerol. 
We observed that the OXPHOS growth of the mutant strain 
was 20% lower as compared to wild type (Fig. 2B). 
To further analyze the respiratory deficiency, oxygen 
consumption and activity of respiratory complexes were 
measured. Accordingly to the OXPHOS growth phenotype 
the oxygen consumption rate of the cab5Δ/COASY
R499C 
was 
25% less than that of cab5Δ/COASY (Fig. 2C). Likewise, the 
NADH-cytochrome c oxidoreductase (NCCR) and cyto-
chrome c oxidase (COX) activities were reduced in the mu-
tant strain respectively to 26% and 42% as compared to 
wild type (Fig. 2D). Accordingly, the steady state levels of 
complex III and IV subunits are decreased (Fig. 2E). Alto-
gether these results indicate a mitochondrial dysfunction 
associated to the reduced CoA level. 
 
 
Mutation in CoA synthase determines an increase of iron 
content and increased sensitivity to oxidative stress 
NBIA disorders, PKAN and CoPAN included, are character-
ized by iron deposition in the brain but the mechanisms 
leading to iron overload and its pathophysiological role 
remain unclear. Since in yeast excessive iron accumulation 
in the mitochondria led to an increased sensitivity to this 
ion [23, 24], we first evaluated the inhibition of cellular 
growth in the COASY
R499C
 mutant strain by the addition of 
FeSO4 to the medium.  
As depicted in Fig. 3A, the mutant strain showed a clear 
growth defect when compared to wild type strain, indirect-
ly indicating a higher iron content.  
We then performed a quantitative determination of 
cellular iron level by a colorimetric assay that relies on the 
formation of colored iron complexes with BPS after nitric 
acid digestion of yeast cells and gives results comparable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3:  Measurement  of iron content. (A) Iron sensitivity. 
Equal amounts of serial dilutions of cells from exponentially 
grown cultures (10
5
,
 
10
4
, 10
3
, 10
2
, 10
1
) were spotted onto 40 
medium without pantothenate supplemented with 5 mM and 7 
mM FeS04. The growth was scored after 5 days of incubation at 
28°C. (B) Iron level.
 
Cellular iron levels was quantified in cells 
grown up to early stationary phase in YNB glucose (0,6%) medi-
um. **P < 0.01 (unpaired two-tailed t-test). (C) PMS/DCPIP 
(phenazyne methosulfate/dichlorophenolindophenol) reduc-
tase and decylubiquinone reductase activities were measured 
in mitochondria extracted from cells grown exponentially at 
28°C in mineral medium (40) plus 0.2% glucose and 2% galac-
tose without pantothenate. The values of the COASY mutant 
are expressed as percentage of the activities obtained in the 
wild type strain. 
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with those with ICP-mass spectrometry [25, 26]. The re-
sults obtained showed a two-fold increase in iron content 
in the COASY
R499C
 mutant respect to the parental strain (Fig. 
3B). 
We then investigated whether the biosynthesis of the 
Fe-S cluster, a marker of mitochondrial functionality linked 
to iron metabolism, was affected by COASY deficiency. We 
determined the activity of succinate dehydrogenase (SDH), 
a mitochondrial Fe-S cluster enzyme. As shown in Fig. 3C, 
SDH activity was decreased by about 50%, in the mutant as 
compared to wild-type strain. 
It is known that an excess of iron causes an altered oxi-
dative status [24, 27, 28], another key feature of disease 
associated to CoA deficiency [14, 29, 30], which may be 
reflected in hypersensitivity to oxidative stress-induced cell 
death. To test this hypothesis COASY
R499C
 mutant and con-
trol strain were exposed to H2O2 and cell viability was de-
termined by both spot assay analysis (Fig. 4A) and by 
counting the formation of colonies (Fig 4B). At the highest 
H2O2 concentration tested (2 mM) wild type cells showed a 
viability of 10%, while mutant cells showed a viability of 2% 
(Fig. 4B) demonstrating that a COASY defect leads to oxida-
tive stress susceptibility. 
 
Evaluation of lipid droplets content 
Acetyl-CoA is necessary for the production of neutral lipids, 
which serve as power reserve for the cell and are stored in 
lipid droplets. Since CoA is involved in the biosynthesis of 
fatty acids and having demonstrated that the mutant 
cab5Δ/COASY
R499C
 shows a 40% reduction of coenzyme A, 
the content of intracellular lipid droplets in the mutant 
compared to the wild type was evaluated by fluorescence 
microscopy and fluorimetric analysis after incubation of 
the cells with the fluorescent lipophilic dye Nile Red [31]. 
As shown in Fig. 5A the content of lipid droplets is de-
creased in the mutant expressing the COASY
R499C
. In order 
to better quantify this reduction, the fluorescence of cells 
stained with Nile Red was measured using a fluorescence 
spectrometer. The measures, performed in triplicate, high-
lighted a reduction of lipid droplets of 25% in mutant strain 
compared to wild-type (Fig. 5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4:  Sensitivity to H2O2. The cells carrying the wild-
type COASY or mutant allele were grown up to exponential 
phase and incubated for 4h at 28°C or 37°C with the addition 
of 1 mM and 2 mM H2O2.
  
(A) After the treatment, equal 
amounts of serial dilutions of cells (10
5
,
 
10
4
, 10
3
, 10
2
, 10
1
) 
were spotted onto YP media plus 2% glucose. The growth 
was scored after 2 days of incubation at 28°C or 37°C. (B) Vi-
ability of wild-type and mutant strains was measured by 
C.F.U counting after exposure of cell to 2 mM H2O2 for 
4h.**P < 0.01 (unpaired two-tailed t-test).  
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DISCUSSION 
In all living organisms Coenzyme A (CoA) is an essential 
cofactor in cellular metabolism. CoA biosynthesis follows a 
highly conserved pathway, involving five enzymatic steps, 
which utilize pantothenate (vitamin B5), ATP, and cysteine. 
Mutations in nuclear genes directly involved in CoA biosyn-
thetic pathway have been identified as responsible for 
some forms of NBIA, namely PKAN and CoPAN. PKAN is 
caused by mutations in PANK2, encoding the pantothenate 
kinase 2 enzyme, that account for about 50% of NBIA cases, 
whereas mutations in CoA synthase COASY have been re-
cently reported as the second inborn error of CoA synthe-
sis leading to CoPAN [9]. In PKAN and CoPAN brain iron 
accumulation is dramatic but its link with defective CoA 
synthesis is unknown. 
Moreover, many neurodegenerative diseases, PKAN 
and CoPAN included, are characterized by mitochondrial 
dysfunctions, oxidative stress, altered lipid metabolism but 
again the complex relationships linking these factors in the 
context of disease conditions remain to be elucidated.  
Previous attempts to understand the mechanism of 
PKAN using animal models have met with limited success. 
A mouse model of PKAN exhibits azoospermia but lacks 
any neurological phenotype [32]. A Drosophila model of 
PKAN does have a brain phenotype, but this involves the 
formation of vacuoles, not iron accumulation [33]. The 
identification and generation of other cellular model may 
allow a deeper characterization of COASY and PANK2 dis-
ease gene products, and the investigation of their patho-
physiology in vivo. With this aim we developed and charac-
terized a yeast model for CoPAN disease. 
Although in yeast, differently from mammalian cells, 
the last two steps of CoA biosynthesis are catalyzed by two 
separate enzymes, namely the products of the essential 
genes CAB4 and CAB5, we have demonstrated that the 
lethality associated to deletion in CAB5 could be comple-
mented by human COASY. This allowed us to study the 
human Arg499Cys substitution in yeast and to support the 
pathogenic role of this mutation associated to a reduced 
level of CoA [9]. 
The evaluation of the metabolic consequences of coen-
zyme A deficiency in yeast revealed mitochondrial dysfunc-
tions; OXPHOS growth was affected and respiration rate 
significantly decreased. Accordingly, the activity of respira-
tory chain complexes and steady state levels of mitochon-
drial respiratory chain subunits were reduced. We also 
demonstrated that the growth of the mutant strain is not 
only strongly inhibited in the presence of iron but that the 
mutant strain showed iron accumulation. This result is con-
sistent with the patient phenotype, with iron overload be-
ing a typical sign of PKAN and CoPAN. We have also found 
that cab5Δ/COASY
R499C
 mutant was more sensitive to the 
ROS-inducing agent H2O2 indicating an increased oxidative 
stress that may contribute to the pathogenesis of these 
diseases. Accordingly, the activity of SDH, a marker of mi-
tochondrial functionality linked to iron metabolism, was 
reduced in the COASY mutant.  
Since Acetyl-CoA, one of the most important deriva-
tives of CoA, is also required for the synthesis of fatty acids, 
we investigated the impact of reduced CoA level by meas-
 
 
FIGURE 5: Evaluation of lipid droplets content. The intracellular lipid droplets content has been detected by fluorescence microscopy (A) 
and fluorimetric analysis (B) after incubation of wild type and mutant cells with the fluorescent lipophilic dye Nile Red (4 μg/ml). The values 
corresponding to mutant COASY are expressed as percentage of the content obtained in the wild type strain. 
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uring the lipid droplets content in mutant cells by fluori-
metric analysis of Nile Red stained cells. Interestingly 
enough, lipid droplets content was 25% lower in mutant 
strain as compared to wild-type. The same altered lipid 
metabolism was also observed in mutant strain for phos-
phopantothenoylcysteine synthetase (PPCS), another es-
sential enzyme in CoA biosynthetic pathway [34]. These 
results are in agreement with the hypothesis that low CoA 
perturbs lipid homeostasis; lipid deregulation was also 
observed in Drosophila CoA mutants and from global met-
abolic profiling studies in patient-derived fibroblasts [8, 35]. 
The transcriptional analysis of key genes involved in lipid 
metabolism would help in elucidating the role of lipid me-
tabolism in the pathology. 
Altogether these results established yeast as an appro-
priate model to study the molecular mechanisms involved 
in CoA metabolism, and to understand the connection be-
tween iron management, mitochondrial function and lipid 
metabolism in neurodegeneration. 
Several pathological phenotypes have been identified 
in the mutant COASY yeast strain thus representing ideal 
readouts for high throughput screening of chemical librar-
ies as described by Couplan et al. [36]. This could allow the 
identification of new molecules, the first step to set up 
future therapeutic experimental approaches. 
 
MATERIALS AND METHODS 
Yeast strains, media and vectors  
Yeast strains used in this study were W303-1B cab5Δ (MATα; 
cab5::KanMx4 ade2-1 leu2-3,112 ura3-1 his3-22,15 trp1-1 
can1-100) carrying pYEX-BX-COASY or pYEX-BX COASY
R499C
 
plasmid [9]. For localization studies we used the strain BY4741 
(MATa; his3∆1 leu2∆0 met15∆0 ura3∆0) transformed with 
pFL38-Cab5-HA plasmid.  
Cells were cultured in mineral medium (40) supplemented 
with appropriate amino acids and bases for auxotrophy as 
previously described [37]. To obtain medium lacking panto-
thenate (40-Pan) a mixture of vitamins without pantothenate 
was prepared. Yeast cells were transformed by the standard 
lithium acetate method [38] and cultured in YNB synthetic 
defined media (For-MediumTM, UK) supplemented with 1 g/l 
of drop-out powder [39] containing all amino acids and bases, 
except those required for plasmid selection. Various carbon 
sources (Carlo Erba Reagents, Italy) were added at the indicat-
ed concentration. Media were solidified with 20 g/l agar (For-
Medium™). Strains were incubated at 28 or 37°C as indicated. 
Plasmid pFL38-Cab5-HA was obtained by PCR overlap 
technique [40]. In the ﬁrst set of PCR reactions, the CAB5 re-
gion was obtained using the forward primer CAB5Fw-
GGGGGGATCCCCATTGCTTAGAATGGGCGG and the following 
reverse tag primer CAB5HARv ATCAACCTTATACAGCGTAATCT-
GGAACATCGTATGGGTACGCTGAAGACTTTTTATTTTG where 
hemagglutinin (HA) tag sequence is indicated in bold. The 
second CAB5 region was obtained using the forward tag pri-
mers CAB5HATERFw complementary to CAB5HARv , and the 
reverse primer CAB5Rv-CCGCGGTACCGAGAACCCATAGAATT-
CGAC. The ﬁnal product was obtained using the overlapping 
PCR fragments as template with CAB5Fw and CAB5Rv as ex-
ternal primers. The product was then digested with BamHI 
and KpnI and cloned in BamHI/KpnI digested pFL38 centro-
meric plasmid [41].  
 
Respiration measurement, biochemical assays and immunob-
lot analysis of respiratory chain subunits. 
Respiratory activity measurement was performed on whole 
cells at 30°C using a Clark-type oxygen electrode (Oxygraph 
System, Hansatech Instruments, England) with 1 ml of air-
saturated respiration buffer (0.1 M phthalate–KOH, pH 5.0). 
The reaction started by addition of 20 mg of wet-weight cells 
[42].  
Complex II (SDH), NADH-cytochrome c oxidoreductase 
(NCCR) and complex IV specific activities were measured spec-
trophotometrically as previously described [42, 43, 44, 45] on 
a mitochondrial enriched fraction prepared according to Soto 
et al. [46]. Protein concentration was determined by the 
method of Bradford using the BioRad protein assay following 
manufacturer’s instructions [47]. For SDS-PAGE, 20 μg of mi-
tochondrial proteins were separated on 12% polyacrylamide 
gels and electroblotted onto a nitrocellulose membrane. The 
subunits of mitochondrial respiratory complexes were im-
munovisualized by specific antibodies. The sources of primary 
antibodies are indicated: anti-Core1 (a kind gift from Prof. 
Antoni Barrientos), anti-Rip1 (a kind gift from Prof. Alexander 
Tzagoloff), anti CoxIIp (Abcam Mitoscience), anti-CoxIV 
(Abcam Mitoscience) and anti-Porin (Abcam Mitoscience). 
Quantification of protein bands was performed using Multi 
Analyst software. The signals were normalized according to 
the control signal (α-Porin) and the signal of the cab5∆/COASY 
(wild-type) strain was set as 1.00. 
 
Intact mitochondria isolation, subcellular localization exper-
iments and membrane association 
Intact mitochondria were isolated from BY4741 strain trans-
formed with a plasmid expressing Cab5-HA under the native 
CAB5 promoter after cell wall removal by Zymoliase20T diges-
tion (Nacalai Tesque) and cell disruption with a glass-teflon 
potter homogenizer [48]. Whole cell extract was centrifuged 
at 12,000 g for 30 min to yield the mitochondrial pellet (M) 
and post-mitochondria supernatant (PMS). These fractions 
were analyzed by immunoblotting with the indicated antibod-
ies (Porin: mitochondrial marker; PGK cytoplasmic marker 
(Abcam Mitoscience)). The Cab5 protein was immunovisual-
ized using an anti-HA (Roche) specific antibody. Proteinase K 
protection assay for sub-mitochondrial localization study was 
performed as previously described [48, 49]. Briefly, 200 μg of 
mitochondrial proteins were kept in 20 mM HEPES pH 7.4, 0,6 
M sorbitol in the presence or absence of proteinase K (1 
mg/ml) for 60 minutes on ice. 0,1 M PMSF (phenylmethyl-
sulfonyl ﬂuoride) was added to stop the reaction. The protein 
pellets were washed once with 20 mM HEPES pH 7.4 plus 0,6 
M sorbitol, and suspended in SDS-PAGE sample buffer.  
A modified version of the membrane association experi-
ments of Trott and Morano [50] was utilized to determine the 
resistance of Cab5p to sodium carbonate (pH 11.5) treatment. 
Equal amounts (150 μg) of the mitochondrial fraction was 
resuspended in TEGN (20 mM Tris-HCl [pH 7.9], 0.5 mM EDTA, 
10% glycerol, 50 mM NaCl) or TEGN and with 0.1 M NaCO3 for 
30 min on ice. The samples were subsequently centrifuged at 
17,000 g at 4°C to obtain soluble and membrane fractions. The 
fractions obtained in all type of extraction were separated by 
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SDS-PAGE and probed with anti-HA and anti-PORIN antibod-
ies.  
 
Measurement of iron content  
The iron content was determined by a colorimetric assay, es-
sentially as described before [25, 51]. 5x10
8 
cells were washed 
twice with H2O, resuspended in 0.5 ml of 3% nitric acid and 
incubated over night at 95°C. After incubation, samples were 
centrifuged at 12,000 rpm for 5 min and the supernatant (400 
µl) was mixed with 160 µl of 38 mg sodium L-ascorbate ml
- 1 
(SIGMA), 320 µl of 1.7 mg BPS ml
-1
 (ACROS ORGANICS), and 
126 µl of ammonium acetate (SIGMA) (saturated solution 
diluted 1:3). Non-specific absorbance was measured at 680 
nm and subtracted from the specific absorbance of the iron-
BPS complex (535 nm). Iron was quantified by reference to a 
standard curve using iron sulfate performed as in Tamarit et al. 
[25]. 
  
H2O2 sensitivity 
To determine the sensitivity to oxygen peroxide, cells growing 
exponentially were exposed to 1 and 2 mM H2O2 at 28°C or 
37°C for 4 h. Cell viability was determined by spotting equal 
amounts of serial dilutions of cells (10
5
,
 
10
4
, 10
3
, 10
2
, 10
1
) onto 
YP plates (1% yeast extract, 2% peptone ForMedium
TM
) sup-
plemented with 2% glucose (YPD). Plates were incubated at 
28°C or 37°C for two days. To better quantify H2O2 sensitivity 
cell survival was determined by counting the formation of 
colonies after the treatment. 
 
Lipid droplets content: fluorescence microscopy and fluori-
metric analysis  
Intracellular lipid droplets were detected using the fluorescent 
lipophilic dye Nile Red (9-diethylamino-5H-
benzo[α]phenoxazine-5-one 3 SIGMA-ALDRICH) by fluores-
cence microscopy and fluorimetric analysis [31, 52, 53]. Wild 
type and cab5∆/COASY
R499C 
strains were grown to mid-log 
phase in mineral medium (40) containing Yeast Extract (1,5 
g/L). To 250 μl of the cultures, adjusted to 1 OD, 10 μl of the 
stock solution of Nile red [100 μg/ml] were added in order to 
obtain a final concentration of 4 µg/ml of dye. Fluorescence of 
the stained cells were obtained with a Leica DM2000 micro-
scope using x 100 magnification and captured using a Leica 
DFC310FX digital camera with Leica’s Imaging Software (Leica 
Application Suite-LASAF 3.7.0, Leica Microsystem). 
To quantify the fluorescence we used the fluorescence 
spectrometer Tecan SPECTRA Fluor Plus using the software 
XFLUOR4 V4.51 (excitation at 535 nm and emission at 595 
nm). Aliquots of 100 μl of cells stained with Nile red were 
transferred into 96-well microplates in 4 replicates. For each 
strain a negative control was performed in which the dye was 
omitted in order to exclude a possible auto fluorescence of 
samples. The evaluation of the fluorescence was repeated at 
5-minute intervals in a time interval of 20 minutes [53]. 
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Figure S1. HPLC Analysis of CoA production by wild-type and mutant human COASY recombinant proteins, 
and wild-type PPAT domain, obtained in bacteria as His-tag fusion proteins.  
A. Chromatogram showing the peak corresponding to the reaction product (green) obtained from incubation of wild-
type COASY recombinant protein with 1mM ATP and 0.1mM dephospho-CoA. The enzyme is able to completely 
convert dephospho-CoA into CoA. 
B. Chromatogram showing the peak corresponding to the reaction product (green) obtained from incubation of mutant 
COASY recombinant protein with 1mM ATP and 0.1mM dephospho-CoA. The enzyme is able to partially convert 
dephospho-CoA into CoA. 
C. Chromatogram showing the peak corresponding to the reaction product (green) obtained from incubation of wild-
type COASY recombinant protein with 1mM ATP and 0.1mM 4-phospho-pantetheine (substrate utilized from PPAT 
domain to obtain dephospho-CoA and consequently CoA). The enzyme is able to completely convert 4-phospho-
pantetheine into CoA. 
D. Chromatogram showing the peak corresponding to the reaction product (green) obtained from incubation of mutant 
COASY recombinant protein with 1mM ATP and 0.1mM 4-phospho-pantetheine. The enzyme is able to partially 
convert 4-phospho-pantetheine into CoA. 
E. Chromatogram showing the peak corresponding to the reaction product (green) obtained from incubation of wild-
type PPAT recombinant domain with 1mM ATP and 0.1mM 4-phospho-pantetheine. The enzyme is not able to 
synthesize CoA, therefore is evident that PPAT does not possess the catalytic synthase activity.  
F. Histogram showing the quantification of in-vitro CoA production by the recombinant proteins, analyzed by HPLC. 
Mutant COASY is able to synthesize about 50% of CoA in the presence of 1mM ATP and 0.1mM dephospho-CoA 
(dpCoA), compared to wild-type protein. Moreover, mutant protein is able to synthesize about 70% of CoA in the 
presence of 1mM ATP and 0.1mM 4-phospho-pantetheine (4PP). 
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Figure S2. In-vitro recombinant wild-type and mutant COASY activity measured by biochemical analysis. 
A. Histogram showing the COASY enzymatic activity in the presence of different concentrations of dpCoA and ATP. 
Mutant COASY shows a reduction of enzymatic activity if compared to wild-type, in all the tested concentration. 
B. Histogram showing the COASY enzymatic activity in the presence of different concentrations of 4PP and ATP. 
Mutant COASY shows a reduction of enzymatic activity if compared to wild-type, in all the tested concentration. 
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Figure S3. Cellular analysis to investigate for a protein complex formation of COASY with the other enzymes 
involved in CoA biosynthesis. 
A. Co-immunoprecipitation analysis on HeLa cell line using phospho-pantothenoyl-cysteine synthetase (PPCS, the 
second enzyme involved in CoA biosynthesis) like bait. In the anti-COASY and anti-PANK2 panels, in the 
immunoprecipitate lane bands are absent. It means that COASY and PANK2 do not co-immunoprecipitate with PPCS. 
B. 2D-Blue native analysis on HeLa cells. The image shows that COASY and PPCS do not belong to the same protein 
complex, maybe they belong to different protein complexes greater than 200kDa (size of cytochrome C oxidase, or 
COX, or complex IV of respiratory chain).  
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